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   INTRODUCTION 
 
NATURE always stands as a golden mark to exemplify the outstanding 
phenomenon of symbiosis. The plants are indispensable to man for his life. 
Nature has provided a complete storehouse of remedies to cure all ailments 
of mankind. 
 In the past, almost all the medicines used were from the plants, the 
plant being man's only chemist for ages. Today, vast store of knowledge 
concerning therapeutic properties of different plants has accumulated. 
 The history of herbal medicines is as that old as human civilization.  
The documents, many of which are of great antiquity, revealed that plants 
were used medicinally in China, India, Egypt and Greece long before the 
beginning of Christian era.  One of most famous surviving remnant is Papyrus 
ebers, a scroll some 60 feet long and a foot wide, dating back to the sixtieth 
century before Christ.  The drugs such as acacia, castor oil and fennel are 
mentioned along with apparent references to such compounds as iron oxide, 
sodium chloride, sodium carbonate and sulphur. In China many medicinal 
plants had been in use since 5000 B.C.  Indians do, worked meticulously to 
examine and classify the herbs, which they came across into groups called 
Gunas. Charka made fifty groups of ten herbs, each which according to him, 
would suffice an ordinary physician's need.  A large portion of the Indian 
population even the present time depends on the Indian System of Medicine – 
Ayurveda – Ancient science of life. The well-known treatises in Ayurveda are 
the Charak Samhita and the Sushruta Samhita. 
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1.1.1 Ayurveda - Indian System of Medicine: 
 Ayurveda is believed to be prevalent since last 5000 years in India. It is 
one of the most noted systems of medicine in the world. Ayurveda is based on 
the hypothesis that everything in the universe is composed of five basic 
elements viz. space, air, energy, liquid and solid. They exist in the human 
body in combined forms like Vata (space and air), Pitta (energy and liquid) 
and Kapha (liquid and solid). Vata, Pitta and Kapha together called Tridosha 
(three pillars of life).  It is believed that they are harmony with each other but 
in every human being one of them is dominating which is in turn is called as 
the prakruti of that person. Tridosha exist in human body in seven forms 
called Saptadhatu viz. Rasa (lymph), Rakata (blood), Meda (adipose tissues), 
Mamsa (flesh), Majja (nervine tissue), Shukra (reproductive tissue) and Asthi 
(bones).  These tissues are subjected to wear and tear so that Mala 
(excretory material) is formed from them.  When Tridosha, Saptadhatu and 
Mala are in balance with each other, it is called as healthy condition while 
imbalance causes a pathological condition. It is hypothesised that the five 
characters of the medicinal herbs viz. Rasa, Guna, Virya, Vipak and Prabhava 
can be applied to treat various pathological conditions.  Ayurvedic pharmacy 
(Bhaisajya – Vigyan) proposes five basic dosage forms like Swaras, Kalka, 
Kwath, Heem and Plant.  A number of dosage forms like Churna, Avaleha, 
Ghrita, Sandhana kalpa, Bhasma are prepared from them. Some important 
herbs from Ayurveda are Rauwolfia, sepentina, Sesamum indicum, Withania 
somnifera etc. (Kokate et al., 1998) 
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1.1.2 Recent Trends and Choice of Therapy: 
 Considerable scope of ethanobotanical studies is found in different 
parts of India; who mainly use natural plant product directly as drugs to get rid 
from various diseases. Much work in the field of medicinal plants has 
accumulated in India during 20th century. Therapeutic use of plants for 
treatment of human illness dates back our many millennia. Evidence of their 
effectiveness in the diagnosis, cure and prevention disease state exist in 
every culture throughout the world. (Kapur, 1994) 
 Plants constitute one of the major raw materials for drugs for treating 
various ailments of human being, although there has been significant 
development in the field of synthetic drug chemistry and antibiotics.  In all over 
the world now considerable changes have taken place during last two 
decades.  Due to the awareness of toxicity associated with the long use of 
synthetic drugs and antibiotic, the western society prefers the drug from 
natural sources than the synthetics. Moreover modern medicine does not 
have a suitable answer for many conditions such as liver disorder and for 
chronic conditions such as asthma, arthritis, etc. and this leads to increase 
interest in herbal drugs. (Naik, 1986) 
 Therapeutic use of plants for the treatment of human illnesses dates 
back our many millennia.  Evidence of their effectiveness in the diagnosis, 
cure and prevention of disease state exists in every culture throughout the 
world.  Today, "traditional medicine", characterized by the use of herbs and 
other natural products, still remains regular component of health care in 
countries such as China, Japan, India, South America and Egypt.  Even today 
more than 40 % of drugs in Allopathic have their origin from plants.  Keeping 
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this significant contribution, there is a need that we should understand the 
original system of medicine and stop calling them as "Alternative Systems". 
(Narayan, 1998) 
1.1.3. Introduction to medicinal plants 
 Man‘s existence on this earth has been made possible only because of 
the vital role played by plant kingdom. Nature always stands as golden mark 
to amplify the outstanding phenomenon of symbiosis. (Kokate, et al., 1996) 
Medicinal plants were existing even before human being made their 
appearance on the earth (Siddhiqui, 1985). Practically every country develops 
its own medical system, which includes the ancient civilization of China, Egypt 
and India. Thus, the Indian Medical System – Ayurveda, came into existence. 
The raw materials for Ayurvedic medicines were mostly obtained from plant 
sources in the form of crude drugs such as dried herbal powders or their 
extracts or mixture of products. Also, Siddha, Unani and Tibb are traditional 
health care systems have been flourishing for many centuries. Apart from 
these systems there has been a rich heritage of ethanobotanical usage of 
herbs by various colorful tribal communities in the country (Handa, 1991). 
 If we do well for a moment on our hoary past, Rigveda, one of our 
oldest repositories of human knowledge written between 4500 – 1500 B.C. 
mentions the use of 67 plants for the therapeutic purposes and Yajurveda 
enlists 81 plants whereas Atharvaveda written somewhere 1200 B.C. 
describes 290 plants. 
India unquestionably occupies the top position in the use of herbal 
drugs. It is one of the foremost countries exporting plant drugs or their 
derivatives, and excels in home consumption too. According to Indian 
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mythology, when the illness and diseases got rampant on the earth, the sages 
learnt the science of healing from Lord Indra and recorded them in scriptures 
(Handa, 1991). 
 It has been estimated that from 25000 to 75000 species of higher 
plants exist on the earth. A reasonable estimate of about 10% has been used 
in traditional medicine. However, perhaps only about 1% of these are 
acknowledged through scientific studies to have therapeutic value when used 
in extract form by human. (Norman et al., 1985) 
 Natural products have been derived from higher plants, microbes or 
animals and those can be of either terrestrial or marine or aquatic origin. The 
medicinal preparations based on these raw materials were in the form of 
crude drug. With the advent of scientific methods, many of these reputed 
medicinal plants came under chemical investigation leading to the isolations 
of active principles. Beginning with 1800 AD there was continuous activity in 
this area and many of the well known medicinal plants were chemically 
analyzed and their active principles characterized. Soon after their isolation 
and characterization these compounds, either in pure state or in the form of 
extracts, became part of pharmacopoeias of several countries. This is where 
herbal medicine and modern medicine have a common link (Handa, 1991). 
According to the Eccleriates “The lord created medicines out of the earth and 
a wise man will not adore them” (Siddhiqui, 1985). 
1.1.3.1. Brief History of Medicinal Plants: 
 Western medicine originates with the Greeks.  
- Hippocrates (460-377 BC) – founder of medicine. 
- Aristotle – was a great natural historian. 
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- Theophrastus (372-287 BC) – founder of botany, described 
many plants.  
- Pliny (43-70 AD) – Major compendium of natural history. 
- Dioscorides (40-90 AD) – De materia medica encyclopedia of 
medicinal plants that was major gospel of plant medicines from 
hundreds of years. 
 Gerard‘s Herbal 
 Herbal medicine eventually gave way to more scientific studies. From 
the Greek notion that pure reason could answer any question, 
empirical studies developed.  
 Herbal medicines in other cultures. Herbs are very important 
components of medicine in other cultures (i.e. Chinese medicine, 
Indian Ayurvedic medicine). 
1.1.4 Herbal medicine 
 World Health Organization (WHO) currently encourages, recommends 
and promotes traditional /herbal remedies in national health care systems 
because such drugs are easily available at low cost, are comparatively safe 
and the people have faith in such remedies (Handa, 1995). WHO defined total 
health, is not just the absence of disease, but a state of physical, mental, 
social and spiritual well-being. Today we are more concerned with life style 
diseases like depression, cancer and heart troubles caused by faulty nutrition 
and stress. Because these diseases have a mental or emotional component, 
there is a growing conviction that allopathy is largely unable to cure them, all 
of it offers is temporary relief from symptoms. There is a need of alternative 
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therapy, to cover a good health for all. Herbal therapy will be one of the best 
practices to overcome the illness (Gupta et al., 2000). 
 Natural products are an integral part of human health care system now 
a day because there is now popular concern over toxicity and side effects of 
modern drugs. There is also a realization that natural drugs are safer and 
allopathic drugs are often ineffective. Due to these facts over the past ten 
years a considerable revival of interest in the use of herbal medicine in the 
world has come up. WHO has also appreciated the fact that most of the world 
population depends on traditional medicine and therefore WHO has evolved 
guidelines to support the member states in their efforts to formulate remedies 
on traditional medicine and to study their potential usefulness, safety and 
efficacy. In the last few decades there has been an exponential growth in the 
filed of herbal medicine. It is getting popularized in developing and developed 
countries owing to its natural origin and lesser side effects (Mukherjee et al., 
1981).  
The Indian contribution in international herbal market has emphasized 
on novel research for capturing as well as to remain in the market. 
‗Phytochemical standardization of herbal drugs and highly processed 
materials in herbal formulation are required. The importance and challenges 
of conducting clinical research in herbal drugs, simple bioassays for biological 
standardization, pharmacological and toxicological evaluation, toxic herbal 
drugs in use, various animal models for toxicity and safety evaluation, were 
dealt with in detail by various experts in the field (Padh, et al., 2000). 
 For pharmaceutical proposes, the quality of medicinal plant material 
must be as high as that of their medicinal preparations. However, it is 
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impossible to assay for a specific chemical entity when the bioactive 
ingredient is not known. In practice, assay procedures are not carried out 
even for those medicinal plant materials where there are known active 
ingredients.  
 Problems in standardization arise from the complex composition of 
drugs which are used in the form of whole plant, parts of the plant(s) and of 
plant extracts. Standardization of the presumed active compounds of drug in 
general does not reflect reality. Only in a few cases does drug activity depend 
upon single component. Generally, it is the result of concerted activity of 
several active compounds as well as of inert accompanying substances. 
Though these inert accompanying components do not directly affect 
pathological mechanism, it is reasonable to use the complex mixtures of 
components provided by a medicinal plant because these inert components 
might influence bioavailability and excretions of the active component. 
Further, by inert plant components the stability of the active component might 
be increased and the rate of side effects be minimized. If there are different 
active compounds present in a plant drug, they might have additive or 
potentiating effects. 
 The purpose of standardization of traditional remedies is obviously to 
ensure therapeutic efficacy. The quality assurance of traditional remedies rely 
upon good manufacturing practices with adequate batch analysis and 
standardized methods of preparation. Various processes used in manufacture 
of herbal drugs lack standardized methods.  
Problems with Modern (Allopathic) Drugs: (Rao, 2000) 
1) High cost and long time taken in development of new drug.  
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2) Toxicity – A new branch of medicine is termed iatrogenic diseases.  
3) Non-renewable source of basic raw materials. Most synthetic drug 
utilizes fossil resources like petrochemicals.  
4) Environmental pollution by the chemical industry.  
5) Inadequate, specially in management of certain chronic diseases.  
Advantages of Plant-based Drugs: (Rao, 2000) 
1) Long history of use and better patient tolerance as well as public 
acceptance. 
2) Renewable source.  
3) Cultivation and processing is environmental friendly. 
4) Local availability, specially in developing countries.  
5) Plants constitute to be a major source of new lead generation. 
1.1.4.1. Steps Necessary for Promoting Herbal Drugs: 
 Phytochemistry or natural product chemistry research is the backbone 
of herbal industry. For promoting use of herbals in modern medicine, 
Phytochemistry should be envisaged for: 
 Isolation, purification and characterization of new phytoconstituents. 
 Use of newly isolated phytoconstituents as ―lead‖ compound for the 
synthetic design of analogues with either improved therapeutic 
activity or reduced toxicity.  
 Conservation of lead phytoconstituents into medicinally important 
drugs. (Graham et al.,1990)  
1.1.4.2 Ethno-Pharmacological Approach to Herbal Drugs:  
 The term ethno-pharmacology refers the interdisciplinary scientific 
observation, description, and experimental investigation of indigenous drugs 
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and biological activities. Recent interest in the use of ethno- pharmacological 
information of plant drugs has greatly increased for several reasons.  
 Scientists showed that of 119 important plant derived drugs used in 
one or more countries, 88 were regarded as having been discovered as a 
result of being derived from a plant used in traditional medicine. (De Smet et 
al., 1989)  
1.1.4.3. Practical Aspects of Herbal Drug Discovery:  
 The following scheme represents a summary of the stages involved in 
the development of pure drug from a plant source. 
 Collection and identification of the plant and deposition of voucher 
sample in local and major herbaria. 
 Literature survey on the plant species selected for studies.  
 Extraction with solvent and preparation of non-polar and polar 
extracts for initial biological testing.  
 Evaluation of plant extract against a panel of biological test methods, 
as exemplified by receptor biding, enzyme inhibition, and or 
cytotoxicity assays.  
 Activity guided fractionation on the extract showing activity, by 
monitoring each chromatographic fraction with bioassay chosen from 
the panel available to the investigation.  
 Structure elucidation of pure active isolate(s) using spectroscopic 
techniques and chemical methods, if necessary.  
 Test each active compound (whether of novel or known chemical 
structure) in all in vitro and in vivo biological test methods available, in 
order to determine potency and selectivity of the drug. 
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 Perform molecular modeling studies and prepare derivatives of the 
active compound of interest.  
 When total synthesis is not practical, carry out large scale reisolation 
of interesting active compounds for toxicological, pharmacological 
and for mutation studies.  
 Clinical trials (phase I – III). 
1.1.4.4 Current Status of Herbal Drugs: 
 Recent years newer and newer diseases are posing threat to humanity. 
In fact diseases are not new but are detected newly. Despite this, WHO had 
taken the vouch of providing ‗Health for all‘ by 2000 A. D. 
 In spite of stupendous advances made by modern medicine, the 
present century has many more health problems than earlier centuries. Drugs 
for viral diseases like ‗AIDs‘, certain type of cancers, arthritis, parkinsonism 
are yet to come. The newer concept about herbal drugs have 
immunomodulators and adaptogens gaining importance and are recognized 
for prophylactic and preventive therapy. 
 Surprisingly, a recent survey revealed that more than 50% of all 
prescription drugs issued by rational physicians are either directly derived 
from the natural sources or synthesized from the natural models as the sole 
ingredient or as one of the several ingredients. It seems certain that the 
continued scientific study of medicinal plants afford a plethora of novel, 
structurally diverse and bioactive compounds. Multidisciplinary research on 
plants has lead to many new drugs, as well as prototype active molecules and 
biological tools. 
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1.1.4.5. Future Prospects in Herbal Medicines: 
 At the moment, scientific research on medicinal plants is continuing 
most intensely in research institutes, universities and pharmaceutical 
laboratories as well as in the clinics of many developed countries. This 
research is oriented mainly in two directions. Firstly the active ingredients of 
plants that have long been known for their healing properties are being 
investigated. The second sphere of basic research has led to the discovery of 
new kinds of medicinal plants and new drugs from the more remote regions of 
the world where new species with unknown substances still remain to be 
looked into. Each and every traditional medicine, drugs of Ayurveda, Unani 
and Siddha need to be tested and validated scientifically. CSIR, New Delhi, 
which is already involved in this field and validated about 350 formulations for 
different activities. This is a welcome trend since it attempt to marry traditional 
practice with modern knowledge for the betterment of health (Gupta and 
Chitme, 2000). WHO has emphasized the need to ensure the quality control 
of herbs and herbal formulations by using modern techniques. Several 
countries have herbal pharmacopoeias and lay down monographs to maintain 
their quality. Ayurvedic Pharmacopoeia of India, which recommends basic 
quality parameters for 400 common herbal drugs. (Dobriyal et al., 1998) 
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1.2. Liver 
1.2.1 Anatomy of Liver 
Liver is heaviest gland of the body lies deep into peritoneum and 
weighs about 3 pounds in an adult. The liver lies to the right of the stomach 
and overlies the gallbladder.  The liver is held in place by ligamentous 
attachments to the diaphragm, peritoneum, great vessels, and upper 
gastrointestinal organs. It receives a dual blood supply; approximately 20% of 
the blood flow is oxygen-rich blood from the hepatic artery, and 80% is 
nutrient-rich blood from the portal vein arising from the stomach, intestines, 
pancreas, and spleen (Dennis et al., 2005).  
Liver is divided into two lobes, large right lobe and smaller left lobe are 
made up of lobules which consist of epithelial cells called hepatocyte, 
arranged in irregular, branching, inter connected plate around a central vein. 
Between each row of hepatocyte are small cavities called sinusoids. Each 
sinusoid is lined with kupffer cells, phagocytic cells. 
1.2.2 Structure of Liver 
The liver is composed of four lobes: the right, left, caudate, and 
quadrate lobes. The right and left lobes are the largest lobes of the liver. A 
conspicuous external duct system emerges from the inferior side of the liver. 
A right and left hepatic duct departs from the right and left lobes respectively. 
The two ducts then fuse forming a common hepatic duct. The common 
hepatic duct joins the cystic duct from the gallbladder and beyond this junction 
the duct is termed the common bile duct. The common bile duct then 
connects with the duodenum. At the base of the bile duct is a sphincter, which 
controls the flow of bile from the liver and gallbladder into the small intestine. 
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The sphincter, called the sphincter ampulla, can therefore remain constricted 
and store bile until it is needed within the digestive tract.  
Structurally and histologically, the liver can be divided into four tissue 
systems: (1) intrahepatic vascular system, (2) stroma, (3) sinusoidal cells, and 
(4) hepatocyte. (Erwin and Hans-Dieter Kuntz, 2005). 
 
     Fig. 1.1 Liver 
1.2.3 Functions of Liver 
 Bile production and excretion  
 Excretion of billirubin, cholesterol, hormones, and drugs  
 Metabolism of fats, proteins, and carbohydrates  
 Enzyme activation  
 Storage of glycogen, vitamins, and minerals  
 Synthesis of plasma proteins, such as albumin and globulin, and 
clotting factors  
 Blood detoxification and purification  
The liver synthesizes and transports bile pigments and bile salts that 
are needed for fat digestion. Bile is a combination of water, bile acids, bile 
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pigments, cholesterol, billirubin, phospholipids, potassium, sodium, and 
chloride. Primary bile acids are produced from cholesterol. When bile acids 
are converted or "conjugated" in the liver, they become bile salts.  
Billirubin is the main bile pigment that is formed from the breakdown of 
haem in red blood cells. The broken-down haem travels to the liver, where it is 
secreted into the bile by the liver. Billirubin production and excretion follow a 
specific pathway. When the reticuloendothelial system breaks down old red 
blood cells, billirubin is one of the waste products. This "free billirubin" is a 
lipid soluble form that must be made water-soluble to be excreted. The 
conjugation process in the liver converts the billirubin from a fat-soluble to a 
water-soluble form. The liver also plays a major role in excreting cholesterol, 
hormones, and drugs from the body.  
The liver plays an important role in metabolizing nutrients such as 
carbohydrates, proteins, and fats. The liver helps to metabolize carbohydrates 
in three ways:  
 Through the process of glycogenesis, glucose, fructose, and galactose 
are converted to glycogen and stored in the liver.  
 Through the process of glycogenolysis, the liver breaks down stored 
glycogen to maintain blood glucose levels when there is a decrease in 
carbohydrate intake.  
 Through the process of gluconeogenesis, the liver synthesizes glucose 
from proteins or fats to maintain blood glucose levels.  
The liver synthesizes about 50 grams of protein each day, primarily in 
the form of albumin. Liver cells also chemically convert amino acids to 
produce ketoacids and ammonia, from which urea is formed and excreted in 
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the urine. Digested fat is converted in the intestine to triglycerides, cholesterol, 
phospholipids, and lipoproteins. These substances are converted in the liver 
into glycerol and fatty acids, through a process known as ketogenesis.  
Prothrombin and fibrinogen, substances needed to help blood 
coagulate, are both produced by the liver. The liver also produces the 
anticoagulant heparin and releases vasopressor substances after 
hemorrhage.  
Liver cells protect the body from toxic injury by detoxifying potentially 
harmful substances. By making toxic substances more water soluble, they 
can be excreted from the body in the urine. The liver also has an important 
role in vitamin storage. High concentrations of riboflavin or Vitamin B1 are 
found in the liver. 95% of the body's vitamin A stores are concentrated in the 
liver. The liver also contains small amounts of Vitamin C, most of the body's 
Vitamin D stores, and Vitamins E and K.  
1.2.4 Disease of Liver 
Although liver disease is stereotypically linked to alcohol or drugs, the 
truth is that there are over 100 known forms of liver disease caused by a 
variety of factors and affecting everyone from infants to older adults. They 
generally present clinically in a few distinct patterns, usually classified as 
hepatocellular, cholestatic (obstructive), or mixed. In hepatocellular diseases 
(such as viral hepatitis or alcoholic liver disease), features of liver injury, 
inflammation, and necrosis predominate. In cholestatic diseases (such as gall 
stone or malignant obstruction, primary biliary cirrhosis, some drug-induced 
liver diseases), features of inhibition of bile flow predominate. In a mixed 
pattern, features of both hepatocellular and cholestatic injury are present 
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(such as in cholestatic forms of viral hepatitis and many drug-induced liver 
diseases) (Dennis et al., 2005). 
Cirrhosis is often considered to be a form of liver disease. Cirrhosis is a 
condition that results from permanent damage or scarring of the liver. It is the 
end stage of many different forms of liver disease and is known to cause a 
number of other health problems, including variceal bleeding, ascites and 
hepatic encephalopathy. 
Some diseases cause bad things to build up in the liver. 
Hemochromatosis causes extra iron to build up in the liver. Wilson's disease 
causes extra copper to build up in the liver. Both of these diseases hurt the 
cells and can cause very bad liver disease that kills people. Many types of 
liver disease still have unknown causes but the most frequent liver diseases 
are generally caused by one of the following factors: 
 Viral hepatitis 
Caused by viruses that attack the liver, viral hepatitis comes in many 
forms. The most common forms world-wide are hepatitis A, B and C. 
Although hepatitis A and B can be prevented by vaccine, there is no 
vaccine for hepatitis C. In Canada, hepatitis C is the leading cause of liver 
transplants. 
 Obesity 
The leading cause of liver disease in Canada is fatty liver disease linked 
to obesity. 
 Alcohol 
Factors such as gender, age, nationality, weight and health can affect how 
a person‘s liver metabolizes alcohol. When the liver has too much alcohol 
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to handle, normal liver function may be interrupted leading to a chemical 
imbalance. If the liver is required to detoxify alcohol continuously, liver 
cells may be destroyed or altered resulting in fat deposits (fatty liver) and 
more seriously, either inflammation (alcoholic hepatitis) and/or permanent 
scarring (cirrhosis). Liver cancer can also result from alcohol induced liver 
disease. 
 Genetics 
Several forms of liver disease are caused or thought to be caused, by 
defective genes. These forms of liver disease may be diagnosed in infancy 
or may not show up until later in life. Examples include 
hemochromatosis, Wilson disease, tyrosinemia, alpha 1 antitrypsin 
deficiency and Glycogen Storage disease. 
 Autoimmune disorders 
Sometimes a body‘s immune system may begin to attack the liver or bile 
ducts causing inflammation and scarring which leads to a progressive form 
of liver disease. Examples of liver diseases believed to be caused by the 
immune system are primary biliary cirrhosis (PBC), primary sclerosing 
cholangitis (PSC) and autoimmune hepatitis. 
 Drugs and toxins 
The liver is responsible for processing most of the chemicals 
and medications that enter your body – this leaves it vulnerable to acute or 
chronic liver disease caused by chemicals. In some cases, this is a 
predictable consequence of overexposure or over-consumption of certain 
chemicals such as acetaminophen or industrial toxins like polyvinyl 
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chloride or carbon tetrachloride. In other cases, chemicals can cause an 
unpredictable reaction. 
 Cancer 
Although primary liver cancer is relatively uncommon, many other forms 
of cancer often metastasize in the liver. Because the liver filters a high 
volume of blood which may be carrying cancer cells, it is susceptible to 
developing a form of secondary cancer. If cancer originates in the liver, it 
is often caused by hepatitis B, hepatitis C or it can develop in cases of 
advanced liver disease when cirrhosis is present. 
1.2.5 Hepatotoxicity 
Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver 
damage. The liver plays a central role in transforming and clearing chemicals 
and is susceptible to the toxicity from these agents. Certain medicinal agents 
when taken in overdoses and sometime even when introduced within 
therapeutic ranges may injure the organ. Other chemical agents such as 
those used in laboratories and industries, natural chemicals (e.g. 
microcystins) and herbal remedies can also induce hepatotoxicity. Chemicals 
that cause liver injury are called hepatotoxins. 
The blood draining the stomach and small intestine is delivered directly 
to the liver via the hepatic portal vein, thus exposing the liver to relatively large 
concentrations of ingested drugs or toxicants. Hepatic exposure to agents that 
undergo bioactivation to toxic species can be significant (Charles and Robert, 
2002). 
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1.2.5.1 Pathogenesis of Drug induced liver damage 
The pathogenesis of drug-induced liver damage is an individual, albeit 
multifactorial process. The main mechanisms known to include: 
Lipid peroxidation: Free radicals induce peroxidation of the unsaturated fatty 
acids of the ER. As a result, there is fatty degeneration of the liver, whereby 
the mitochondria and biomembranes are damaged (possibly leading even to 
cell death). 
Oxidative stress: This process causes a depletion of glutathione in the 
hepatocytes with subsequent damage to (and even death of) liver cells. 
Inhibition of β-oxidation: The enhanced formation of mitochondrial oxygen 
radicals in the presence of fatty degeneration of the liver causes lipid 
peroxidation, which can lead to steatohepatitis and fibrosis or cirrhosis. 
Inhibition of protein synthesis: Some substances can inhibit RNA 
polymerase II and III. This in turn impairs the synthesis of enzymes, structural 
proteins and apolipoproteins. The result is fatty degeneration of the liver and 
cell necrosis. 
Disorder of haem synthesis: Inhibition of hepatic coproporphyrinogen-
oxidase and uroporphyrinogen-decarboxylase can give rise to secondary 
copro- and uroporphyrinuria or porphyria  cutanea tarda. 
Inhibition of bile acid transport: More than 100 medicaments can cause  
intrahepatic cholestasis. In this case, the canalicular transport mechanisms 
are impaired. The retained bile acids damage the cells. 
Immunoallergenic reactions: Chemically generated neoantigens trigger a 
cytotoxic immune response to those hepatocytes that have such neoantigens 
on their surface. 
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Carcinogenesis: Highly active or metabolically activated foreign substances 
may form DNA adducts, which culminate in mutations, above all in the p 53 
gene. Drug metabolism in the liver is subject to numerous endogenic and 
exogenic influences. They interfere with various biotransformation reactions, 
alter the sensitivity of the liver to drug products and determine the pattern of 
damage (Erwin and Hans-Dieter Kuntz, 2005). 
A.   Non-variable factors are genetics, gender and age. 
B. Variable factors are coexisting diseases (diabetes, liver or renal disease, 
endocrinopathies), overweight, malnutrition (e. g. lack of protein), alcohol, 
additional medication, tobacco smoke particles, heavy metals and 
pregnancy as well as drug-related overdose, long term intake or 
application form, etc. Foreign substances, including medicinal products, 
are classified as obligate (directly effective) or as facultative (indirectly 
effective) hepatotoxins, depending on their degree of hepatic toxicity. 
Hepatotoxins are therefore grouped as either directly toxic or indirectly 
toxic according to the pathogenetic mechanisms of liver damage. Indirect 
hepatotoxins may, however, also cause an idiosyncratic type of liver 
impairment through immunological or metabolic mechanisms. 
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Fig. 1.2 Pathogenetic mechanism of drug induced liver injury 
 
Table 1.1: List of Drug having Hepatotoxicity 
Sr. No. Name of drugs Category of drug 
1 Paracetamol Antipyretic, Analgesic 
2 Isoniazide Antituberculosic 
3 Rifampicin Antituberculosic 
4 Chlorpromazine Antipsychotic 
5 Halothane Anesthetic 
6 Chloroform Anesthetic 
7 Statines Hypolipidemic 
8 Sodium Valproate Antiepileptic 
9 Pyrazinamide Antituberculosic 
10 Tetracycline Antibiotic 
Hepatotoxin Combined 
form 
Hepatotoxin Hepatotoxi
nnnnnnnn 
Global cell 
damage 
Metabolic 
type 
Immunological 
type 
Partial 
cell 
damage 
 
a. Selective metabolic  
disturbaces 
Necrosis 
Steatotis 
Cholestasi
s 
 
Necrosis 
Steatotis 
Cholestasis 
Tumour 
formation 
 
b. Selective  secretory   
disturbaces 
 
Necrosis 
Cholestasis 
 
Necrosis 
Cholestasi
s 
 
Idiosyncra
cy 
Chapter 1  INTRODUCTION  
 23   
 
11 Amiodarone Antianginal 
12 Valproic acid Anticonvulsive 
13 Estrogen Female sex hormone 
Many therapeutic drugs cause liver damage, manifested clinically as 
hepatitis or (in less severe cases) only as laboratory abnormalities (e.g. 
increased activity of plasma aspartate transaminase, an enzyme released 
from damaged liver cells). Paracetamol, isoniazid , iproniazid and halothane  
cause hepatotoxicity by the mechanisms of cell damage. Genetic differences 
in drug metabolism have been implicated in some instances (e.g. isoniazid , 
phenytoin ). Mild drug-induced abnormalities of liver function are not 
uncommon, but the mechanism of liver injury is often uncertain (e.g. statins). 
It is not always necessary to discontinue a drug when such mild laboratory 
abnormalities occur, but the occurrence of irreversible liver disease (cirrhosis) 
as a result of long-term low-dose methotrexate treatment for arthritis or 
psoriasis argues for caution. Hepatotoxicity of a different kind, namely 
reversible obstructive jaundice, occurs with chlorpromazine and androgens. 
(Rang and Dale, 2003) 
 1.2.5.2. Types of drug induced liver damage 
 Hepatocellular Necrosis 
A. Zonal Necrosis (CCl4 type) 
CCl4 
Helogenated benzenes 
Acetamenophen 
B. Viral Hepatitis like (cincophen type) 
Isoniazid 
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Iproniazide 
Halothane 
 Uncomplicated cholestasis (Steroid type) 
Anabolic Steroid 
Estrogen 
 Nonspecific Hepatitis with Cholestasis (Chlorpromazine type) 
Phenothiazines 
Isoniazide 
Erythromycin estolate 
 Drug Induced Steatosis 
Tetracycline 
1.2.5.3 Hepatotoxins 
For every liver disease that cannot be clarified with certainty, each 
differential diagnosis should always include toxic substances in food, at work, 
in the house or garden and in those places where people pursue leisure 
activities. It is extremely difficult to identify the causal noxa. In the individual 
case, however, identification can be of considerable importance for general 
assessment purposes. 
1.2.5.3.1 Industrial toxin 
Example: Arsenic, Carbon tetrachloride, Vinyl Chloride, Thiocetamide, Alcohol 
Carbon Tetrachloride 
Carbon tetrachloride (CCl4), a potent hepatotoxic agent is biotransformed to a 
trichloromethyl radical by the cytochrome P450 system in liver microsomes, 
and consequently causes lipid peroxidation of membranes that leads to liver 
injury (Recknagel, 1983; Slater, 1984; McCay et al., 1984) 
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Thioacetamide 
Toxicity experienced by the liver during thioacetamide poisoning results 
from the production of a metabolite, thioacetamide s-oxide, which is a direct 
hepatotoxin (Neal and Halpert, 1982) responsible for change in cell 
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permeability and it inhibits mitochondrial activity followed by cell death 
(Ambrose et al., 1950). It has also been reported that chronic thioacetamide 
exposure produced cirrhosis in rats (Chieli and Malvadi, 1985). 
Alcohol  
In the United States, about half of the adult population actively 
consumes alcoholic beverages and about 15 to 20 million people suffer from 
alcoholism (Stinson et al., 1997) and it is the fourth leading cause of death in 
urban American males (Libber, 1991). Alcohol consumption can lead to a 
variety of abnormalities in the liver including steatosis, alcoholic hepatitis, and 
hepatic fibrosis, which typically precede the development of alcoholic 
cirrhosis, an end-stage liver disease most often requiring liver transplantation. 
Alcoholic cirrhosis is also a major risk factor for hepatocellular carcinoma that 
accounts for nearly 6% of all human cancers. Alcoholic liver disease affects 
more than 2 million people in the United States. According to a US 
surveillance report, liver cirrhosis was the 10th leading cause of mortality in 
1997 accounting for approximately 25,000 deaths in that year (Saadatmand et 
al., 2000). 
CYP2E1-dependent ethanol metabolism produces oxidative stress 
through generation of reactive oxygen species (ROS), a possible mechanism 
by which ethanol is hepatotoxic (Bondy, 1992; Dianzani, 1985). 
Induction of cytochrome P4502E1 by ethanol is a central pathway by 
which ethanol generates oxidative stress and in the intragastric model of 
ethanol feeding a prominent induction of CYP2E1 occurs along with significant 
alcohol liver injury (Morimoto et al., 1994; Nanji et al., 1994). Lipid 
peroxidation also occurs, and ethanol-induced liver pathology correlates with 
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CYP2E1 levels and elevated lipid peroxidation, which is blocked by inhibitors 
of CYP2E1. 
1.2.5.3.2 Mycotoxins 
Example: Aflatoxins (Erwin and Hans-Dieter Kuntz, 2005) 
1.2.5.3.3 Phytotoxins 
Example: Amanita phalloides, Pyrrolizidine alkaloids, Helvella esculenta 
(Erwin and Hans-Dieter Kuntz, 2005) 
1.2.5.3.4 Endotoxin 
Endotoxins are fragments of long-chain lipopolysaccharides. They pass from 
the cell membrane mainly from gram-negative bacteria in the intestine into the 
circulation and, as potential hepatotoxins, subsequently lead to liver damage 
(Erwin and Hans-Dieter Kuntz, 2005). 
1.2.5.3.5 Drugs 
Example: Paracetamol, Isoniazide, NSAIDS, Glucorticoids  
Acetamenophen 
Acetaminophen (paracetamol) is usually well tolerated in prescribed 
dose but overdose is the most common cause of drug induced liver disease 
and acute liver failure worldwide (Keeffe et al., 2004).Damage to the liver is 
not due to the drug itself but to a toxic metabolite (N-acetyl-p-benzoquinone 
imine NAPQI, or NABQI) which is produced by cytochrome P4502E1 
enzymes in the liver (Wallace, 2004). In normal circumstances this metabolite 
is detoxified by conjugating with glutathione in phase 2 reaction. In overdose 
large amount of NAPQI that can induce a dose dependent depletion of 
intracellular glutathione and perturbations of calcium homeostasis and lead to 
damage to liver cells (Lee et al., 1996; Chup et al., 1999; Holownia and 
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Braszko, 2004) Administration of Acetylcysteine, a precursor of glutathione, 
can limit the severity of the liver damage by capturing the toxic NAPQI. 
Nitric oxide also plays role in inducing toxicity (James et al., 2003). 
Peroxynitrite, a highly reactive nitrating and oxidizing species formed by the 
rapid reaction of nitric oxide (NO) and superoxide, produces nitrated tyrosine 
(Beckman, 1996; Pryor and Squadrito, 1995). Since acetaminophen-protein 
adducts correlate with development of necrosis (Hart et al., 1995; Roberts et 
al., 1991), it follows that nitration of tyrosine correlates with necrosis.  
Nonsteroidal anti-inflammatory drugs 
Although individual analgesics rarely induce liver damage, due to their 
widespread use NSAIDs have emerged as a major group of drugs exhibiting 
hepatotoxicity. Both dose dependent and idiosyncratic reactions have been 
documented (Manov et al., 2006). Aspirin and phenylbutazone are associated 
with intrinsic hepatotoxicity; idiosyncratic reaction has been associated with 
ibuprofen, sulindac, phenylbutazone, piroxicam, diclofenac and indomethacin. 
Glucocorticoids 
Glucocorticoids are so named due to their effect on carbohydrate 
mechanism. They promote glycogen storage in liver. Enlarged liver is a rare 
side effect of long term steroid use in children (Iancu et al., 1986). The 
classical effect of prolonged use both in adult and paediatric population is 
steatosis (Alpers, 1982). 
Isoniazid 
Isoniazide (INH) is one of the most commonly used drugs for 
tuberculosis. It is associated with mild elevation of liver enzymes up to 20% of 
patients and severe hepatotoxicity in 1-2% of patients (Sarich et al., 1999). 
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Isoniazide (INH) the first line drug used for tuberculosis chemotherapy is 
associated with hepatotoxicity (Tasduq et al., 2005). For decades, it has been 
well documented that INH can cause adverse effects on the liver, ranging from 
mild transient elevations in aminotransferases (transaminases), which occur in 
approximately 10 to 20% of patients, to overt hepatitis, occurring much more 
rarely (Randolph & Joseph, 1953; Cohen et al., 1961; Black et al., 1975; 
Kopanoff et al., 1978). The rate of hepatotoxicity with INH has been reported 
to be much higher in developing countries like India (8%-30%) compared to 
that in advanced countries (2%-3%) with a similar dose schedule (Sharma, 
2004). 
Isoniazide is acetylated and then hydrolyzed, resulting in isonicotinic 
acid and monoacetylhydrazine; the latter compound can be activated to a 
toxic species by cytochrome    P-450 (Thomas, 1981). In vitro studies indicate 
that metabolic oxidation of acetylhydrazine leads to a reactive acylating 
species that binds covalently to microsomal protein. It is postulated that 
acetylhydrazine and hydrazine act as acetylating agents by binding covalently 
with liver cell macromolecules, causing hepatocyte injury (Noda, 1983) 
Isoniazid-induced hepatitis is associated with ballooning degeneration, focal 
hepatocyte necrosis, with minimal cholestasis (Mitchell, 1976). Study reported 
diffuse microvesicular fatty infiltration with mild portal triaditis (Sodhi, 1997).  
Halothane 
Halothane is a widely used inhalation anesthetics cause allergic liver damage. 
Trifluoracetychloride, a reactive metabolite of halothane, couple to a 
macromolecule to form an immunogen. Most patient with halothane induced 
liver damage have antibodies that react with halothane-carrier conjugates. 
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Halothane-protein antigen can be expressed on the surface of hepatocytes. 
Destruction of cell occurs by type II hypersensitivity reaction involving killer T 
cell. If antigen-antibody complexes are released by damaged cells, type III 
reaction can occur.  
1.2.6. Herbal Remedies for Hepatotoxicity 
Herbal medicines have been used in the treatment of liver diseases for a long 
time. A number of herbal preparations are available in the market (Dhiman & 
Chawla, 2005). Medicinal herbs and extracts are widely used in the treatment 
of liver diseases like hepatitis, cirrhosis, and loss of appetite (Cupp, 1999). 
Silybum marianum, Picrrorhiza kurroa, Andrographis paniculata, Strychnos 
potatorum, Aquilegia vulgaris, Phyllanthus niruri, and Eclipta alba are some of 
the well known plants those have shown genuine utility in liver disorders 
(Bisset, 1994; Sanmugapriya and Venkataraman, 2006; Liebert et al., 2005). 
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1.3 Clinical Trials 
1.3.1. What is a clinical trial? (http://www.biotechmedia.com/definitions-
c.html) 
A clinical trial is a research study in which a treatment or therapy is tested in 
people to see whether it is safe and effective. The information learned from 
clinical trials helps to improve health care and to keep people healthier. 
Researchers also conduct clinical trials to find out which treatments are more 
effective than others. The results from trials can also contribute to our 
understanding of diseases and conditions—for example, how a disease 
progresses or how it affects different systems in the body. Clinical trials are 
also called medical research, research studies, or clinical studies. Each trial 
follows a protocol—a written, detailed plan that explains why there is a need 
for the study, what it is intended to do, and how it will be conducted. The 
protocol is written by the trial‘s principal investigator (the person who is in 
charge of the trial). 
1.3.2. What are the major types of clinical trials?  
(http://www.biotechmedia.com/definitions-c.html) 
Clinical trials are used to study many aspects of medical care: 
 Treatment trials tests for a specific disease or condition. 
  Supportive care trials, also called quality-of-life trials, study ways of 
making sick people more comfortable and giving them a better quality 
of life. 
 Prevention trials study ways, to reduce the chance of the disease to 
people who are healthy, but may be at the risk for a disease, will 
develop the disease. 
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 Early detection or screening trials, study new ways of finding diseases 
or conditions in people who are at risk, before they have any signs or 
symptoms. 
 Diagnostic trials, test new ways to identify, more accurately and earlier, 
whether people have diseases and conditions. 
Clinical trials have sometimes been thought of as a last resort for those who 
have a disease and have tried all other treatment options. This is not true. 
There are trials for healthy people (for example, to study disease prevention) 
and trials for all different types and stages of diseases. 
1.3.3. What are the different phases of Clinical trials? 
(http://www.biotechmedia.com/definitions-c.html) 
Because the therapy will be tested in people, before a clinical trial can start, 
there needs to be some evidence that it is likely to work. This evidence can 
come either from previous research studies in animals or from reported 
information on its use by people. Clinical trials take place in phases. In each 
phase, different research questions are answered. 
Phase 1:  (http://www.nccam.nih.gov) 
Initial safety trials on a new medicine in which investigators attempt to 
establish the dose range tolerated by about 20-30 healthy volunteers for 
single or multiple doses. Although usually conducted with healthy volunteers, 
Phase 1 trials are sometimes conducted with severely ill patients, for example 
those with cancer or AIDS. When pharmacokinetic issues are being 
addressed (for example, metabolism of a new antiepileptic medicine on stable 
epileptic patients whose microsomal liver enzymes have been induced by 
other antiepileptic medicines), trials may be conducted in less ill patients. 
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Pharmacokinetic trials are usually considered Phase 1 trials regardless of 
when they are conducted during a medicine's development.  
Phase 2a:  (http://www.nccam.nih.gov) 
Pilot clinical trials to evaluate efficacy and safety in selected populations of 
about 100 to 300 patients who have the disease or condition to be treated, 
diagnosed or prevented. Often involve hospitalized patients who can be 
closely monitored. Objectives may focus on dose-response, type of patient, 
frequency of dosing, or any of a number of other issues involved in safety and 
efficacy. 
Phase 2b: (http://www.nccam.nih.gov) 
Well controlled trials to evaluate safety and efficacy in patients who have the 
disease or condition to be treated, diagnosed or prevented. These trials 
usually represent the most rigorous demonstration of the efficacy medicine. 
Synonym: pivotal trials.  
Phase 3a: (http://www.nccam.nih.gov) 
Multicenter studies in populations of 1000 to 3000 patients (or more)  
for whom the medicine is eventually intended. Phase 3 trials generate 
additional safety and efficacy data from relatively large numbers of patients in 
both controlled and uncontrolled designs and are used to support a PLA 
(Product License Application). Trials are also conducted in special groups of 
patients or under special conditions dictated by the nature of the particular 
medicine and/or disease. Phase 3 trials are often providing much of the 
information needed for package insert and labeling of the medicine.  
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Phase 3b:  (http://www.nccam.nih.gov):  
Trials are conducted after submission of a new drug application (NDA), but 
before the product's approval for market launch. Phase 3b trials may 
supplement or complete earlier trials, or they may seek different kinds of 
information (for example, quality of life or marketing). Phase 3b is the period 
between submission for approval and receipt of marketing authorization.  
Phase 4:  (http://www.nccam.nih.gov) 
After a medicine is marketed, Phase 4 trials provide additional details about 
the product's safety and efficacy. They may be used to evaluate formulations, 
dosages, and duration of treatment, medicine interactions, and other factors. 
Patients from various demographic groups may be studied. An important part 
of many Phase 4 studies is detecting and defining previously unknown or 
inadequately quantified adverse reactions and related risk factors. Phase 4 
studies that are primarily observational or non experimental are frequently 
called post marketing surveillance.  
1.3.4. What are some common elements of Clinical trials? 
(http://www.biotechmedia.com/definitions-c.html) 
Trials can be randomized. Each participant in a randomized trial is assigned 
by chance (through a computer or a table of random numbers) to one of two 
groups: 
 The investigational group, made up of people who will receive the 
therapy, also called the active treatment 
  The control group, made up of people who will receive either the 
standard treatment (if there is one) for their disease or condition, or a 
placebo 
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Each participant has an equal chance of being assigned to either group. In 
some complex trials, there are more than two groups. Randomization is used 
in all phase III studies and in some phase II studies. It gives the best chance 
of knowing that the study results are caused by the treatment and not some 
other factor, such as people‘s choices or beliefs. Trials can be double-blind. 
This means that neither the researchers nor the participants know who has 
been assigned to which group. Blinding is another way to help minimize the 
chance of bias influencing the trial results. The information is kept on file at a 
central office, so if there is an urgent need for the research team to find out 
who was assigned the active treatment, they can.  
Researchers design clinical trials to have one or more endpoints. An endpoint 
is a measure that determines whether the treatment under study has an 
effect. An example of an endpoint is whether a person‘s tumor shrinks after 
receiving chemotherapy. 
1.3.5. What is a placebo? (http://www.biotechmedia.com/definitions-c.html) 
A placebo is designed to resemble as much as possible the treatment being 
studied in a clinical trial, except that the placebo is inactive. An example of a 
placebo is a pill containing sugar instead of the drug being studied. By giving 
one group of participants a placebo and the other group the active treatment, 
the researchers can compare how the two groups respond and get a true 
picture of the effect of active treatment.  
Another type of placebo is called a ―sham‖ procedure. When the treatment 
under study is a procedure (not a drug or other substance), a sham procedure 
may be designed that resembles the active treatment but does not have any 
active treatment qualities. For example, in a clinical trial of acupuncture, the 
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sham procedure might consist of placing acupuncture needles in areas of the 
body that are not expected (from previous knowledge) to have any therapeutic 
response. 
In recent years, the definition of placebo has been expanded to include other 
things that could have an effect on the results of health care. Examples 
include how a patient and a health care provider interact, how a patient feels 
about receiving the care, and what he or she expects to happen from the 
care. Therefore, when a treatment is compared to a placebo in clinical trials, 
the patients should differ only in whether they receive treatment, and not in 
other aspects. Not all clinical trials compare an active treatment to a placebo. 
No patient is denied treatment in a clinical trial if there is a standard therapy 
available that could improve the comfort and survival of the patient. 
1.3.6 Who can participate in a clinical trial?  
(http://www.biotechmedia.com/definitions-c.html) 
Clinical trials include people of various ages and ethnic groups and both 
genders as much as possible, so that the results can apply to the general 
population. Each clinical trial, however, is unique in its eligibility criteria (rules 
for who can and cannot participate). Examples of criteria include sex, age, 
type of disease, severity of disease, and history of prior treatment. If a disease 
is being studied in a trial, participants must have a similar degree of illness, so 
that there is a good chance they will respond in similar ways to the treatment 
being studied. 
1.3.7. Are there protections for people who participate in clinical trials? 
(http://www.biotechmedia.com/definitions-c.html) 
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Yes, the Federal Government requires many protections for people who 
participate in federally funded clinical trials. Before a clinical trial can start, the 
written protocol must be approved and monitored by an Institutional Review 
Board (IRB). An IRB is an independent group of health care providers, other 
experts, and lay people from the community who make sure that the study is 
set up and run safely and fairly. IRBs review protocols and the consent 
documents that people must sign in order to participate in a clinical trial. 
Participants are also protected by a process called informed consent. If you 
are considering taking part in a clinical trial, during this process you will meet 
with a member of the research team. He or she will provide you with key facts 
about the study, such as: 
  Who is sponsoring and conducting the research. 
 Who has reviewed and approved the study. 
  What the researchers want to learn. 
  How the research team will monitor your health and safety. 
 What participants will be required to do during the trial, and for how 
long. 
 Possible benefits and risks of participating. 
  Other treatments that are available for your disease or condition. 
  How the privacy of your medical records will be protected. 
You have a right to have all your questions answered. If you do not 
understand an answer you receive, ask again. It can be helpful to make a list 
of questions and concerns before you talk to the study team. 
The staff will also give you a consent form, an agreement that you will sign if 
you decide to join the trial. Consent forms can be long, and they contain a lot 
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of information. It is a good idea to take the consent form home, so that you 
can think about it and review it with family members or friends. If you have an 
interest in joining a study, it is also very helpful to discuss it with your health 
care practitioner and others whose advice you trust. 
Participating in a clinical trial is completely voluntary. You can leave the trial at 
any time, for any reason even after you have signed the consent form. 
1.3.8. What happens once a clinical trial starts?  
(http://www.biotechmedia.com/definitions-c.html) 
The research team will check the participant‘s health at the beginning of the 
trial, give specific instructions for participating, and monitor their health 
carefully during the trial. Participants may be required to do some things 
between appointments, such as take medication according to a schedule or 
make a phone call to report their experiences. 
Clinical trials take place in a variety of settings, depending on the type of trial 
and what is being studied. For example, participants in a trial of an herb might 
follow the protocol at home, while a trial that involves specialized equipment 
(such as acupuncture) might be carried out in a clinic or other health care 
setting. Still other trials may require participants to be in a hospital, clinic, or 
research center while the therapy is given. 
1.3.9. What happens after a clinical trial ends? 
(http://www.biotechmedia.com/definitions-c.html) 
The researchers carefully analyze the data from the trial. Then they conclude 
about their findings and decide whether further testing is required or not. If the 
trial is completed, the results have medical importance, they usually report the 
results first in a peer-reviewed medical journal (―peer reviewed‖ means that 
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each report is reviewed before publication by a group of experts in the same 
field). A new treatment which is found safe and effective in a carefully 
conducted clinical trial become new standard practice. The results of clinical 
trials are given to the participants after its completion.  
1.3.10. What are the possible benefits of being in a clinical trial?  
(http://www.biotechmedia.com/definitions-c.html) 
 You will receive expert medical care. 
 Your health will be closely watched throughout the study. 
 Clinical trials can be one treatment or prevention option for a disease 
or condition. 
  In some types of trials, you may be among the first to get benefit from 
a new treatment or get new knowledge about a current treatment. 
 You can motivate others to take part in the clinical trial or to be treated 
in the clinical trial.  
1.3.11. What are the possible risks in a clinical trial? 
(http://www.biotechmedia.com/definitions-c.html) 
There are some risks for being in a clinical trial, as they are treatment with any 
other illness in a clinical trial: 
  The treatment under study does not always turn out to be better than, 
or even as good as, standard treatment.  
  The treatment may have side effects which are not known to the 
researchers. 
  If you are in a randomized trial, you may be assigned to the control 
group, where you may not receive the drug but you may receive 
placebo treatment. 
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 Participation may require more tests and more visits or treatments than 
regular care. 
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OBJECTIVE 
2.1 Aim of the present work: 
 To study different effects of Phyllanthus amarus in the patients of 
jaundice. The plant is described in Ayurveda and is proven 
pharmacologically for the hepatoprotective activity. 
 To study different effects of treatment of the marketed polyherbal 
formulation containing Phyllanthus amarus in patients with jaundice.  
 Compare the effects of Phyllanthus amarus and its market formulation 
in the patients of jaundice.       
2.2 Plan of the work: 
 Collect the plant Phyllanthus amarus. Confirmation of its identity by the 
government authority and comparing its morphological and 
microscopical characters with the published literature.  
 Drying, powdering and storage of the collected drug.  
 Determination of quality of the powder drug by determining its water 
soluble extractive value, alcohol soluble extractive value, ash value, 
acid insoluble ash value and water soluble ash value. 
 TLC study of the powdered drug and comparison with the published 
literature to determine the quality.     
 To form ethical committee to surprise protocol and condition of patients 
etc. To explain importance of this medicine, regarding different tests 
and importance of this study to the patients.   
 Confirming the hepatoprotective activity (Ayurvedic claim) of the 
powder of Phyllanthus amarus by giving it to the patients with jaundice 
and determining their biochemical markers like SGPT, bilirubin at 
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different time interval. Also to study effect of this herb on other 
biochemical parameters like Haemoglobin, Urine sugar, Creatinine, etc.  
 To study effects of different marketed polyherbal formulations 
containing Phyllanthus amarus on the patients having jaundice by 
determining different biochemical markers like SGPT, bilirubin, 
haemoglobin etc. 
 Comparison of the activity of Phyllanthus amarus and its marketed 
formulations.  
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REVIEW OF LITERATURE 
 
3. 1 Phyllanthus amarus. 
A genus of herbs or undershrub chiefly distributed in tropical and subtropical 
regions of the world.  About 24 species occur wild in India (Wealth of India, 
1969) but very few have been used in medicine.  
Synonyms: Phyllanthus niruri Avet non L. 
Phyllanthus amarus Schum & Thonn (Kirtikar and Basu, 1933; Thakur et al., 
1989; Wealth of India, 1969). 
 
Fig. 3.1 Plant of Phyllanthus amarus 
3. 1. 1 Introduction  
Common Name (Kirtikar and Basu, 1933; Thakur et al., 1989; Wealth of 
India, 1969) 
Bengali : Bhuiamla, Sadahazurmani 
Gujarati : Bhony aanmali  
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Hindi  : Jaramla, Jangli amli 
Malayalam : Kizhanelli, Kilarnelli 
Marathi : Bhuiavali 
Oriya  : Bhuin amla, Badianla 
Sanskrit : Bhumyamalaki , Bahupatra, Bahuphala, Bahupushpi 
Tamil  : Kilaneli, Kilakkainelli 
Telugu : Nela usirika 
Biological Source: Drug consists of dried whole plants of Phyllanthus 
amarus (Fam. Asteraceae). 
Scientific Classification (Bagchi et al., 1992) 
Kingdom : Plantae 
Division : Angiospermae 
Class  : Dicotyledoneae 
Order  :Tubiflorae 
Family : Euphorbiaceae 
Genus : Phyllanthus 
Part Used : Leaves, Flowers, Whole plants 
Geographical Source: (Kirtikar and Basu, 1933; Thakur et al., 1989; Ross, 
1999) Probably native to America but found throughout India and almost all 
tropical countries.  
3.2. MACROSCOPIC: (Ayurvedic Pharmacopoeia, 2001; Patel, 2000) 
A herb that grows upto 10-60 cms tall, erect, Stem terete, younger 
parts rough, cataphylls 1.5-1.9 mm long, deltoid acuminate. Leaf: 3.0-11.0 x 
1.5-6.0 mm, elliptic oblong to obvate, obtuseor minutely apiculate at apex, 
obtuse or slightly in equilateral at base. 
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Flowers axillary, proximal 2-3 axils with unisexual 1-3 male flowers and all 
succeeding axils with bisexual cymules. Male flowers-pedicel 1mm long, calyx 
5, sub equal 0.7 x 0.3 mm, oblong, elliptic, apex acute, hyaline with 
unbranched mid rib; disc segments 5, rounded, stamens 3, filaments connate. 
Female flowers-pedicel 0.8-1.0 mm long, calyx lobes 5, 0.6 x 0.25 mm, ovate-
oblong, acute at apex; disc flat deeply 5 lobed, lobes often toothed at apex, 
styles 3, free, shallowly bifid at apex. Capsule 1.8 mm in diameter, oblate and 
rounded. 
 Seeds about 0.9 mm long, triangular with 6-7 longitudinal ribs and many 
transverse striations on the back  
Medicinal uses (Kirtikar and Basu, 1933; Wealth of India, 1969;  Sivarajan et 
al., 1994): 
Whole plant is bitter, stomachic and medicinal. The drug is highly 
reputed as a single drug remedy in the treatment of jaundice in traditional 
medicine (Joshi et al., 1996; Indian Herbal Pharmacopoeia. 1999; Prakas et al 
1995: Asha et al 1998). It is carminative, styptic, astringent, cooling and used 
in cough and indigestion. It is also used in diabetes. It is also much used as a 
diuretic in dropsial affections, gonorrhoea and other troubles of the genito-
urinary tract. An infusion of the young shoot is given in dysentery. The 
powdered leaves and roots are made into poultice with rice-water and used to 
lessen the oedematous swelling and ulcers. 
The fruit is bitter, useful for tubercular ulcers, wounds, sores, bruises, 
scabies, ringworm etc. (antifungal, antibacterial activity) and the fresh root is 
said to be an excellent remedy for jaundice. In the Konkan, the root rubbed 
down with rice water is given as a remedy for menorrhagia. 
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Leaves are stomachic; juice is a good application to offensive sores. A 
poultice of the leaves with salt cures scabby affections (antifungal action) and 
without salt may be applied to bruises (antibacterial action) etc. The leaves 
are boiled and the liquor is drunk to stop acute pains in the stomach. The 
chief use of the plant is to allay griping in cases of dysentery. 
Kirtikar and Basu has also proved the efficacy of the plant in the case 
of paroxysm, where tincture was made up from whole plant and two drachms 
was given in the morning. Sometimes the dose was repeated, which acted 
upon the bowels as a slight purgative and was very useful in inveterate 
intermittents with infarcts of the spleen and liver. (Kirtikar and Basu, 1933) 
The infusion of the root and leaves is a good tonic, and a diuretic when 
taken cold in repeated doses. 
3.3. Microscopic 
3.3.1. Lamina in surface view (Lower surface) (Patel, 2000) 
The cells of both the epidermis are polygonal and wavy in outline, the 
lower being more wavy than the upper one. Three types of stomata are 
present; paracytic, anomocytic and anisocytic, the later being more frequent. 
It shows clusters and prisms of Ca-oxalate in the mesophyll cells, palisade 
cells and vein. Trichomes are absent on both the surface Average stomatal 
index of lower epidermis is 25, palisade ratio is 12 and vein islet number is 22. 
Chapter 3  REVIEW OF LITERATURE  
 
 
47 
 
Fig: 3.2 Lamina of P. amarus in surface view (Lower surface) 
3.3.2. Transverse section of the leaf passing through midrib (Patel, 2000) 
The leaf is a dorsiventral, a layer of palisade cells being present below 
the upper epidermis. It is discontinuous over the midrib. The cells of both the 
epidermis are tabular a shape, devoid of trichomes and are covered with thin 
cuticle. A small collateral vascular bundle consisting of few spirally thickened 
xylem vessels and parenchymatous phloem lies in the center of the midrib. 
Occasionally few parenchymatous cells lying below the upper epidermis in the 
midrib region become thick walled and lignified. The spongy parenchyma of 
lamina and midrib contain clusters of Ca-oxalate, while the palisade cells 
contain prisms of Ca-oxalate. 
Lots of controversial reports are found to be existing regarding the 
types of Ca-oxalate crystals in the leaf and the types of stomata. (De et al., 
1990) have mentioned the presence of rosettes and few prisms in the leaf 
while Indian Herbal Pharmacopoeia vol560 –II (HP-II) has mentioned the 
presence of clusters in the leaf and (Bagchi et al., 1992) have not mentioned 
this content at all. In fact both clusters and prisms of Calcium oxalate crystals 
are found in the leaf. 
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The presence of paracytic and sometimes anomocytic types of stomata 
have been reported by (De et al., 1990) while anisocytic type by (Bagchi et al., 
1992) and anisocytic and paracytic type by (IHP, 1999). In fact the leaf 
contains many anisocytic stomata and few paracytic and anomocytic. 
 
Fig: 3.3 T.S. of P. amarus leaf through midrib.  
3.3.3. Transverse section of the stem (Patel, 2000) 
The transverse section of the stem is circular in outline, and show wide 
central pith encircled by the ring of xylem, phloem and groups of 
discontinuous pericyclic fibres, cortex is very narrow. 
The cells of the epidermis are tabular in shape and are covered with 
thin cuticle. Cortex is made up of 5 to 10 layers of parenchyma, the outermost 
2 to 3 layers are collenchymatous. The cells of cortex contain cluster and 
prisms of Ca-oxalate crystals, chloroplasts, tannin and starch grains. The cells 
of endodermis are quite big in size and contain starch grains. Pericyclic region 
is characterized by groups of 10 to 20 thick-walled lignified fibers forming a 
discontinuous ring. Phloem is made up of sieve tube companion cells and 
parenchyma containing Ca-oxalate cluster and prisms and tannin. Xylem is 
made up of xylem vessels, isolated or in groups, annular thickened, arranged 
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in radial rows; trachieds, fibres, parenchyma and medullary rays. The 
parenchymatous cells of the pith contain clusters and prisms of Ca-oxalate 
and simple starch grains. 
The controversial aspect regarding the presence of Ca-oxalate crystals 
is noticed in stem also. (De et al., 1990) have mentioned the presence of 
rosettes and prisms of Ca-oxalate crystals while (Bagchi et al., 1992) the 
cluster and (IHP, 1999) has not mentioned anything regarding Ca-oxalate 
crystals. Contrary to these earlier finding, infact the parenchymatous cells of 
the stem contain clusters and prisms of Ca-oxalate. Beside this (De et al., 
1990) and (IHP, 1999) do not mention anything about the tannins content 
also, which are found to be abundant in the parenchymatous cells of the stem. 
Regarding the thickening of xylem vessels, (De et al., 1990) have mentioned 
bordered pitted thickening and (IHP, 1999) has mentioned pitted thickening, 
which is infect not found, instead it shows annular thickening. 
 
Fig: 3.4 Diagrammatic T.S. of stem of P. amarus. 
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Fig: 3.5 Detail T.S. of stem of P. amarus. 
3.3.4. Transverse section of the root (Patel, 2000) 
Transverse section of the root is circular in outline with central lignified 
wood occupying more than 2/3 area of the root. Cortex and phloem are 
narrow. 
In the young root, outermost region is occupied by a layer of epidermis 
but in older roots 2-3 layers of cork cells containing tannins are seen. Cortex 
is parenchymatous contains simple starch grains and tannin. Inner cortex is 
characterized by the presence of lignified sclerides isolated or in groups of 2-
5. In L.S. their walls appear irregularly projected. The phloem is 
parenchymatous. Xylem is composed of radially arranged xylem vessels with 
bordered pitted thickening. Xylem fibres are thick-walled; parenchyma and 
medullary rays which are usually biserriate contain starch grains. 
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Fig: 3.6 Diagrammatic T.S. of root of P. amarus. 
 
 
Fig: 3.7 Detail T.S. of root of P. amarus. 
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3.3.5. Powder study of the P. amarus herb: (Patel, 2000) 
It shows the surface characters of leaf, stem, root and seed. The 
diagnostic important characters of the powder are: 
Leaf : As described in 3.3.1 and shown in fig 3.2, it shows the surface 
characters of lamina like annular thickened xylem vessels, clusters and 
prisms of Ca-oxalate crystals; anisocytic, paracytic and anomocytic  stomata. 
Stem (fig 3.8a to 3.8d): It shows prisms and clusters of Ca-oxalate and tannin 
containing cells of cortex (3.8a) and phloem (3.8b); groups of pericyclic fibres 
(3.8c) and annular thickened xylem vessels (3.8d). 
Root (fig3.8e to 3.8g): It shows polygonal brownish cells of cork (3.8e), 
sclerides of cortex (3.8f), and bordered pitted xylem vessels along with thick-
walled xylem fibres (3.8g). 
Seed (fig 3.8h): It shows thick-walled rectangular lignified cells of testa. 
Commercially the powder of P. amarus is available and hence it’s 
microscopically evaluation becomes the important criteria for its correct 
identification but the microscopically character reported earlier appears to be 
very scanty e.g. no body has mentioned the testa of the seed which is 
frequently found in the powder. The mesophyll cells of leaf containing Ca-
oxalate crystals have also not been reported. The other characters which are 
missing are the cortex and phloem cells of the stem filled with tannin. 
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Fig: 3.8 Powder of P. amarus herb. 
3.4. Ethnomedical uses.  
Different parts of the plant are used by the traditional people in different 
countries for various ailments. In India, it is mainly used in jaundice, pyrexia, 
veneral diseases, eye disease, skin disease, diabetes etc. The plant has more 
or less similar uses in the other parts of the world which are mentioned below; 
name of place and parts of plants are mentioned in the bracket. 
3.4.1. Antiasthamatic: Decoction (Hb-India) is used orally. (Sircar, 1984) 
3.4.2. Anti diabetic: Decoction (Sd and Ft- Brazil; Hirschmann et al., 1990) or 
Hb- India (Jain et al., 1967), East Indies (Dragandorff, 1898), and West Indies 
(Aspray et al., 1955) or Lf-India (Hukeri et al., 1988) are taken orally. 
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3.4.3. Antidiarrhoeal and antidysenteric: Powder of young shoot (Orrisa 
India; Reddy et al., 1989) or decoction of the fresh shoot are used to orally in 
the treatment of dysentery (India; Hukeri et al., 1988): Decoction (Ar- India; 
Gupta et al., 1993) or Lf- Papau New Guinea; Holdsworth et al., 1992) are 
used orally in the treatment of diarrhea. Infusion of dried leaves is 
administration orally for treatment of diarrhea and dysentery (Fiji; Singh, 
1986).  
3.4.5. Antiinflammatory: Decoction (Hb- Thailand) is administered orally as 
an anti inflammatory. (Wasuwat, 1967) 
3.4.6. Antimalarial: Decoction (Hb- Thailand; Kitisin, 1952) and Hb-West 
Indies (Aspray et al., 1955) are used orally.  
3.4.7. Antipyretic: Decoction (Hb- Thailand; Kitisin, 1952: Mokkhamit et al., 
1971), Haiti (Weninger et al., 1982), Bohmianisland (Halbertstein et al., 1978) 
and Fiji (Singh, 1986), Ar- Puerto Rico (Loustalot et al., 1949) and Lf- 
Dominican Republic (Ricardo, 1944) are used orally, the leaf decoction is 
taken orally and is also used for bathing as an antipyretic (Haiti, French 
Guiana; Weniger et al.,1986). Decoction (Lf- India) is administered orally in 
fever (Krishnamurthi et al., 1946). 
3.4.8. Antiseptic: Fresh juice of leaf is applied externally on cuts and wounds 
(Fiji; Singh, 1986). Decoction of dried entire plant is used to bath newborns. It 
removes disease causing elements from the skin (Philippines; Velazco, 1980). 
3.4.9. Cholagogue: Decoction (Lf- French Guiana; Luu, 1975) is administered 
orally. 
3.4.10. Cough treatment: Decoction (Hb- Philippines; Velazco, 1980) is used 
orally for cough in infants. 
Chapter 3  REVIEW OF LITERATURE  
 
 
55 
3.4.11. Diuretics: Decoction (Ar- India; Ogata et al., 1992) and Hb- E. Africa 
(Stanilas et al., 1967), Thailand (Kitisin, 1952), Peru (Remirez et al., 1988) 
and West Indies (Halbertstein et al., 1978) are used orally. 
3.4.12. Emetic: Decoction (Lf- Mexico; Schulters, 1969) is taken as a strong 
tea. 
3.4.13. Eye disease: People (Kondh tribe, Orrisa; Girach et al., 1994) use 
drop of plant juice to treat conjunctivitis. Plant juice mixed with castor oil is 
applied to the eyes (Fiji; Singh, 1986).  
3.4.14. Gall stone: Decoction (Hb- Peru; Kitisin, 1952) is administered orally. 
3.4.15. Genitourinary disorders: Fresh plant juice is taken orally for genito-
urinary troubles (India; Sahu, 1984). 
3.4.16. Jaundice: 
 People (Kani tribe, Keala; John, 1984) taken paste of the plant with 
cow’s milk for 3 days to cure jaundice.   
 Traditional healers (Chittoor district, A. P; Reddy, 1988: Reddy, 1989) 
prepare a paste of leaves with few pieces of Allium sativum, Piper 
nigrum fruits and buttermilk. The paste is given orally for seven days 
for the treatment for jaundice. 
 Traditional people used decoction (Rt- Brazil; Sircar, 1984) or fresh Ar- 
India (Hukeri et al., 1988) orally for the treatment of jaundice. Dried 
entire plant is churned with buttermilk and is used orally (Fiji; Singh, 
1986) for the purpose. 
3.4.17. Viral hepatitis: Herbalists (Anantapur district, A.P; Reddy et 
al.,1989) make small pills (size of Ziziphus mauritiana seeds) from powder 
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of P. amarus, cardamom and pepper with the help of tamarind juice. One 
pill per day is given orally to treat viral hepatitis. 
3.4.18. Laxative: Traditional people use orally decoction (Hb- Bahamian 
Island; Halberstein et al., 1978). 
3.4.19. Menstrual regulation:  
 People use decoction (Hb –Argentina; Moreno, 1975), Phillipines 
(Holdsworth et al., 1982) as an emmenogogue. 
 Decoction (Hb- East Indies; Dragandorff, 1898) is administered orally 
for menstrual troubles. 
 Decoction of the leaves is given orally after a miscarriage; it is also 
used as emmenogogue (Burkhill, 1966).  
3.4.20. Ring worm: Fruits are used externally (India; Chauhan, 1977). 
3.4.21. Scabies: Fruits are used externally (India; Chauhan, 1977). 
3.4.22. Sores: The herbalists (Anantapur district, A.P; Reddy et al., 1989) 
Apply juice of the plant externally for offensive sores. 
3.4.23. Spasmolytic: Hot water extract of the entire plant is administered 
orally (Haiti, French Guiana; Weniger et al., 1986). 
3.4.24. Stomachic:  
 Decoction of leaves (India; Chauhan, 1977) and herb (Virgin island; 
Oakes et al., 1958) are used orally. 
 Decoction of roots of P. niruri and Citrus aurantifolia are mixed and 
taken orally to increases the appettite (West Indies; Aspray et al., 
1955). 
3.4.25. Tonic: Decoction (Hb- East Indies; Dragandorff, 1898) and Fiji 
(Singh, 1986) is taken orally. 
Chapter 3  REVIEW OF LITERATURE  
 
 
57 
3.4.26. Urinary calculi: 
 Infusion of dried leaves and stem is taken orally to treat kidney and 
bladder calculi (Brazil 1990). 
 Decoction (Hb- Peru; Kitisin, 1952) is administered orally for renal 
calculi. 
3.4.27. Veneral diseases:  
 People (New Ireland of Papua New Guiena) used orally the juice 
squeezed from the leaves or decoction of whole plant daily as per 
requirement to treat veneral diseases. They also chew the roots for the 
same purpose (Holdsworth et al., 1989). In Manns Island decoction of 
the bark and leaf is used to combat gonorrhoea (Holdsworth et al., 
1989). People of Admiralty Island also use hot water extract of dried 
bark and leaves twice a day orally (500 ml) up to six months to treat 
acute condition of veneral diseases. 
 Decoction (Hb- India) is administered orally for leucorrhoea (Jain, 
1989) gonorrhoea and urogenital tract infections (Hukeri,  et al., 1988). 
 Decoction (Hb- Tanzania) is used orally for gonorrhoea. 
3. 5. Pharmacognostical Review 
 Saha and Krishnamurthy (1959) have studied the Pharmacognosy of 
P. niruri (Saha et al., 1959). 
 Webster (1957) has reported revision of the taxonomy of the genus 
Phyllanthus. He has shown that P. niruri is an entirely American 
species, found in West Indies. The other three closely related species 
are reported from India viz. P. amarus, P. debilis and P. fraternus. 
Chapter 3  REVIEW OF LITERATURE  
 
 
58 
 Mitra and Jain (1985) have described the concept of P. niruri. Their 
studies have also revealed that P. niruri in ‘Flora of British India’ in a 
mixture of three distinct species viz. P. amarus Schum and Thonn, P. 
fraternus Webster and P. debilis Klein ex. Willd. They have given a key 
to identify these species and also given their detail description in Table 
no 3.1 (Mitra et al., 1985). 
Table 3.1: Comparative macroscopic characters of three Phyllanthus species 
Sr. 
no 
Phyllanthus amarus  Phyllanthus 
fraternus 
Phyllanthus 
maderaspatensis 
1 Plant 10–60 cm tall Plant 7–50 cm tall Plant 30–90 cm 
long 
2 Stem terete, younger 
part rough 
Stem terete, mostly 
naked below and 
tetragonous above 
Stem glabrous 
 
3 Branchlet 2–6 cm long 
with 10–20 leaves  
 
Branchlet 2–11 cm 
long with 10–30 
leaves 
Branchlet absent 
4 Leaf elliptic, oblong to 
ovate, obtuse or 
minutely apiculate at 
apex 
 
Leaves elliptic, 
oblong, rounded at 
the apex 
Leaves, rounded 
truncate or 
somewhat 
obcordate at the 
apex, mucronate, 
much tapering into 
a very short petiole 
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5 Flowers axillary, 
proximal two to three 
axils with unisexual 
one to three male 
ﬂowers and all 
succeeding axils with 
bisexual cymules 
Flowers in axillary, 
unisexual cymules 
proximal three to 
four male ﬂowers, 
succeeding solitary 
female ﬂowers 
 
Flowers axillary, 
male ﬂowers 
minute in small 
clusters, 
subsessile female 
ﬂower solitary and 
larger with shortly 
stalked 
6 Sepals five Sepals six Sepals six 
 
 Joshi (1996) has mentioned the characters to distinguish P. fraternus 
from P. amarus; they   have 6 and 5 sepal’s respectively.  
 Bagchi et al. (1992) have reported morphological and microscopical 
characters of four species of Phyllanthus viz. P. amarus, P. fraternus, 
P. urinaria and P. virgatus. They have compared microscopical 
characters of leaf, branch, stem and root. A key also given to identify 
these four species.  
 Blumeberg et al. (1991, 1993) have reported that these plants can be 
cultivated without loss in the activity. 
 Choudhary et al. (1998) have reported that seeds shown in April, 
Plantlets transplanted in May and herb harvested in September gives 
maximum yield of leaves as compared to harvesting in October, 
November and December. Sowing the seeds in May or June, 
transplanting the plantlets in June and July and harvesting from Sep to 
Dec. also give low yield of leaves. However, yield of leaves in 
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September is maximum. Leaves are rich in the active constituent 
(Phyllanthin and Hypophyllanthin), so they should be more when the 
herb is harvested.  
 Indian Herbal Pharmacopoeia, Vol. II (1999) has described morphology 
of the herb; microscopical character of powdered leaf, stem and fruit; 
extractive and ash value of the aerial parts. 
3.6. Chemical Constituents: 
Various types of chemical constituents have been isolated from P. 
amarus, either under the name of P. niruri or P. amarus in India and outside 
India. Lignans, phyllanthin and hypophyllanthin and triterpene, triacontnal are 
reported to be hepatoprotective constituent of the plant (Syamasundar et al., 
1985). Besides Lignans, it is also reported to contain various flavenoids, 
alkaloids, tannis, sterols, triterpenoids, aliphatic diterpene and triterpene 
derivatives etc. 
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Phyllanthin (a bitter principle) and hypophyllanthin (a non bitter principle) 
where isolated by Krishnamurthy and Seshadri (1946), their structures were 
not assigned (Krishnamurthy et al., 1946). Row et al. (1964, 1966, and 1967) 
have established the structures of phyllanthin and hypophyllanthin. (Row, et 
al., 1964: Row, et al., 1966: Row, et al., 1967). Structure of hypophyllanthin 
was proposed and revised several times (Row, et al., 1964: Row  et al., 1966:  
Subha Rao, et al., 1971: Bhadbhade et al., 1980: Sureshpure et al., 1981) 
and was established finally by Somanbandhu et al. (1993). Following 
constituents have been reported from the plant.  
Lignans: Phyllanthin (Krishnamurthy et al., 1946: Row et al., 1964: Row et al., 
1966: Row et al., 1967: Somanabandhu et al., 1993: Huang et al., 1992:  Nara 
et al., 1977: Sharma et al., 1993), hypophyllanthin (Krishnamurthy et al., 
1946: Row et al., 1964: Row et al., 1966: Row et al., 1967: Subha Rao et al., 
1971: Bhadbhade et al., 1980: Sureshpure et al.,1981:  Somanabandhu et al., 
1993: Rao et al., 1970: Huang et al., 1992: Nara et al., 1977: Sharma et al., 
1993), nirtetralin (Sureshpure et al., 1981: Stevenson et al., 1977: Singh et al., 
1986), lintetralin (Stevenson et al., 1977: Huang et al., 1992: Singh et al., 
1986), phylltetralin (Sureshpure et al.,1981: Stevenson et al., 1977: Singh et 
al., 1986), niranthin (Huang et al., 1992: Singh et al., 1986), seco-4-hydroxy 
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lintetralin, seco-isolariciresinol trimethyl ether; hydroxy niranthin, dibenzyl 
butyrolactone.(Satyanarayan et al., 1988), nirphyllin, phyllnirurin (Singh et al., 
1989, isolintetralin (Huang et al., 1992), niruriside (Cutrone et al., 1996) etc.;  
Flavonoids: Quercetin, quercetrin, isoquercetrin, astragalin (Nara et al., 1977), 
rutin (Nara et al., 1977: Foo et al., 1993: Agrawal et al., 1991), quercetin-3-O-
glucopyranoside ( Foo et al., 1993), kaempferol-4-rhamnopyranoside, 
eriodictyol-7-rhamnopyranoside (Chauhan J. S. et al.,1977), nirurin (Gupta D. 
R. et al., 1984) (a prenylated flavonoid), fisetin-4-glucoside.(Gupta et al., 
1984) and 3, 5, 7, 4,-tetrahydroxy flavone (Agrawal et al.,1991). 
Alkaloids: Ent-nor securinine (Rouffiac et al., 1969: Joshi et al., 1986), 4-
methoxy securinine(phyllanthin), 4-methoxy nor securinine, 4-methoxy 
dihydrosecurinine, 4-methoxy tetrahydrosecurinine, 4-methoxy 
securinine,securinol A, securinine B, securinine, dihydrosecurinine, tetrahydro 
securinine, allosecurinine, nor securinne (Hassarajani et al., 1990), 
isobubbialine and epibubbialine (Houghton et al., 1996) 
Tannins: Geraniin (Foo, 1993: Veno et al., 1988), gallic acid( Veno et al., 
1988), ellagic acid (Veno et al., 1988, phyllanthusiin-D.(Foo et al., 1992), 
amariin, corilagin, 1, 6-digalloyl glucopyranoside (Foo , 1993) and amiriinic 
acid.(Foo et al., 1995) Triterpenes: Lupeol, lupeol-3-acetate (Chauhan et al., 
1979), 7-lupeol, α-amyrin (Agrawal et al., 1991).  
Euphane Triterpenoids: Phyllanthenol, phyllanthenone and phyllantheol 
(Singh et al., 1989) 
Sterols: Β-sitosterol and isopropyl cholesterol (Singh et al., 1986). 
Steroidal hormone: Estradiol (Mannan et al., 1978) 
 Acyclic diterpene: Trans-phytol (Singh et al., 1991) 
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Acyclic triterpenes: Triacontanal, triacontanol (Syamsunder et al., 1985), 32-
methyl-1-triacontanol. (Agrawal  et al., 1991), dotriacontanoic  acid (Singh et 
al., 1986), Phthalic acid bis-ester: Phyllester (Singh et al., 1986). 
Miscellaneous: Vitamin C (Sinha et al., 1984), ricinoleic acid, linoleic acid and 
linolenic acid (Ahmed et al.1981). 
3.7. Pharmacological review: 
 Phyllanthus amarus is reported to have varieties of activities from 
various types of extracts prepared from its different parts using different 
solvents. It is reported to have hepatoprotective, antihepatitis B, anticancer, 
antihypertensive, antinociceptive, antifungal, contraceptive, diuretic, 
hypoglycaemic, hypotensive etc. activities. The literature survey of all these 
activities are separately mentioned below: 
3.7.1. Anticancer activities: 
 Dhar et al. (1968) have reported that ethanol: water (1:1) extract was 
active when administered (i.p) to mice on LEUK (Friend Virus solid). 
However the extract was inactive on CA-9KB at ED50 > 20.0 mcg/ml. 
 Macrae et al. (1988) have reported the activity of the ethyl acetate and 
aqueous fraction of methanolic extract of aerial part (Amazon). The 
EC50 value is 0.05 and 1.31 μg/ml against Agrobacterium induced 
tumour. 
 Srinivasulu (1992) has reported that phyllanthin and hypophyllanthin, 
lignans constituents of P.niruri when tested on various cancer cell lines, 
did not show significant cytotoxic effect on any cell line. Phyllanthin 
showed modest inhibition on small cell lung line and hypophyllanthin on 
CNS cancer line640. However dibenzyl-butyrolactone which is also 
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present in P.niruri is reported to exhibit antitumor activites. (McDoniel 
et al., 1972). 
 Somanabandhu et al. (1993) have reported that neither phyllanthin nor 
hypophyllanthin demonstrated significant cytotoxic activity when 
cultured with battery of cultured mammalian cells, but both were found 
to enhance the cytotoxic response mediated by vinblastine with 
membrane vesicles derived from these cell line, suggesting the 
interaction with the P- glycoprotein.. 
3.7.2. Anticlastogenic activity: 
 Dhir et al. (1990) have found that oral administration of aqueous extract 
of P. niruri leaves to mice for a week; significantly reduce the cytotoxic 
action of lead nitrate and aluminium sulphate. The frequency of 
chromosomal breakage, gaps and rearrangement induced by three 
concentrations of these salts was decreased when compared to control 
animals which had received the salts alone. The extract was given at 
the dose of 685 mg of leaf per kg body weight. It was effective in 
modifying the clastogenic effects of both the salts. Same group of 
workers have also reported similar results for the protection afforded by 
the aqueous extract of P. niruri at the same dose level against toxicity 
produced by three different dose of nickel chloride on mice. (Agrawal et 
al., 1992). 
3.7.3. Antihepatotoxic activity.  
 Syamsunder et al. (1985) have shown the significant antihepatotoxic 
activity of the hexane extract of the plant in rat hepatocytes intoxicated 
with CCl4. The individual isolates of the extract, phyllanthin, 
Chapter 3  REVIEW OF LITERATURE  
 
 
65 
hypophyllanthin, triacontanal, and triacontanol were also tested 
separately in rat hepatocytes intoxicated with CCl4 and galactosamine. 
The former two compounds showed significant antihepatotoxic activity 
in these two models while triacontanal showed activity against later 
intoxicant only and triacontanol did not show significant activity in any.. 
 Naduveettil (1985) has also reported the activity of phyllanthin and 
hypophyllanthin, isolated from P. niruri and its extract (alcohol: water) 
through oral route on mice intoxicated with CCl4. Phyllanthin (100 
mg/ml) normalized the sleeping time of hexobarbitone, hypophyllanthin 
(20 mg/ml) was inactive and the extract (600 mg/kg) did not show 
significant activity.  
 Rao (1985) has shown that pretreatment with water extract of P. niruri 
orally 2ml/kg one month protected the liver of albino rats against CCl4 
toxicity. 
 Urmani et al. (1985) administered the powder of P. niruri orally for 45 
days (200 mg/kg) to ethanol induced fatty liver rats and studied its 
effect on the increased deposition of triglycerides, cholesterol and 
phospholipids of liver, heart and kidney. All of them were brought down 
to the normal value.  
 Murthy et al. (1993) have studied the effect of alcoholic extract of P. 
niruri on rats intoxicated with CCl4. It reduces the SGPT, SGOT, serum 
billirubin etc indicating its significant antihepatotoxic activity.  
 Prakash et al. (1995) have reported the effect of alcohol extracts of 
three spices of Phyllanthus against CCl4 induced hepatic damage on 
rats. The extracts of P. niruri, P. urinaria and P. simplex were 
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administered orally at three different dose level 100 and 400 mg/kg to 
the rats. Statistically significant reversal of the elevated serum levels 
were observed in the animals in P. niruri and P. urinaria extracts. 
Hepatoprotective activity of P. urinaria was about 60% in comparison 
with P. niruri, it may be consider as a substitute of P. niruri but P. 
simplex lacked in significant activity.   
 Sane et al. (1995) have compared the hepatoprotective activity of P. 
amarus and P. debilis on the rats intoxicated with CCl4. Slurry prepared 
from each of the whole plant powder was fed 0.66 mg/kg for 3 days, 
CCl4 was given on the first day. Study of serum enzyme levels and 
hepatocellular damage revealed that both the plants are effective in 
protecting the liver damage. P. debilis has more activity than P. 
amarus. (Macrae et al.,1988) 
 Subramanian (1995) has criticized the hepatoprotective studies of 
Sane et al. and pointed out some of the mistake in his calculations. He 
has suggested the following formula for finding out the 
hepatoprotective of the drug. 
 
3.7.4. Antihepatotoxic polyherbal formulations:  
 The pharmacological activity of antihepatotoxic polyherbal formulations 
have not been found to be much investigated. Reports of some of the 
formulations mentioned below are available. 
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 Sharma et al. (1991) have reported hepatoprotective activity of M-Liv 
against CCL4 induced toxicity in rats. (Subramanian et al., 1999). 
 Bhaumik and Sharma (1993) have studied the antihepatotoxic activities 
of a formulation consisting of mixture of equal proportion of P. niruri, 
Andrographis paniculata and Solanum nigrum. Sheep were intoxicated 
with paracetamol and subsequently administered 1.0 g/kg drug by 
gastric intubation daily for 10 days. The drug protected the animals 
from jaundice and increased AST, ALT etc. 
 Kapur et al. (1994) have reported hepatoprotective activity of Jigrine, a 
polyherbal formulation containing 14 medical plants, some amongst 
them being Phyllanthus niruri, Solanum nigrum, Cichorium intybus and 
Foeniculum vulgare. The effects of oral pretreatment with Jigrine (0.5 
ml and 1.0 ml/kg for 7 days) were studied on hepatic damaged induced 
by alcohol-carbon tetrachloride (40% alcohol 2.0 ml/100 g, p.o for 21 
days and CCl4 1:1 in groundnut oil,(o.1 ml/kg, S.C. on 20
th day ) and 
paracetamol (750 mg/kg i.p.) In rats. The study of biochemical 
parameters and histopathology confirmed its hepatoprotective activity.  
3.7.5. Antihepatitis B. Surface Antigen activity: 
 Mehrotra et al. (1990); (Thyagarajan et al., 1982) have reported in vitro 
inactivation of HBsAg by P. niruri extract. Four extracts were prepared 
separately from aerial parts and roots of the plants, by macerating at 
room temperature as well as by Soxhlet extraction 0.2 ml solution of all 
the four extracts (2% solution of dried extracts) incubated with 0.2 ml of 
HBsAg positive sera (1:64 CEP titre), brought about in vitro inactivation 
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of HBsAg within 24 hours at 37oC and also at room temperature. All 
these extracts contain a red pigment, which is active.  
 Venkateswaran et al. (1987) have reported in vitro and in vivo studies 
of an aqueous extract of P. niruri on hepatitis B and Woodchuck 
hepatitis B virus. The extract inhibits endogenous DNA polymerase of 
Hepatitis B virus and binds to the surface antigen of hepatitis B virus in 
vitro. The extract also inhibits Woodchuck hepatitis virus (WHV) DNA 
polymerase and binds to the surface antigen of WHV in vitro. In trials 
using six long term WHV-carrier Woodchuck, five treated animals 
showed a faster decrease in Woodchuck hepatitis virus surface antigen 
titre compared to untreated control. In animals recently infected with 
WHV, the extract was effective when administered i.p. in three out of 
four animals eliminating both the surface antigen titre and DNA 
polymerase activity in serum. The treatment was discontinued after 10 
weeks, and the treated animals have remained free detectable markers 
of WHV for more than 45 weeks. In contrast, three untreated controls 
remained positive for both markers for WHV for more than 45 weeks. 
One of the controls died after 8 weeks. In a third trial with long term 
carries, test animals treated subcutaneously with the extract for 12 
weeks did not respond; but on switching the mode of administration to 
i.p., two out of the five animals showed a significant decrease in 
Woodchuck hepatitis virus surface antigen titre compared to controls.  
 Venkateswaran et al. (1987) have also reported that both water and 
methanol extracts of the dried entire plant were active against 
woodchuck hepatitis virus at variable concentrations. They inhibited 
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DNA polymerase of woodchuck hepatitis virus; water extract afforded 
25% inhibition at 50 mg/ml concentration.  
 Jayram et al. (1989) have reported in vitro inactivation of the hepatitis B 
surface antigen by the crude extract of P. niruri in 48-72 hours. A red 
pigment was found to be active.  
 Mehrotra et al. (1990) have reported that alcoholic extract of P. niruri 
has in vitro anti HBsAg activity (68%) at a concentration ranging from 
1.6 to 2.6 mg/ml against 0.039 µg/ml HBsAg at 37oC after 24 hours 
incubation. HBsAg were collected from different type of patients, like 
patients with acute HBV infection, chronic carrier of HBV or having liver 
cirrhosis along with HBV.  
 Mehrotra et al. (1990) have also further studied in vitro effects of P. 
amarus on hepatitis B virus. Ethanolic extract of whole plant and 
subsequent fractions prepared from it, viz. hexane, chloroform, butanol 
and finally water were tested for in vitro effects on HBsAg, HBeAg and 
HBV- DNA in serum samples positive for HBV antigen. The extracts 
were effective against HBV antigens, the n-butanol extract being the 
most potent; its further fractionation showed enhance activity. The 
active fractions inhibited the interaction between HBsAg, HBsAg, and 
their corresponding antibodies suggesting anti-HBs, anti-HBe like 
activity and also an effect on HBV-DNA.  
 Unander et al. (1991) have studied in vitro activity of different species 
of  Phyllanthus against DNA polymerase of hepatitis viruses, effects of 
growing environment and inter and intra specific differences. 
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1) Aqueous extracts of several herbaceous species of Phyllanthus 
inhibited the endogenous DNA of hepadnavirues in vitro. This inhibitory 
activity varied among the pieces viz. P. urinaria, P. debilis, P. fraternus, 
P. mimics, P. odontadenius, P. caroliniensis, P. niruri etc. 
2) Within P. urinaria, there were highly significant differences among 
plants grown from seeds of diverse origin. Within P. amarus, plant from 
seeds of diverse origin did not differ significantly. 
3) One seed lot which was tested for intra-accession variability showed 
highly significant plant to plant differences in viral DNA polymerase 
inhibition, but these differences were not highly heritable. 
4) Differences in general fertility, soil moisture, PH or calcium generally 
did not significantly affected the in vitro inhibition of DNAp. 
5) Plant grown at low temperature (winter) showed decreased DNAp 
activity as compared to high temperature (summer) grown plants. 
6) Plants of P. amarus were successfully grown as a raw crop with 
fertilizers and irrigation without loss of activity relative to samples from 
the wild. 
7) Roots of P. amarus were more active than the herb.  
 Pousset et al. (1993) have reported in vitro inactivation of HBsAg by 
water and methanol extract of the dried leaves; IC50 for water extract 
was 3.3 mcg/ml and for later extract 1.2 mcg/ml. 
3.7.6. Anti HIV activity:  
 Ogeta et al. (1992) have shown that water extract of dried entire plant 
is active on HIV I virus; ID50 is 50.0 mcg/l.  
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 Hussain et al. (1995) studied that phyllanthin, hypophyllanthin and 
nirtetralin inhibit labeled ET1 binding receptor expressed in Chinese 
hamster ovary cells(CHO-ETA) but were inactive against the 
recombinant ETB receptors.  
 Cutrone et al. (1996) have isolated niruriside from the methanol extract 
of the plant. It inhibited HIV REV/RRE binding, the IC50 value was 
3.3μm.  
3.7.7. Antihypercholesterolemic activity (antihyperlipemic activity):  
 Urmani et al. have reported that dried entire plant was active in the rats 
in which fatty liver was induced with alcohol. The drug powder was 
given orally, 200 mg/kg for 45 days. It reduces the increases deposition 
of triglycerides, cholesterol and phospholipids in the liver, heart and 
kidney that resulted from alcohol treatment.  
3.7.8. Molliscidal activity: 
 Ahmed et al. (1984) have reported molluscidal activity of certain 
Sudanese plants. Successive petroleum ether extract and successive 
alcohol extract of P. niruri have molluscidal activity at concentration of 
25 ppm and 250 ppm respectively. These extracts produced 100% 
mortality in Bulinus trunctatus and Biomphakria pfeifferi. 
3.7.9. Nematocidal activity: 
 Kiuchi et al. (1989) have shown that decoction of commercial sample of 
bark, at a concentration of 1.0 mg/ml was active on Toxacare canis. 
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3.7.10. Antinociceptive activity:  
 Antinociceptive activity of P. niruri has been compared with number of 
other species of Phyllanthus found in China and America. These 
activities are mentioned below: 
 Analgesic effects of hydro alcoholic extract (HEs, 50% alcohol water) of 
P. urinaria, P. tenellus, P. niruri and P. sellowiarius have been 
investigated. The extract of four species of Phyllanthus (1-90 mg/kg, 
i.p.) caused a dose related inhibition of acetic acid induced abdominal 
constriction in mice with ID50 values of 5.4, 8.4, 18.2 and 53 mg/kg and 
maximum inhibition (%) of 80, 67, 63 and 50 for  P. urinaria, P. niruri, 
P. tenellus and P. sellowiarius. 
 In the formalin tests, the HEs of all Phyllanthus species (0.3-60 mg/kg, 
i.p.) caused graded inhibition of both the phases of formalin induced 
pain, but they were, however, more potent in relation to the second 
phase of the pain. The ID50 values (mg/kg) for the first phase were 20, 
23, > 60 and > 60 for P. urinaria, P. tenellus P. niruri and P. 
sellowiarius respectively. The ID50 value respectively and percentage of 
maximum inhibition were 63, 70, 41 and 33 with maximum inhibition 
percentage of 91, 97, 97 and 92 respectively. Given orally, the extract 
caused significant antinociceptive profile, but they were about one 
tenth to one twentieth as potent when given intraparitonially. However 
the HEs of Phyllanthus failed to affect formalin induced rat paw edema 
and did not completely reversed the analgesic effect of HEs of 
Phyllanthus. Further more; the HEs of Phyllanthus in contrast to 
Chapter 3  REVIEW OF LITERATURE  
 
 
73 
morphine had no analgesic effect in either tail-flick or hot plate tests 
(Santos et al., 1994). 
3.7.11. The antinociceptive activities are in following order: 
 P. urinaria > P. corcovadensis > P. tenellus > P. niruri > P. sellowiarius 
(Santos et al., 1994). 
 The methanolic extract of callus culture (grown on media containing 2, 
4 –D: IAA and IBA) of P. tenellus, P. corcovadensis and P. niruri have 
antinociceptive activity (3-90 mg/kg, i.p.). The extract caused graded 
inhibition of abdominal constrictions induced by acetic acid (0.6). ID50 
values are 30, 19 and > 30 mg/kg for P. corcovadensis, P. niruri and P. 
tenellus respectively (Santos et al., 1994). 
3.7.12. Anti pyretic activity.  
 Mokkhamit et al. (1972) have reported that ethanol: water (1:1) extract 
of commercial sample of entire plant, when administered at variable 
dosage levels by gastric intubation of rabbits was inactive against yeast 
induced pyrexia  
3.7.13. Antispasmodic activity.  
 Patel et al. (1965) has reported that phyllanthin, alcohol extract and 
aqueous extract has antispasmodic activity on rat’s duodenum against 
Ba-induced contraction. Activity of phyllanthin was more than alcohol 
and water extract  
 Dhar et al. (1968) have reported that ethanol: water (1:1) extract of 
entire plant was active on guinea pig ileum against acetyl chloride and 
histamine induced spasms. 
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 Santos et al. (1994) have reported that methanol extract of dried callus 
tissue at a concentration of 320.0 mcg/ml was inactive on guinea pig 
ileum against acetyl chloride induced contractions. 
3.7.14. Contraceptive effects: 
 Feeding an alcoholic extract of P. amarus to male mice at a dose of 
500 mg/kg for 45days, induced gradual inhibition of fertility potential. 
There was 72% reduction in the fertility, it reduced sperm count, sperm 
motility, sperm viability, weight of testis etc. it has no adverse effect on 
blood biochemical profile and cell count. Upon withdrawal of feeding 
the extract, the anti fertility effects were reversed gradually (Rao et al., 
1997). 
3.7.15. Diuretic activity:  
 Woers (1941) have reported diuretic activity of the plant  
 Patel et al. (1965) have also reported that aqueous extract of P. niruri 
is having significant diuretic activity on rats at the dose of 0.05 ml/kg (1 
ml extract = 1 g drug) through oral route. Alcohol extract has less 
activity and phyllanthin has feeble activity. 
3.7.16. Hypoglycaemic activity  
 Jain and Sharma et al. (1967) have reported that alcohol extract of 
entire plant is inactive in reducing blood sugar level at 10 mg/kg dose 
level through oral route in normal rabbits. 
 RamKrishnan et al.(1982) have reported that an aqueous extract of the 
leaves of P. niruri at a dose of 5 ml (representing 5 g leaf) per kg body 
weight, through oral route, lowered blood sugar level in normal and 
alloxan diabetic rabbits and the effects is more than that of tolbutamide 
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(250 mg/ kg p.o.). The extract also lowers blood sugar level even after 
the administration of glucose. 
 Hukeri et al. (1988) have reported that water extract of dried entire 
plant when administered by gastric intubation to rats, was active 
against alloxan induced hyperglycemia.   
 Moshi et al.(1997) have reported that aqueous extract of aerial parts of 
P. amarus (in Tanzania), 0.1 and 1 g/kg body weight, significantly 
enhanced clearance of glucose from the blood as compared to control 
during an oral glucose tolerance test, using normal fasted albino 
rabbits. Both dose had no effect on blood glucose in the unfed rabbits. 
Chlorpropamide, 0.1 g/kg body weight, has shown a greater effect than 
both dose, on glucose clearance in the fed state and on blood glucose 
on fasted rabbits. A methanol extract of the aerial parts, 1 g/kg body 
weight, worsened glucose tolerance causing a significant increase in 
glucose in blood, use of an aqueous extract tolerance causing a 
significant increase in glucose in the blood, use of an aqueous extracts 
as suggested by traditional healers appears to be the correct remedy. 
3.7.17. Hypoglycaemic activity – clinical trials:  
 Sivprakash et al. (1995) have carried out clinical studies of P. amarus 
on 25 diabetic patients in the age of group of 35-55 years with 
moderate to severe diabetic blood sugar level (250 – 400 mg/ 100ml). 
The drug brought down statistically significant lowering of blood sugar 
level at a dose of 1 g thrice a day for the period of 3 months. 
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3.7.18 Hypotensive, chronotropic and cardiotoxic activity:  
 Patel (1965) has reported that aqueous extract, alcohol extract and 
phyllanthin have hypotensive activity on dog. Phyllanthin is having 
maximum activity followed by alcohol and water extract. 
 Mokhamit et al. (1971) have reported that ethanol: water (1:1) extract 
of commercial sample of the entire plant was devoid of hypotensive, 
chronotropic or cardiotoxic activity at variable concentration through i.v. 
route.   
3.7.19. Diuretic, Hypoglycaemic and Hypotensive activity- Clinical trials: 
 Srividya and Periwal (1995) have carried out a clinical trial on nine mild 
hypertensive patients (four of them also suffering from diabetes 
mellitus). They were treated with 5 gm pellets (prepared from whole 
plant powder and honey) per day (orally) in three divided doses for 10 
days. After the treatment there was a significant increase in 24 hour 
urine volume, urine and serum sodium levels. There was also a 
significant reduction in systolic blood pressure in non- diabetic 
hypertensive and female subjects. There was also reduction in blood 
glucose levels (5 to 50 mg/10 ml) in both diabetic and non-diabetic 
subjects. 
3.7.20. Antibacterial activity: 
 Collier and Van (1949) have reported that saline extract of leaves was 
active on Pasteurella pestis and Staphylococcus aureus and inactive 
on Escherichia coli at a 10 % concentration using agar plate method. 
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 Khan et al. (1978) have reported that water extract of fresh entire plant 
of P. niruri was inactive on Neisseria gonorrhoea at 1.0% concentration 
on agar plate. 
 Khan et al. (1980) have reported antibacterial activity of alcoholic 
extract of P. niruri against Staphylococcus aureus and E. coli using 
filter paper disc assay method with 1 % solution of the extract for the 
assay. 
 Farouk et al. (1983) have reported that chloroform extract at a 
concentration of 1.0 gm/ml on agar plate was inactive on Bacillus 
subtilis, E. coli, Pseudomonas aeruginosa and Staphylococcus aureus. 
Methanol extract was active on Staphylococcus aureus but inactive on 
B. subtilis, E. coli and P. aeruginosa. 
 Macrae et al. (1988) have reported the activity of ethyl acetate and 
water fractions of methanol extract of aerial part (Amazon). The ethyl 
acetate fraction is inactive against E. coli and S. aureus while aqueous 
fraction is active against S. aureus but inactive against E. coli. 
 Macrae et al. (1988) have reported the activity of ethyl acetate and 
water fraction of the methanol extract of the aerial part (Amazon). Ethyl 
acetate fraction and aqueous fraction are active against Microsporum 
canis, M. gypseum and Trichophyton gallinae. Aqueous fraction is also 
against M. fulvum. 
3.7.21. Antifungal activity: 
 Bhatnagar et al. (1961) have shown that petroleum ether extract of 
whole plant has antifungal activity against Helminthosporium sativa. 
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3.7.22. Antiviral activity: 
 Khan et al. (1991) have reported that ethanol extract of fresh entire 
plant when tested on Tobacco Mosaic virus in cell culture was 
equivocal. The viral inhibitory activity was 7%. 
 Saigopal et al. (1986) have reported that the fresh leaf and fresh root 
extract (in 0.05 M Phosphate buffer, pH 7.5) of the plant have antiviral 
activity on Peanut Mosaic Virus, Tobacco Mosaic Virus and Tobacco 
Ring Spot Virus at 4% concentration. 
 Macrae et al. (198) have reported the activity of ethyl acetate and 
aqueous fractions of the methanol extract of the aerial parts (Amazon) 
against Sindbis virus and Murine cytomegalovirus. Ethyl acetate 
fraction is active (1 to 100 µg/ml) against pre-infection by both the 
viruses treatment (100 % activity) but inactive against post-infection 
treatment (1 to 100 µg/ml concentration level); while ethyl acetate 
fraction is active against both the viruses by pretreatment at 10 to 100 
µg/ml concentration (100 % activity).  Aqueous fraction is having 
moderate activity when used for post-infection treatment against 
Sindbis virus and pre-infection treatment against Murine 
cytomegalovirus. 
3.7.23. Anti-yeast activity: 
 Macrae et al. (1988) have reported the activity of ethyl acetate and 
aqueous fractions of the methanolic extract of aerial parts (Amazon). 
Both the extracts are inactive against Saccharomyces cerevisiae and 
Candida albicans. 
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3.7.24. Brine Shrimp mortality:  
 Macrae et al. (1988) have reported the activity of ethyl acetate and 
aqueous fractions of methanolic extract of the aerial part (Amazon). 
Ethyl acetate fraction has LD50 value 114 µg/ml, aqueous fraction has 
no activity. 
3.7.25. Biochemical effects  
 John and Krishnamurthy (1993) have studied some biochemical effects 
of P. niruri after oral administration to rats. In vitro tissue respiration 
and hepatic K+, Mg ++ and inorganic phosphorous content were not 
significantly altered by the drug for a period of two weeks, however the 
concentration of Na+  in the liver was elevated by 4 dosed of the drug. 
Aspartate and alanine transaminases and alkaline phosphatase of 
serum and liver as well as liver microsomal glucose-6-beta 
phosphatase, ali-esterase and glucopyronyl transferase were 
unaffected by feeding the aqueous extract of the drug. Erythrocytes 
from rats receiving the drug were more resistant to chronic haemolysis. 
The drug however, showed antidiuretic and antioxidant activity. 
3.8 Clinical trials- P. amarus. 
3.8.1. Hepatoprotection - Clinical trials: 
 Dixit and Achar (1983) have studied the result of clinical trials by 
administrating the powder of P. niruri to 160 children (1 to 12 years old) 
suffering from jaundice. Majority of them (90%) were admitted after 5 
days of jaundice attack while the remaining were still more severe 
cases (6 to 10 to 15 or more days attack). They were given 50 mg P. 
niruri powder per kg body weight in three divided doses for the period 
Chapter 3  REVIEW OF LITERATURE  
 
 
80 
of 6 weeks. They were examined twice a week for 6 weeks clinically 
and by laboratory reports and followed up for 3 months after the 
recovery. There was restoration of appetite within one week (77% 
cases) to two weeks (20% cases); disappearance of jaundice, liver 
tenderness and bile pigment salts from urine within 1 to 3 weeks in 
about 95% cases. There was complete recovery within six weeks in 
101 patients out of 160 patients who continued the treatment. There 
was a drop out of 59 patients within 1 or 2 weeks. The follow up study 
for 3 months indicated there was no reappearance of jaundice. These 
studies indicated the remedial cure of jaundice by P. niruri. 
3.8.2. Antihepatitis B virus activity – Clinical trials 
 Thyagarajan et al. (1988) have reported the effect of P. amarus on 
chronic carriers of hepatitis B virus. 200mg of dried and sterilized 
powder prepared from whole plant was given in a capsule form; 3 
capsules/day for 30 days to the chronic carriers of hepatitis B virus. 22 
of 37 (59%) treated patients lost hepatitis B surface antigen (HBsAg) 
when tested 15-20 days after the end of the treatment; compared with 
placebo treated control, 1 of 23 (4%) lost HBsAg. Some subject 
followed for 9 months, in no case the surface antigen has returned. 
Clinical observation revealed no toxic effects.  
 Thumlikitul et al. (1991) have studied they efficacy of P. amarus for 
eradication of hepatitis B virus in chronic carriers in Thailand. The 
aerial parts of P. amarus grown in central part of Thailand, at a dose of 
200 mg TDS for 60 days or 400 mg TDS for 30 days through oral route 
has a minimal effect on eradication of HBsAg from Thai adult 
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asymptomatic chronic carriers. These results are contradictory to that 
reported by Thyagarajan et al. (1988) from India probably because of 
the different environment condition or the age of the plant or the 
subjects in India were younger than those in the present study.  
 Doshi et al. (1994) have studied the role of P. amarus in eradication of 
hepatitis B virus in carriers. They have showed that P. amarus is not 
effective in clearing HBsAg in asymptomatic carriers at the doses of 
250 mg and 500 mg TDS for 4 to 8 weeks in 30 subjects.  
3.9. Toxicity assessment: 
 Dhar et al. (1968) have reported that ethanol: water (1:1) extract of the 
entire plant administered orally to mice, tolerated a maximum dose of 1 
gm/kg. 
 Naduveettil (1985) has reported LD 50 for phyllanthin 800 mg/kg and 
hypophyllanthin 20 mg/kg in mice. 
 Venkateswaran et al. (1987) have reported that water extract of dried 
entire plant at a dose of 0.1 mcg/animal was inactive. No weight loss 
was found seven days after the treatment. 
 Jayram et al. (1987) have reported the safety study of P. niruri in vitro 
and in vivo while using it for anti HBV properties, using mice as the 
model and Vero cell line as the tissue culture system. Acute and 
chronic toxicity was carried out. There was no mortality, weight loss, 
behavioral change, and change in histopathological pictures of liver, 
spleen and kidney or biochemical profile after 90 days treatment. Vero 
cell- line also indicated no cytotoxicity.  
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 After summarizing the review of the literature it was noticed that 
eventhough much of the Pharmacognostical, Pharmacological and 
chemical evaluation of P. amarus is reported the polyherbal 
formulations were not clinically evaluated so far for their quality. So the 
activity of P. amarus and two of the marketed formulations Livercare 
Churna and Hepatogard forte Tablet is planned to evaluate in the 
patients having liver toxicity. 
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   METHODOLOGY 
4.1. Material and Method: 
4.1.1 Plant material 
 The plant of Phyllanthus amarus was collected in the month of August 
2006 from the fields of a village Dugarwada in Modasa Taluka in Sabarkatha 
(S.K.) District (Gujarat) where it is growing wild. The herb was authenticated 
by Dr. H.B. Singh, Scientist F & Head, Raw Materials Herbarium & Museum, 
Council of Scientific and Industrial Research (CSIR), NISCAIR, New Delhi. 
(Date: 04-08-08, Ref. 1031/62). After authentication, the herbs were subjected 
to study of physicochemical parameters. Livercare Churna manufactured by 
Rajsha pharmaceuticals, Ahmadabad and Hepatogard Forte Tablet 
manufactured by Surajmani Enterprises, Daman were purchased from local 
market.    
4.1.2 Study protocol 
The ability of whole dried drug powder of Phyllanthus amarus was tested at 
Sapan Hospital, Bayad, Dist-S.K., Gujarat, for hepatoprotective activity on 
patients who were suffering from liver disease. Before starting this study on 
the patients an ethical committee was formed (consisting of an ayurvedic 
physician, modern physician MD, social worker, advocate, scientist etc. 
Annexure II). The strategy of work was planned and before starting the work 
with patients. Their written consent was taken, after explaining the details 
regarding the effect of the drug and the analysis of blood sample at different 
time interval. The powder of Phyllanthus amarus was given thrice a day 
(morning, noon and night, 3 gm each time) orally with glucose to the first 
group of liver damage 107 patients of different age groups and sex for one, 
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two, three, four and six weeks as per severity of the patient and treatment was 
continued until the recovery. The marketed formulation Livercare Churna was 
given thrice a day (morning, noon and night, 3 gm each time) orally with 
honey to the second group of liver damage 93 patients of different age groups 
and sex for one, two, three, four and six weeks as per severity of the patients 
and treatment was continued until the recovery. Tablet Hepatogard Forte was 
given thrice a day (morning, noon and night, 1 tablet each time) orally to the 
third group of liver damage 95 patients of different age groups and sex for 
one, two, three, four and six weeks as per severity of the patients and 
treatment was continued until the recovery. Biological parameter like SGPT, 
Bilirubin, Haemoglobin, Creatinine, HBsAg, urine sugar, blood pressure, etc 
were measured and monitored during the treatment.  
The reagents used in clinical investigations were collected from Span 
Diagnostic Ltd, Shivam Surgical, Ahmadabad, for estimation of SGPT, 
Bilirubin and Haemoglobin. 
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Table 4.1: Different age of patients who were treated with Phyllanthus 
amarus as hepatoprotective drug. 
PHYLLANTHUS AMARUS 
Age Male Female 
Total 
Patients 
0-15 6 3 9 
16-30 27 6 33 
31-45 26 15 41 
46-60 9 8 17 
61-ABOVE 5 2 7 
Total  73 34 107 
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M = Male, F = Female  
Figure 4.1: Patients v/s Age. Column graph showing patients of 
Phyllanthus amarus with different age. 
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Table 4.2:  Different age of patients who were treated with Livercare 
Churna as hepatoprotective drug. 
LIVERCARE CHURNA 
Age Male Female 
Total 
Patients 
0-15 1 1 2 
16-30 15 8 23 
31-45 22 15 37 
46-60 21 9 30 
61-ABOVE 0 1 1 
Total  59 34 93 
 
 
M = Male, F = Female  
Figure 4.2: Patients v/s Age. Column graph showing Patients of 
Livercare Churna with different age. 
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Table 4.3:  Different age of patients who were treated with Hepatogard 
Forte Tablet as hepatoprotective drug. 
HEPATOGARD FORTETABLET 
Age Male Female 
Total 
Patients 
0-15 1 2 3 
16-30 8 11 19 
31-45 22 14 36 
46-60 21 15 36 
61-ABOVE 1 0 1 
Total  53 42 95 
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M = Male, F = Female  
Figure 4.3: Patients v/s Age. Column graph showing patients of tablet 
Hepatogard Forte with different age 
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Table 4.4:  Total number of patients for Phyllanthus amarus, Livercare 
Churna, and Hepatogard Forte Tablet . 
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M = Male, F = Female 
Figure 4.4: Patients V/S Total number of patients M/F. Column graph 
showing total number of Patients for Phyllanthus amarus, Livercare 
Churna, and Hepatogard Forte Tablet. 
 
M/F 
Phyllanthus 
amarus 
Livercare 
Churna 
Tablet 
Hepatogard 
Forte 
Total 
M 73 59 53 185 
F 34 34 42 110 
Total  107 93 95 295 
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4.2. TLC studies of the herbs (Patel, 2000) 
TLC studies of the extracts of fresh herb as well as their market formulations 
were carried out to know their TLC finger prints and to compare them and also 
to identify the presence of the active hepatoprotective compound present in 
them. 
Phyllanthus amarus 
Extraction: 50 mg of dry herb Phyllanthus amarus (PP) and marketed 
formulations containing 50 mg equivalent amount of Phyllanthus amarus of 
Livercare Churna (PL) and 50 mg equivalent amount of Phyllanthus amarus of 
Hepatogaurd Forte Tablet (PH) were extracted with 10 ml of petroleum ether 
(60 – 80 C) by heating on water bath for 10 minutes and filtered. The marc 
was extracted similarly twice taking 5 ml of petroleum ether each time. The 
combined filtrate was concentrated to 0.5 ml and used for TLC studies. 
TLC: 
Extract of each of the above dry fresh herb (PP), and marketed formulation 
Livercare Churna (PL) and tablet Hepatogaurd Forte (PH) were spotted on 
TLC plate separately. It was developed in Toluene: Ethyl acetate (4: 2) dried 
and observed in day light, UV light and after spraying 10 % methanolic 
sulphuric acid followed by heating at 110 C for 10 minutes.  
Detection:  
1. 10 % methanolic sulphuric acid (day light) 
2. UV light (254) 
Extracts: Petroleum ether extracts of dry fresh herb of Phyllanthus amarus 
(PP), and marketed formulations containing Livercare Churna (PL) and tablet 
Hepatogaurd Forte (PH). 
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4.3. PHYSICOCHEMICAL PARAMETER 
4.3.1. Ash values. (Harbone, 1998; WHO/QCMMPM guidelines, 1992) 
Ash content of the crude drug is generally taken to be the residue remaining 
after incineration. It represents the inorganic salts naturally occurring in the 
drug and adhering to it, but it may also include inorganic matter added for the 
purpose of adulteration. 
Total ash is the residue remaining after incineration. Acid insoluble ash is the 
part of the total ash, which is insoluble in dilute hydrochloric acid. Water-
soluble ash is the part of total ash, which is soluble in hot water.  
4.3.1.1. Determination of Total Ash. 
About 2g of the powdered drug was accurately weighed (W) in a tarred silica 
crucible. The powdered drug was spread as a fine layer at the bottom of the 
crucible. The crucible was incinerated at a temperature not exceeding 450°C 
until free from carbon. The crucible was cooled and weighed. 
The procedure was repeated till a constant weight was observed. The 
percentage of the total ash was calculated with reference to the air-dried 
drug. 
4.3.1.2. Determination of Acid Insoluble Ash 
The ash obtained as described in the determination of total ash was boiled 
with 25 ml of hydrochloric acid for 5 min. The insoluble ash was collected on 
an ashless filter paper and washed with hot water. The insoluble ash was 
transferred into a tarred silica crucible along with filter paper, ignited, cooled 
and weighed. The procedure was repeated till a constant weight was 
observed. The percentage of acid insoluble ash was calculated with 
reference to the air-dried drug. 
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4.3.1.3. Determination of Alcohol-Soluble Extractive: 
Macerate 5 gm of the air dried coarsely powdered drug with 100 ml of alcohol 
in a 250 ml volumetric flask for 24 hours, shake frequently during six hours 
and allow to stand for 18 hours.  Filter rapidly taking precaution against loss of 
alcohol, evaporate 25% of the filtrate to dryness in a tarred shallow dish dried 
at 1050c and weighed. Calculate the percentage of alcohol soluble extractive 
with reference to the air dried drug. 
4.3.1.4. Determination of Water-Soluble Extractive: 
Macerate 5 gm of the air dried coarsely powdered drug with 100 ml of 
chloroform water in a 250 ml volumetric flask for 24 hours, shake frequently 
during six hours and allow to stand for 18 hours.  Filter rapidly, evaporate 25% 
of the filtrate to dryness in a tarred shallow dish dried at 105 0C and weighed. 
Calculated the percentage of water soluble extractive with reference to the air 
dried drug. 
4.4. Estimation of SGPT (Reitman et al., 1957: Nobert, 1970, Godkar et al, 
2006) 
4.4.1. Intended Use: 
 This reagent kit is intended for in-vitro quantitative determination of 
SGPT (ALT) activity in serum/plasma.  
4.4.2. Principle:  
Glutamate pyruvate transaminase (GPT) or Alanine aminotransferase (ALT) 
catalyses alphaketoglutarate and L-Alanine. Pyruvate formed by this catalysis 
reacts with 2, 4 dinitrophenylhydrazine (2, 4 DNPH) to give a brown-red 
colored hydrazone complex in an alkaline medium.  The concentration of 
brown red colored complex is directly proportional to the activity of SGPT 
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present in sample and it is measured colorimetrically at 505nm or with green 
filter. 
4.4.3. Reaction: 
i. Alpha-ketoglutarate + L-Alanine       
GPT
         L-Glutamate + Pyruvate. 
ii. Pyruvate + 2, 4 DNPH   
.
 
Alk medium
        Brown-Red Hydrazone Complex 
4.4.4. Clinical Significance: 
Even though glutamate pyruvate transaminase is widely distributed in various 
tissues of the body; it is a useful parameter in evaluating liver function.  The 
elevated serum levels are found in case of hepatitis, obstructive jaundice, 
metastatic carcinoma, hepatic congestion and myocardial infarction or in 
kidney diseases. 
4.4.5. Reagent Preparation:  
Reagent 1: Buffered alanine -KG substrate. 
Reagent 2: DNPH color reagent. 
Reagent 3: sodium hydroxide, 4N. 
Reagent 4: Working pyruvate standard, 2mM. 
Solution 1: One ml of Reagent No.3 was diluted to 10 ml with distilled water.  
Reagent 1, 2 & 4 are ready for use as such.  
4.4.6. Test Procedure: 
Reagent 1(Buffered alanine -KG substrate) 0.5 ml is taken in a test tube. It is 
incubated at 37oC for 5 min, fasted serum 0.1 ml is added to the test tube. It is 
mixed well and incubate at 37oC for 30 min. Reagent 2, (DNPH color reagent) 
0.5 ml is added to the above test tube. It is allowed to stand at room 
temperature for 20 min. Solution 1; 5 ml is added to the solution of the test 
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tube. It is mixed well and allow to stand for 10 min. The absorbance of the 
solution is measured 505 nm using water as blank.   
4.4.7. Test Results: 
The calibration graph is used to obtain test results in U/ml. 
4.4.8. Linearity:  
This method is linear up to 150 U/ml of SGPT in serum.  Samples having 
higher values are diluted with 0.9% saline and assay results were multiplied 
with dilution factor. 
4.5. Estimation of Bilirubin (Malloy et al., 1937, Godkar and Godkar, 2006) 
4.5.1. Intended Use: 
This diagnostic reagent kit is intended for in-vitro quantitative estimation of 
direct and indirect bilirubin from serum/plasma. 
4.5.2. Principle: 
The direct or conjugated bilirubin reacts with diazotized sulphanilic acid to 
form purple colored complex, whereas indirect or unconjugated Bilirubin 
reacts only in presence of DMSO reagent to give purple colored complex.  
The intensity of the purple color developed is proportional to the amount of 
either total or direct bilirubin present in sample and it is measured 
colorimetrically at 540 nm or with yellow-green filter. 
4.5.3. Reaction: 
Direct/ conjugated Bilirubin + Diazotized Sulphanilic acid  Purple colored 
azo bilirubin complex  
Indirect / unconjugated bilirubin + Diazotized sulphanilic acid    
DMSO
 
 Purple colored azo bilirubin complex. 
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4.5.4. Clinical Significance: 
Bilirubin is produced from Haemoglobin in reticulo endothelial system and 
circulates in normal concentration in blood.  It is conjugated with glucuronic 
acid in liver and excreted through bile.  The estimation of total and direct 
bilirubin is of importance for diagnosis, differentiation and follows up of 
jaundice.  The serum levels of unconjugated Bilirubin rises in the cases of 
hemolytic jaundice.  Whereas conjugated serum bilirubin levels rises in the 
cases of obstructive jaundice.  Hepatic jaundice is characterized by 
simultaneous rise in both, conjugated and unconjugated serum bilirubin 
levels.  
4.5.5. Reagent Preparation: 
Reagent A: Total bilirubin reagent. 
Reagent B: Direct bilirubin reagent. 
Reagent C: Sodium nitrite reagent. 
Reagent D: standard bilirubin = 10mg% bilirubin.  
All reagents in the kit are ready to use as such. 
4.5.6. Procedure for Colorimetric estimation of Bilirubin: 
For total bilirubin estimation 3 ml of reagent A and 0.1 ml of reagent C are 
mixed by inversion of test tube No T and waited for 30 seconds. For total 
bilirubin blank 3 ml of reagent A is taken in test tube No TB. Fasted serum 
0.15 ml is added in each test tube No T and TB. The content of both the test 
tubes are mixed well and incubated at 37oC for 5 min and absorbance is read 
at 540 nm using water as blank. 
For direct bilirubin estimation 3 ml of reagent B and 0.1 ml of reagent C are 
mixed by inversion of test tube No D and waited for 30 seconds. For direct 
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bilirubin blank 3 ml of reagent B is taken in test tube No DB. Fasted serum 
0.15 ml is added in each test tube No D and DB. The content of both the test 
tubes are mixed well and incubated for 37oC for 5 min and absorbance is read 
at 540 nm using water as blank. 
The absorbance of the reagent D (standard bilirubin) is read directly against 
distilled water. The standard once used is discarded. Serum Bilirubin in mg% 
calculated as below. 
4.5.7. Test Results: 
 
Where T= Total bilirubin, TB= Total bilirubin blank, D= Direct bilirubin, DB= 
Direct bilirubin blank. 
4.5.8. Linearity: 
This method is linear up to bilirubin concentration of 15 mg%, for sample 
having higher values of bilirubin are diluted with 0.9% normal saline and 
multiplied with dilution factor.  
4.6. Estimation of Creatinine (Tora and Ackermann, 1975; Bonses and 
Taussky, 1945, Godkar and Godkar, 2006) 
4.6.1. Method: Alkaline Picrate Method 
4.6.2. Principle: Creatinine in a protein free solution reacts, with Alkaline 
Picrates and produces a red colored complex, which is measured 
colorimetrically. 
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4.6.3. Advantages: 
 Very popular method 
 Simple, convenient and highly reproducible. 
 One minute deprotenization step with a single deprotenization reagent. 
 Result within half an hour. 
 Economic. 
Sample: 24hrs urine is preferred. Dilute 1ml of urine to 250 ml with purified 
water. 
4.6.4. Reagent: 
Reagent 1: Picric acid 
Reagent 2: Sodium Hydroxide, 0.75N 
Reagent 3: Stock Creatinine Standard, 150 mg% 
Preparation of working solution: Dilute 0.1 ml of reagent 3 to 10 ml with 
purified water and mix well. All other reagents are ready for use. 
Storage and stability: All reagents are stable at room temperature till the 
expiry date mentioned on the individual label. Once opened Reagent 3 is 
stable at 2-8 0C. Working standard has to be prepared fresh everyday.  
4.6.5. Precautions: 
1) Use clean and dry glassware. 
2) Bring all solution to room temperature before use. 
3) Prepare one blank and one standard for each series of estimations. 
4) Mark the test tube properly as blank (B), standard (S), and test (T) 
before proceeding for the estimation, because markings may come off 
when the tubes are placed in the boiling water bath during 
deprotenization (step A). 
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5) Do not fail to dilute the urine during creatinine estimation from urine. 
4.6.6. Procedure 
A. For colorimetry 
Step A. Deprotenization of test sample: 
Dilute urine   0.5 ml  
Purified water   0.5 ml 
Reagent 1: Picric acid  3.0 ml 
Mix well; keep in a boiling water bath exactly for one minute. Cool 
immediately under running tap water and centrifuge or filter 
Step B. Color Development:  Blank   Standard  Test 
Filtrate/Supernant (From Step A.)   -    -  2.0 ml 
Working Standard     -  0.5 ml    - 
Purified water    0.5 ml    -    - 
Reagent 1: Picric acid   1.5 ml  1.5 ml    - 
Reagent 2: NaOH, 0.75N  0.5 ml  0.5 ml  0.5 ml 
Mix well and allow to stand at room temperature exactly for 20 minutes 
and measure immediately the optical density of Blank (B), Standard(S) 
and Test (T) against Purified water on a colorimeter with a green filter. 
B. For Spectrophotometer: All the volumes mentioned under colorimetric 
procedure can be adjusted proportionately depending on flow 
cell/cuvette capacity. Rest of the procedure remains unchanged. 
Measure the O.D. at 520nm. 
4.6.7. Calculation: 
Urine Creatinine in mg/ 100ml = O.D. test – O.D. blank 
         O.D. std – O.D. blank    
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Normal values of Urine Creatinine: Men: 1.1- 2.8 g/ 24hrs 
           Women: 0.9- 1.6 g/24 hrs 
4.6.8. Note:  
1) If the O.D. of test exceeds 0.8 repeat the test after diluting the urine 1 
→ 50 or more if necessary and multiply the final result so obtained with 
2.0 or an appropriate factor. 
2) Optical density should be measured exactly after 20 minutes after the 
addition of sodium hydroxide.  
3) The filtrate/ supplement obtained during deprotenization should be 
crystal clear.  
4.6.9. Clinical significance 
In renal disease, Creatinine determinations have one advantage over urea 
determinations that they are not affected by a high protein diet as is the case 
for urea determinations. In addition to renal disease, elevated levels of Serum 
Creatinine and Creatinuria may be observed in extensive muscle destruction. 
4.7. Estimation OF HBsAg test (Godkar and Godkar, 2006) 
4.7.1. Intended use: 
The Advanced quality one step HBsAg test is a rapid, one step, 
immunochromatographic assay for the detection of Hepatitis B surface 
antigen (HBsAg) in human serum or plasma. The presence of 5ng/ml HBsAg 
can be detected within 10 minutes and 1ng/ml HBsAg in 30 minutes. The test 
provides a visual, qualitative result, and is intended for professional use. 
4.7.2. Principle of the assay 
Solid phase “Sandwich” immunoassay for the detection of HBsAg was 
described by Wisdom (Wisdom, 1976, Wolters et al., Wei et al., 1977). The 
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production, characterization and application of monoclonal antibodies for the 
detection of HBsAg have previously been reported (David, 1981: Goodall, et 
al., 1981: Kennedy. et al., 1983: Shih, et al., 1980: Wands et al., 1981). 
The advanced quality one step HBsAg test is a colloidal gold enhanced 
immunoassay that detects Hepatitis B surface antigen in human serum or 
plasma. The sample initially reacts with the monoclonal antibody-colloidal 
conjugate on the sample pad. This mixture migrates across the membrane by 
capillary action and reacts with the anti-HBsAg in the test region. If the sample 
contains HBsAg a line will form on the membrane at this point. If the antigen is 
not present in the sample no line is formed, indicating a negative result. The 
mixture continues to flow to the control area of the membrane, where it forms 
a line indicating the test result valid. 
 4.7.3. Storage conditions 
The kit must be stored at 2-30C. 
4.7.4. Precautions 
It is recommended that all specimens be handled in accordance with biosafety 
level 2 practices as described in the CDC NIH publication, Biosafety on 
microbiological and biomedical laboratories (USDHHS, 1988) or other 
equivalent guidelines (WHO, 1983: NCCLS, 1989) 
1. For in vitro diagnostic use only. 
2. Wear gloves to perform this procedure and treat all specimens and 
used devices as potentially infectious. 
3. Clean and disinfect all spills of specimens and reagents using a 
suitable disinfectant, such as 1% sodium hydrochlorite12. 
4. Sterilize all devices used in this assay prior to disposal. 
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5. Do not use test beyond the expiration date 
4.7.5. Specimen collection 
1. Serum or plasma may be used in this test .Anticoagulants typically 
used for blood collection do not interfere with this test. 
2. Remove the serum or plasma from the clot or red cells as soon as 
possible to avoid hemolysis. 
3. Haemolyzed extremely thickened or fatty specimens are not suitable 
for this assay. Specimens containing particulate matter may give 
inconsistent results and should be clarified prior to testing. 
4. Serum or plasma specimens should be refrigerated at 2 to 8 oC up to 3 
days and frozen at -20 oC for longer periods. 
5. Shipped specimens should be packed in compliance with federal and 
international regulations covering the transportation of etiologic agents. 
6. Avoid frequent (more than 3 times) thaw- and freeze of specimens. 
7. 0.1% sodium azide can be added to the specimen as a preservative 
without affecting results of the assay. 
4.7.6. Materials provided 
 10 or 40 test cards individually foil pouched with a desiccant. 
 Instruction for use. 
 Sample dispensing plastic dropper with each test pouch. 
4.7.7. Assay procedure 
Do not open pouch until you are ready to the sample. 
1. Bring all reagents and specimens to room temperature. 
2. Remove the test card from the foil pouch and place on a clean dry 
surface. 
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3. Identify the test card for each specimen or control. 
4. Dispense 2-3 drops of the specimen or control into the sample well on 
the card by provided plastic sample dropper. Caution: Use only 
provided sample dropper for every sample to avoid cross- 
contamination. 
5. Read the result between 5 to 10 minutes for 5ng/ml, and 30 minutes for 
1ng/ml. A positive result may be interpreted early, however read any 
negative at 30 minutes to ensure sample is negative and not a low 
concentration of the HBsAg, requiring more time to develop. Do not 
interpret the result after 30 minutes. 
It is recommended to run a known positive and negative control in each 
performance to ensure the assay procedure. 
4.7.8. Interpretation of Results 
Negative: Only one purplish red colored band appears in the control 
region. 
Positive: In addition to the purplish red control band, a distinct purplish 
red colored band also appears in the test region. 
Invalid: Neither test band nor control band appears. The specimen should 
be tested again using a new test card. 
4.7.9. Limitations:  
Although the association between the presence of HBsAg and infection is 
strong, available methods for HBsAg detection are not sensitive enough to 
detect all potentially infectious units of blood or possible hepatitis 
infections. 
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4.7.10. Performance characteristics 
Serum or plasma concentration as low as 1ng/ml is detected by this assay. 
The advanced quality one step HBsAg test has been compared to an 
equivalent EIA system. A result of 99.5% correction to EIA test was 
demonstrated by a clinical study of 1208 patient‟s specimens. 
4.8. Estimation of Urine Sugar (Godkar and Godkar, 2006, Goyal et al., 
2006) 
4.8.1. Principle:  
Benedict‟s quantitative reagent consists of copper sulphate, potassium 
thiocyanate and other chemicals in alkaline media. Copper sulphate is 
reduced to cuprous oxide by glucose. Potassium thiocyanate reacts with 
cuprous oxide and form white precipitates of cuprous thiocyanate instead of 
usual precipitates of cuprous oxide. Disappearance of blue tint from solution, 
indicate complete reaction of copper sulphate. 
4.8.2. Reaction  
 2 Cu (OH) 2  (reduction) → Cu2O + 2 H2O 
4.8.3. Reagents:  
1) Benedict‟s quantitative reagent:   
(A)  Dissolve with the aid of heat, 100 gm of anhydrous sodium carbonate, 
200 gm of sodium or potassium citrate and 125 gm of dry potassium 
thiocyanate in 800 ml water and filter if necessary. 
(B) Dissolve 18gm of copper sulphate in 100ml of water. Cool the solution. 
Add „B‟ to „A‟ with constant stirring. Add 5 ml of 5% potassium 
ferricyanide solution. Add water to make 1000 ml. 25ml of the reagent 
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is reduced by 50 mg of glucose. Check the strength by titrating with 
standard solution of glucose; 1ml of reagent = 2mg of glucose. 
2) Anhydrous sodium carbonate:  
Dilution: The urine is diluted in such a way that the burrate reading is 
between 5 to 15 ml for 10 ml of the reagent. For this, take 5 ml of 
Benedict„s qualitative reagent. Add 8 drops of urine, boil and cool. 
Green ppts: Dilute urine 1 in 2 or 3 
Yellow ppts: Dilute urine 1in 5 or 8 
Brick red ppts: Dilute urine 1 in 10 or more 
End point: Complete disappearance of the blue color. 
4.8.4. Procedure: 
(A) Pipette out 10 ml of Benedict„s qualitative reagent solution in a 100 ml 
conical flask. Add 20 ml of water, 5gm of anhydrous sodium carbonate and 
few pieces of porcelain to prevent bumping. Heat the flask on a flame to 
boiling. Keeping the mixture just boiling, add this urine in a flask rapidly, 
until white precipitates begin to form. After this add urine, drop by drop at 
the interval of 10 seconds until the blue color just disappear. The solution 
must be kept vigorously boiling and be stirred continuously throughout the 
entire titration. 
(B)  Add 5ml of the Benedict„s qualitative reagent and mix with 0.5 ml of 
urine, Boil for 2 minute and cool 
Green precipitates    Glucose up to 1% 
Yellow precipitates   Glucose up to 2% 
Red precipitates    Greater than 2% 
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4.8.5. Calculation: 
If n ml of urine, dilution 1 in D (if not diluted D=1) required, then the 
glucose contents of urine are, 
0.02 x 100     x D        =     2D gm% 
N                                 n 
Note: In Benedict„s qualitative reagent, small amount of potassium 
ferricyanide assists in maintaining the cuprous oxide in solution. The use of 
sodium carbonate as alkali instead of sodium hydroxide, prevent the 
destruction of the small amount of sugar. 
4.8.6. Interpretation; Normal value of glucose excretion is 2 to 10 mg 
glucose/100 ml or 78.5 mg/day, which is not detected by common qualitative 
test. Determination of sugar concentration in urine is important for the 
management of diabetics. Presence of sugar in urine is known as glucosuria 
and the persistent presence indicate diabetes mellitus. 
4.9. Determination of Heamoglobin. (Godkar and Godkar, 2006, Goyal et 
al., 2006) 
4.9.1. Reagent and Glassware: 
Sahil haemoglobinometer or hemometer which consists of two sealed 
comparison tubes fixed in rack, a specially graduated diluting tube,  a thin 
glass rod and micropipette of 20 cubic millimeter capacity, pricking needle, 
N/10 HCl, distilled water, 70% alcohol and absorbent cotton. 
4.9.2. Principle: 
When blood is mixed with N/10 HCl, RBCs are haemolyzed and Hb is librated. 
This Hb is converted into acid hematin which is reddish brown in color. The 
solution is diluted with distilled water till it matches with the standard glass 
(Comparison) tubes. The Hb% can directly be read from the graduated tube. 
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4.9.3. Procedure:  
The graduated diluting tube and the micropipette are cleaned thoroughly and 
dried. The graduated diluting tube is filled with N/10 HCl up to the mark 2 gm 
or till the micropipette touches the level of acid in the tube. The finger is 
cleaned with 70% alcohol and it is pricked to obtain a drop of blood. First drop 
is wiped out. Second drop is sucked in the micropipette upto the mark 
20cmm. The blood is immediately deposited at the bottom of the graduated 
tube. The pipette is rinsed two to three times in HCl. The blood is mixed with 
the help of stirrer and then solution is allowed to stand for 10-15 minutes so 
that all Hb is converted into acid haematin. Then mixture is diluted with 
distilled water. Distilled water is added drop by drop and every time it is stirred 
till the exact match with standard glass tubes is obtain and the scale is read 
on the side of tube. 
4.9.4. Observation and Calculation 
Observed Hb gm % = --------- gm % 
Observed Hb % = ---------- % 
International value of Hb is 14.5 gm% = 100 % 
Calculation Hb% =   gm %    x 100 
                                 14.5 
4.9.5. Normal value 
  Normally 14.5 gm of Hb in 100 cc of blood is considered to be 100 % 
Hb according to British Standards. The value may vary according to sex, 
age and altitude. In female adults it may vary from 12 to 15 gm (average 
13.7 gm %) and in adult males it ranges from 13 gm to 16 gm (average 
14.8 gm %). New born child has an average of 23 gm% by the end of third 
month it falls below the normal. After this it gradually recovers within a 
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year to 12.5 gm. People at higher altitude have higher value, because 
oxygen of air is less at that level. 
4.9.6. Precautions; 
 While filling the micropipette, entry of air bubbles should be 
avoided. It is advisable to fill up the micropipette more than 20 cmm 
marks. The excess of blood in the micropipette may be removed by 
touching the tip of the pipette on palm. 
 While depositing blood into graduated tube, one should not blow it 
forcibly so that blood sticks to the side of pipette. Rinsing should 
also be done slowly. 
 Never take less quantity of N/10 HCl. 
 While observing for color match, stirrer should be kept out of 
solution, and the calibrated side should not come in view. The 
observation must be done while facing it against uniform intensity of 
light. 
4.10. Estimation of Blood Pressure (Godkar and Godkar, 2006, Goyal et al., 
2006) 
Blood pressure (B.P.) is defined as the lateral pressure exerted on the 
walls of the vessels by the contained blood. This is due to muscularity and 
elasticity of the walls of blood vessels. The B.P. also depends on the force 
with which heart pumps the blood. The maximum pressure during systole 
is defined as systolic B.P whereas the minimum pressure during diastole is 
defined as the diastolic B.P. The difference between systolic and diastolic 
B.P is described as the pulse pressure. 
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4.10.1. Principle: 
The blood flow through a large sized artery is obstructed by means of 
air pressure exerted through a rubber bag wrapped around the limb. The 
pressure is slowly released and the entry of blood through the obstruction 
is studied by  
 Feeling of the pulse(Palpatory method) 
 Observation of oscillation of the mercury level ( oscillatory method) 
 Hearing with the stethoscope the sounds produced in the segment 
of the artery distal to obstruction (Auscultatory method) 
The blood flow stops when the pressure transmitted to the artery through 
the rubber bag is equal to or more than the blood pressure. The first entry 
of blood through an obstruction indicates the blood pressure. Usually the 
arm or thigh is used because there is only one big vessel which runs 
superficially in each of these parts of the extremities. 
4.10.2. Procedure: 
1. The cuff is tied around the arm. It should be neither too tight to 
cause any discomfort to the subject, nor too loose to allow its 
movement round the arm. 
2. The artery is felt and its course is marked in the cubital fossa. 
Also the radial pulse is felt and marked at the place where it is felt well. 
3. The manometer is placed by the side of the subject, between his 
arm and the body. The screw of the rubber pump is tightened and the 
pump is pressed to inflate the bag. It is inflated to raise the mercury to 
200 mm level or 20-25 mm hg higher after the disappearance of pulse. 
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4. Keeping the eyes fixed at mercury level and the finger at the 
pulse, pressure is slowly released by unscrewing the valve of the 
rubber pump. The reading of the level of mercury when the pulse 
reappears gives systolic pressure. This is Palpatory method. This 
method does not give idea of diastolic pressure. The systolic pressure 
recorded by this method is about 5-10 mm lower than the actual 
systolic pressure. 
When the pulse appears, it is also noted that mercury starts oscillation. 
The first oscillation starts increasing in magnitude and then slowly 
diminishes. The level at which the oscillation are maximum is taken as the 
diastolic pressure. This is oscillatory method. In this method the deflation 
has to be carried out slowly the systolic pressure should be read within 
fifteen seconds and the diastolic pressure within thirty second. 
In the Auscultatory method after as usual the chest piece of stethoscope is 
placed over the brachial artery in the cubital fossa and deflation is started 
by slowly releasing the pressure. The level at which a sudden tap is 
heared is the systolic blood pressure. The sound suddenly gets muffled 
and disappears. The level at which the sinus muffles is the diastolic 
pressure, the sounds heared are korokorr‟s sounds. These are due to 
interrupted flow of blood. 
In many instances when the systolic blood pressure is very high, the first 
sound is a faint tap and is then missed. As the pressure in the bag is 
reduced the sound produced become louder and audible at a much lower 
level. This reading is then erroneously taken as the systolic blood pressure 
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reading.  The difference between this reading and the true systolic reading 
is described as the „Auscultatory gap‟. 
4.11 Statistical analysis 
 Results of biochemical estimation were reported as Mean, S.D, SEM 
and Median for determination of significant inter group difference each 
parameter was analyzed separately and one way analysis of variance P value 
was carried out Graph Pad statistics software. 
 Results of biochemical estimation were reported as Mean, S.D, and 
SEM for determination Student T Test of significant inter group difference 
each parameter was analyzed separately and one way analysis of variance t 
value and P value was carried out by SPSS 12.0 statistics software. 
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RESULT AND DISCUSSION 
Result and Discussion 
The herb of Phyllanthus amarus collected from the field of village Dugarwada 
in Modasa was identified as Phyllanthus amarus by scientist of NISCAIR, New 
Delhi (4/8/08; Ref: 1031/62). 
The physicochemical parameters of the powder of the herb were determined 
which are shown in Table no. 5.1     
Table 5.1: Physicochemical parameter for Phyllanthus amarus 
Sr. 
no 
Name of 
parameter 
Experimental 
Value 
Indian Herbal 
Pharmacopoeia 
Ayurvedic 
Pharmacopoeia 
of India  
1 Water soluble  
extract value 
18% NLT 15 % NLT 13 % 
2 Alcoholic soluble 
extractive value 
14% Not mentioned NLT 3 % 
3 Total ash 7% NMT 8 % NMT 16 % 
4 Acid insoluble 
ash value 
4% NMT 5 % NMT 7 % 
Water soluble extractive value, Alcoholic soluble extractive value, Total ash 
and Acid insoluble ash value of the Phyllanthus amarus herb collected for the 
use comply with the Ayurvedic Pharmacopoeia of India as well as Indian 
Herbal Pharmacopoeia.  
Chapter 5  RESULT AND DISCUSSION  
111 
 
5.2 TLC of Phyllanthus amarus and its market formulations 
         PLATE   1                 PLATE   2              PLATE   3  
                               
       PP     PL    PH               PP     PL    PH            PP     PL    PH 
Figure 3: TLC study of Phyllanthus amarus and their formulations. 
Where A= Spot of hypophyllanthin (Rf =0.54, identified through literature as 
hypophyllanthin), B =Spot of phyllanthin (Rf = 0.58, identified through 
literature as phyllanthus), S = Place of spotting, F = Solvent front. (through Rf 
value and literature study) 
Stationary phase:  Silica gel G 
Mobile phase:   Toluene: Ethyl acetate (4: 2) 
Detection:    Plate 1: as seen in day light,  
Plate 2: as seen in UV 254 light,  
Plate 3: 10 % methanolic sulphuric acid followed by 
heating in a oven at 100oC for 10 min  
PH; Petroleum ether extract of Hepatogard forte 
PL; Petroleum ether extract of Liver care 
PP; Petroleum ether extract of Phyllanthus amarus 
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TLC was observed in day light, UV light (254nm) and after spraying with 10% 
methanolic sulphuric acid solution as seen in day light. 
In day light, UV and after spraying with 10% methanolic sulphuric acid reagent 
spot at Rf = 0.54 and 0.58 are prominent. It turns red and blue spots after 
spraying with 10% methanolic sulphuric acid reagent. As per the literature 
description red spot at Rf= 0.54 is hypophyllanthin and blue spot at Rf = 0.58 
is phyllanthin, which are present in the collected herb sample, Livercare 
Churna and Hepatogard forte Tablet. However the intensity of the spot (Rf = 
0.54 and 0.58) and diameter was bigger in the sample of in collected herb and 
Livercare Churna than Hepatogard forte Tablet. 
Total 3 spots were seen in Phyllanthus amarus herb and Livercare Churna in 
day light, but there was less in number in Hepatogard forte Tablet.  
About 10 spots were seen in Phyllanthus amarus herb chromatogram after 
spraying with 10% methanolic sulphuric acid reagent. All the spots were red, 
blue to dark blue in colour. The number of spots were less in Hepatogard forte 
Tablet after spraying with 10% methanolic sulphuric acid reagent. 
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Clinical Data 
Table 5.2:  SGPT values of the patients after treatment with Phyllanthus 
amarus 
Sr. no 
of 
patients 
Age  SGPT values after different weeks treatment 
Initial 
(zero 
week) First Second Third Forth Six 
1 28 109 52 - - - - 
2 51 45 40 - - - - 
3 20 110 45 - - - - 
4 16 460 210 110 50 45 - 
5 42 980 430 210 80 65 - 
6 17 105 65 35 - - - 
7 65 34 30 - - - - 
8 65 60 45 - - - - 
9 36 399 240 65 35 - - 
10 42 104 50 - - - - 
11 35 885 590 315 45 - - 
12 21 784 620 310 40 - - 
13 32 436 210 70 - - - 
14 32 144 64 58 - - - 
15 28 1560 1210 880 410 60 - 
16 45 325 40 35 - - - 
17 17 65 40 - - - - 
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18 32 72 40 - - - - 
19 20 594 470 240 85 55 - 
20 38 2400 1890 930 310 160 65 
21 19 1900 1180 430 120 - - 
22 38 360 90 - - - - 
23 16 3100 2200 1650 740 390 85 
24 19 1600 680 290 65 - - 
25 22 1500 740 330 90 - - 
26 65 700 320 160 50 - - 
27 35 260 65 45 - - - 
28 32 345 200 55 - - - 
29 42 290 65 - - - - 
30 43 1045 740 370 210 140 80 
31 28 1120 740 550 320 65 - 
32 50 800 480 300 140 35 - 
33 55 600 210 85 35 - - 
34 45 460 290 100 65 - - 
35 55 490 140 45 - - - 
36 40 270 120 60 - - - 
37 20 800 340 110 35 - - 
38 50 500 190 45 - - - 
39 45 520 210 65 - - - 
40 50 1950 870 430 210 45 - 
41 50 2100 1090 420 95 - - 
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42 45 980 320 85 - - - 
43 32 1700 840 430 270 40 - 
44 55 130 60 45 - - - 
45 21 3200 1745 795 380 95 - 
46 50 3890 1640 890 490 120 - 
47 19 185 60 - - - - 
48 42 1300 673 290 45 - - 
49 71 235 95 - - - - 
50 38 1340 690 305 130 95 - 
51 30 226 170 110 45 - - 
52 30 200 90 - - - - 
53 54 107 55 - - - - 
54 42 296 165 65 - - - 
55 22 560 190 45 - - - 
56 42 580 320 190 55 - - 
57 46 780 620 370 240 90 - 
58 11 152 60 - - - - 
59 38 700 390 170 80 - - 
60 70 230 95 - - - - 
61 20 700 430 240 95 - - 
62 23 640 210 45 - - - 
63 35 680 290 75 45 - - 
64 36 790 390 120 - - - 
65 24 165 110 45 - - - 
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66 40 160 55 - - - - 
67 28 150 110 45 35 - - 
68 13 160 75 - - - - 
69 45 970 430 280 95 - - 
70 15 160 65  - - - 
71 32 1590 570 170 55 - - 
72 55 2900 1890 590 230 75 - 
73 11 972 310 95 - - - 
74 30 1110 540 270 80 - - 
75 12 300 110 45 - - - 
76 13 170 75 - - - - 
77 65 238 170 85 60 30 - 
78 30 238 65 - - - - 
79 50 320 140 65 - - - 
80 49 2100 990 520 270 95 - 
81 45 590 240 60 - - - 
82 36 2840 1920 1140 455 110 - 
83 40 590 190 55 - - - 
84 11 2390 1520 910 330 65 - 
85 50 681 209 95 - - - 
86 35 700 310 95 - - - 
87 30 1010 510 190 95 - - 
88 25 210 95 45 - - - 
89 65 248 140 60 - - - 
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90 30 180 75 - - - - 
91 35 100 65 - - - - 
92 50 620 470 270 95 - - 
93 37 175 65 - - - - 
94 53 930 520 340 95 - - 
95 42 500 290 130 45 - - 
96 12 1000 430 210 65 - - 
97 40 460 270 190 110 90 35 
98 45 157 55 - - - - 
99 27 550 310 170 85 - - 
100 25 103 45 - - - - 
101 21 716 230 65 - - - 
102 30 1520 980 630 210 65 - 
103 20 105 95 55 - - - 
104 51 175 62 - - - - 
105 5 940 730 430 210 95 - 
106 42 185 90 - - - - 
107 32 670 450 290 70 - - 
Average  747.943 402 262.126 152.843 92.391 66.25 
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Table 5.3.a : P value of SGPT after treatment with Phyllanthus amarus 
Group 
 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median 
Initial 747.94 771.02 74.192 535.00 
First 402.00 469.50 45.178 210.00 
Second 262.13 291.23 32.561 170.00 
Third 152.84 144.42 20.027 95.00 
Fourth 92.391 71.229 14.540 82.00 
Sixth 66.250 19.486 8.714 66.25 
 
Table 5.3.b: Paired Samples Test of SGPT for Phyllanthus amarus. 
Pai
r  
Paired Differences 
t test df 
P value 
Signific
ant  (2 
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
345.943 351.729 34.003 278.529 413.358 10.174 106 0.000* 
696.215 569.257 64.046 568.708 823.721 10.870 78 0.000* 
1088.74 749.371 104.933 877.980 1299.50 10.376 50 0.000* 
1573.13 991.899 206.825 1144.20 2002.05 7.606 22 0.000* 
1685.00 1196.85 598.428 219.466 3589.46 2.816 3 0.067 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.4: SGPT values of the patients after treatment with Livercare 
Churna  
Sr. no 
of 
patients 
Age  SGPT values after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 17 210 130 70 - - - 
2 47 1050 630 290 80 - - 
3 49 490 270 85 - - - 
4 51 2450 1760 1030 540 230 40 
5 31 610 310 110 - - - 
6 53 890 470 190 45 - - 
7 47 298 170 110 45 - - 
8 40 3200 2350 1430 770 310 35 
9 47 2250 1770 1090 440 130 - 
10 50 1450 730 470 180 90 - 
11 44 790 410 100 - - - 
12 46 3480 2570 1720 1070 645 95 
13 35 780 590 310 80 - - 
14 55 450 195 60 - - - 
15 50 1270 1040 770 490 110  
16 60 3610 2140 1950 1170 640 80 
17 43 270 110 - - - - 
18 45 320 185 65 - - - 
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19 40 3200 1530 890 540 360 40 
20 29 492 240 80  - - 
21 44 2015 1310 430 190 28 - 
22 25 2540 1070 610 310 35 - 
23 17 2215 1130 680 210 42 - 
24 40 195 45 - - - - 
25 35 2250 1240 700 240 60 - 
26 25 2600 1330 790 320 75 - 
27 21 1810 1020 570 270 40 - 
28 52 285 70 25 - - - 
29 45 1420 830 440 180 65 - 
30 62 2470 1820 1180 830 540 90 
31 50 430 110 55 - - - 
32 45 1350 760 320 85 - - 
33 50 1845 1130 680 210 80 - 
34 30 1530 890 570 390 100 - 
35 19 1745 1090 630 210 55 - 
36 45 515 270 65 - - - 
37 25 1420 690 120 60 - - 
38 25 1240 640 210 90 - - 
39 27 1420 890 480 110 75 - 
40 17 945 540 320 90 - - 
41 57 1200 580 270 85 - - 
42 45 260 190 65 - - - 
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43 60 380 210 100 - - - 
44 49 360 170 65 - - - 
45 36 200 120 65 - - - 
46 49 2200 1870 1170 775 390 50 
47 50 1240 730 370 85 - - 
48 40 3290 2500 1390 820 380 75 
49 40 2100 1870 1070 390 90 - 
50 39 245 95 - - - - 
51 41 2700 2250 1785 1190 540 95 
52 45 480 170 80 - - - 
53 29 1210 650 320 65 - - 
54 52 560 270 62 - - - 
55 50 1265 775 390 100 - - 
56 49 1750 1080 680 310 45 - 
57 39 340 110 - - - - 
58 11 680 240 60 - - - 
59 19 715 210 45 - - - 
60 52 550 430 240 90 - - 
61 21 1320 940 690 360 120 - 
62 29 750 580 310 180 55 - 
63 40 140 80 45 - - - 
64 55 180 40 - - - - 
65 50 750 480 370 210 70 - 
66 39 310 110 54 - - - 
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67 38 380 160 45 - - - 
68 19 1075 490 210 85 - - 
69 35 2650 1280 630 290 80 - 
70 45 340 190 75 - - - 
71 31 1625 745 320 65 - - 
72 49 190 60 - - - - 
73 45 130 65 - - - - 
74 53 470 190 75 - - - 
75 48 230 40 - - - - 
76 20 160 45 - - - - 
77 17 750 370 60 - - - 
78 27 3010 1830 1110 830 460 80 
79 31 800 380 45 - - - 
80 50 180 50 - - - - 
81 35 2190 1745 1070 470 90  
82 39 130 50 - - - - 
83 29 380 85 - - - - 
84 41 118 45 - - - - 
85 22 120 85 - - - - 
86 31 1060 470 270 95 - - 
87 47 260 75 - - - - 
88 28 425 190 40 - - - 
89 12 390 90 - - - - 
90 41 140 50 - - - - 
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91 36 410 85 - - - - 
92 44 460 180 65 - - - 
93 39 540 280 65 - - - 
Average  1092.344 651.075 446.28 334.893 194.516 68 
 
Table 5.5.a: P value of SGPT after treatment with Livercare Churna 
Group 
(week) 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median 
Initial 1092.3 933.22 96.254 750.00 
First 651.08 658.63 67.932 420.00 
Second 446.28 463.63 53.182 310.00 
Third 334.89 309.64 44.692 210.00 
Fourth 194.52 192.65 34.056 90.00 
Sixth 68.000 22.935 6.915 75.00 
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Table 5.5.b: Paired samples test of SGPT after treatment with Livercare 
Churna 
Pai
r  
Paired Differences 
t test df 
P value 
Signific
ant (2 
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
397.374 354.245 34.407 329.151 465.597 11.549 105 0.000* 
779.914 558.323 60.918 658.750 901.077 12.803 83 0.000* 
1342.05 698.744 96.898 1147.52 1536.58 13.850 51 0.000* 
1862.10 777.905 135.41 1586.26 2137.93 13.751 32 0.000* 
2893.00 474.881 150.17 2553.29 3232.70 19.265 9 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
Table 5.6:  SGPT values of the patients after treatment with Hepatogard 
forte Tablet  
Sr. no 
of 
patients 
Age 
SGPT values after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 370 190 45 - - - 
2 34 700 390 210 85 - - 
3 50 2250 1890 1200 970 535 110 
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4 39 3690 2980 2110 1340 650 210 
5 39 2700 2260 1390 810 390 110 
6 60 3250 2790 1770 1090 435 110 
7 32 1250 810 645 290 85 - 
8 49 780 610 370 230 65 - 
9 55 260 170 90 - - - 
10 60 380 210 85 - - - 
11 35 520 310 140 65 - - 
12 36 290 130 90 - - - 
13 58 680 490 330 290 170 65 
14 40 300 130 60 - - - 
15 50 340 170 65 - - - 
16 29 235 165 90 - - - 
17 38 180 112 65 - - - 
18 42 210 150 75 - - - 
19 59 205 130 65 - - - 
20 11 340 190 70 - - - 
21 32 1150 740 390 190 45 - 
22 60 1800 845 340 190 65 - 
23 35 470 190 75 - - - 
24 59 1100 590 240 85 - - 
25 49 680 390 110 55 - - 
26 21 1260 740 320 110 - - 
27 60 260 180 80 - - - 
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28 45 220 170 110 45 - - 
29 50 1490 970 530 320 110 - 
30 55 250 120 85 45 - - 
31 51 940 430 190 110 - - 
32 23 1110 820 520 310 90 - 
33 20 210 120 50 - - - 
34 22 115 50 - - - - 
35 48 220 130 60 - - - 
36 47 1500 980 590 310 95 - 
37 41 940 470 230 110 - - 
38 32 1040 725 410 210 110 - 
39 21 740 360 95 - - - 
40 21 810 430 220 65 - - 
41 22 140 60 - - - - 
42 50 180 70 - - - - 
43 42 120 55 - - - - 
44 30 375 110 55 - - - 
45 18 425 340 210 63 - - 
46 30 150 45 - - - - 
47 40 410 180 120 58 - - 
48 35 180 50 - - - - 
49 28 430 370 290 180 70 - 
50 37 895 710 410 310 170 60 
51 49 130 100 45 - - - 
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52 30 125 110 65 - - - 
53 29 190 70 - - - - 
54 41 470 310 190 85 - - 
55 42 450 300 95 - - - 
56 37 130 55 - - - - 
57 18 650 430 280 160 60 - 
58 13 145 65 - - - - 
59 23 485 240 180 150 100 45 
60 28 110 53 - - - - 
61 45 635 540 320 120 80 - 
62 15 670 480 370 80 - - 
63 50 1310 840 530 210 80 - 
64 32 380 90 - - - - 
65 43 2100 1400 790 460 320 80 
66 36 2020 970 470 310 70 - 
67 38 390 90 - - - - 
68 35 648 320 110 - - - 
69 51 290 180 80 - - - 
70 55 550 430 220 110 50 - 
71 43 270 120 60 - - - 
72 46 390 190 70 - - - 
73 59 270 90 - - - - 
74 39 320 280 170 110 70 - 
75 55 1060 630 480 210 90 - 
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76 35 1100 620 310 80 - - 
77 51 155 60 - - - - 
78 45 980 610 290 85 - - 
79 40 600 310 90 - - - 
80 17 1920 1010 640 380 200 49 
81 50 825 580 320 75 - - 
82 50 280 95 - - - - 
83 20 700 350 85 - - - 
84 51 430 220 75 - - - 
85 55 320 120 60 - - - 
86 50 1250 570 310 45 - - 
87 39 250 150 55 - - - 
88 47 2190 1540 630 310 45 - 
89 37 538 230 110 - - - 
90 40 280 130 45 - - - 
91 51 1750 880 320 75 - - 
92 47 2380 1790 1430 910 425 90 
93 49 1390 870 530 290 95 - 
94 39 300 140 55 - - - 
95 35 550 290 130 45 - - 
Average  746.484 470.157 308.812 254.916 170.357 92.9 
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Table 5.7.a: P value of SGPT after treatment with Hepatogard forte Tablet 
Group 
(week)  
Mean  Standard 
Deviation  
Standard 
Error of Mean  
Median 
Initial 746.48 690.95 66.486 430.00 
First 470.15 533.54 52.318 285.00 
Second 308.81 370.96 39.771 180.00 
Third 254.91 280.11 38.477 120.00 
Fourth 170.35 159.93 28.725 90.000 
Sixth 92.900 45.658 13.767 90.000 
 
Table 5.7.b: Paired samples test of SGPT after treatment with 
Hepatogard forte Tablet 
Pai
r  
Paired Differences 
t test  df 
P value 
Signific
ant (2 
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
271.822 218.012 21.076 230.037 313.607 12.89 106 0.000* 
536.329 395.935 42.206 452.438 620.220 12.70 87 0.000* 
907.944 528.325 71.895 763.739 1052.14 12.62 53 0.000* 
1255.645 728.786 130.893 988.324 1522.96 9.593 30 0.000* 
1804.181 1082.89 326.506 1076.67 2531.68 5.526 10 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.8:  Comparative average SGPT values for different week 
treatment using Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet.  
Week 
Phyllanthus 
amarus 
Livercare 
Churna 
Hepatogard 
forte Tablet 
Initial 747.944 1092.344 746.484 
First 402.000 651.075 470.157 
Second 262.126 446.280 308.812 
Third 152.843 334.893 254.916 
Fourth 92.391 194.516 170.357 
Sixth 66.250 68.000 92.900 
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Figure 5.2: SGPT v/s Week of treatment. Column graph showing 
comparative value of SGPT for different week treatment using 
Phyllanthus amarus, Livercare Churna and Hepatogard forte Tablet as 
hepatoprotective drugs. 
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For Phyllanthus amarus the mean SGPT value of the group on zero 
day is considered as 100%. In comparison with zero week, SGPT level are 
recovered on first week 46.18% on second week 64.92% on third week 
79.65%, on fourth week87.63% and sixth weeks 91.13% respectively. The P 
value is < 0.0001.  
For Livercare Churna the mean SGPT value of the group on zero day 
is considered as 100%. In comparison with zero week, SGPT level are 
recovered on first week 40.38%, on second week 59.15%, on third week 
69.41%, on fourth week 82.23% and sixth weeks 93.77% respectively. The P 
value is < 0.0001.  
For Hepatogard forte Tablet the mean SGPT value of the group on 
zero day is considered as 100%. In comparison with zero week, SGPT level 
are recovered on first week 36.99%, on second week 58.71%, on third week 
65.95%, on fourth week 77.21% and sixth weeks 87.66% respectively. The P 
value is < 0.0001.  
Table 5. 9: Percentage recovery of SGPT with different formulations 
Treatment %Recovery 
Formulation First week 
Second 
week 
Third week 
Fourth 
week 
Sixth week 
Phyllanthus 
amarus 
46.18 64.92 79.65 87.63 91.13 
Livercare 
Churna 
40.38 59.15 69.41 82.23 93.77 
Hepatogard 
forte Tablet 
36.99 58.71 65.95 77.21 87.66 
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Table 5.10:  Bilirubin values of the patients after treatment with 
Phyllanthus amarus.   
Sr. no of 
patients 
Age Bilirubin value mg % after different week treatment 
Initial 
(zero 
week) First Second Third Forth Six 
1 28 1.6 1.1 - - - - 
2 51 3.2 1.4 - - - - 
3 20 3 1.1 - - - - 
4 16 9.6 6.2 4.6 2.9 1.1 - 
5 42 12.2 8.2 5.2 2.8 1 - 
6 17 4.2 1.9 0.9 - - - 
7 65 2.6 1 - - - - 
8 65 1.3 0.9 - - - - 
9 36 12 7.3 4.3 1.1 - - 
10 42 2.7 1.2 - - - - 
11 35 11.2 7.4 4.3 1.1 - - 
12 21 6.1 5.8 4.3 1 - - 
13 32 4.7 3.1 1.2 - - - 
14 32 13 5.4 1.2 - - - 
15 28 12.4 10.2 8.2 6.3 1.2 - 
16 45 1.5 1.2 1 - - - 
17 17 3.2 1.2 - - - - 
18 32 3.5 1.1 - - - - 
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19 20 12.5 11.1 7.8 3.8 0.9 - 
20 38 10.6 9.8 6.5 3.6 1.3 0.9 
21 19 1.8 1.6 1.2 0.9 - - 
22 38 1.8 1.1 - - - - 
23 16 4.8 4.1 3.9 2.9 2.1 1.1 
24 19 3.9 2.8 2 1 - - 
25 22 4.8 3.9 2.4 1.1 - - 
26 65 12.1 6.2 3.1 1.3 - - 
27 35 5.4 2.6 1.1 - - - 
28 32 4.8 2.1 0.9 - - - 
29 42 2.2 1 - - - - 
30 43 18 13.4 8.3 5.3 3 1.2 
31 28 12.3 8.1 4.4 2.1 1.2 - 
32 50 13.3 9.2 6.1 3.2 1.3 - 
33 55 7.4 3.1 0.9 0.9 - - 
34 45 9.4 5.2 2.1 0.9 - - 
35 55 7.3 3.9 1 - - - 
36 40 3.2 1.6 1 - - - 
37 20 4.2 2.1 1 0.9 - - 
38 50 4.3 2.1 0.9 - - - 
39 45 4.3 1.9 1 - - - 
40 50 5.5 3.2 2 1.2 0.9 - 
41 50 7.3 4.2 2.1 0.9 - - 
42 45 4.9 1.7 1.2 - - - 
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43 32 6.4 2.2 1.6 1.2 0.9 - 
44 55 3.9 1.7 1 - - - 
45 21 10.2 6.4 3.2 2.1 0.9 - 
46 50 9.8 4.8 3.4 2.2 1 - 
47 19 3.4 1.2 - - - - 
48 42 8.5 4.3 1.7 0.9 - - 
49 71 2.5 1.2 - - - - 
50 38 14 9.2 6.2 3.6 1.3 - 
51 30 11.5 7.3 3.4 1.1 - - 
52 30 1.9 0.9 - - - - 
53 54 2.9 1 - - - - 
54 42 1.7 1 0.9 - - - 
55 22 2.9 1.4 0.9 - - - 
56 42 7.4 4.8 2.3 1 - - 
57 46 10.1 8.2 6.3 3.4 1 - 
58 11 2.9 0.9 - - - - 
59 38 6.5 3.4 1.9 0.9 - - 
60 70 2.7 1 - - - - 
61 20 11.2 8.2 4.2 1.2 - - 
62 23 4.5 1.2 0.9 - - - 
63 35 8.5 5.1 2.4 1 - - 
64 36 3.4 2 1 - - - 
65 24 6.1 2.8 1.1 - - - 
66 40 2.9 0.9 - - - - 
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67 28 9.3 4.2 2 1 - - 
68 13 2.9 1 - - - - 
69 45 3.2 2.1 1.1 0.9 - - 
70 15 3.2 1 - - - - 
71 32 4.8 2.1 1.3 0.9 - - 
72 55 5.1 3.2 2.7 1.4 0.9 - 
73 11 3.4 2.1 1 - - - 
74 30 5.9 3.1 1.9 1 - - 
75 12 4 2.1 1 - - - 
76 13 3.2 1.2 - - - - 
77 65 12 8.4 5.4 3.1 1.1 - 
78 30 3.4 1.3 - - - - 
79 50 6 2.9 1 - - - 
80 49 4.9 3.2 2.2 1.7 1 - 
81 45 3.9 1.8 1 - - - 
82 36 4.3 3.3 2.3 1.7 0.9 - 
83 40 6.1 2.9 1.2 - - - 
84 11 3.9 3 2.4 1.3 0.8 - 
85 50 4.5 2.4 1.1 - - - 
86 35 4.2 2.1 0.9 - - - 
87 30 6.5 3.2 1.8 0.9 - - 
88 25 4.5 2.3 1 - - - 
89 65 3 1.7 0.9 - - - 
90 30 1.5 1 - - - - 
Chapter 5  RESULT AND DISCUSSION  
136 
 
91 35 2.8 1 - - - - 
92 50 7.8 5.1 3.2 0.9 - - 
93 37 1.7 1 - - - - 
94 53 5 3.2 2.1 1 - - 
95 42 7 4.5 2.9 1.1 - - 
96 12 3.9 2.9 1.4 0.9 - - 
97 40 17 11.2 8.3 6 3.2 1 
98 45 3 1 - - - - 
99 27 9.1 6.2 3.8 1 - - 
100 25 2.4 1 - - - - 
101 21 2.5 1.8 11.7 - - - 
102 30 4 3.2 2.1 1.7 0.9 - 
103 20 7.8 4.2 1.3 - - - 
104 51 3.2 1.2 - - - - 
105 5 14 8.4 5.3 2.9 1 - 
106 42 3.3 1.1 - - - - 
107 32 7.5 4.7 2.1 1 - - 
Average  5.9401 3.5149 2.7202 1.8470 1.2565 1.05 
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Table5.11.a: P value of Billirubin after treatment with Phyllanthus amarus 
 Group Mean Standard 
Deviation 
Standard 
Error of Mean 
Median 
Initial 5.940 3.744 0.3602 4.600 
First 3.515 2.804 0.2698 2.700 
Second 2.720 2.226 0.2489 2.000 
Third 1.847 1.339 0.1856 1.150 
Fourth 1.257 0.6261 0.1278 1.000 
Sixth 1.050 0.1118 0.0500 1.050 
Table 5.11.b: Paired samples test of bilirubin after treatment with 
Phyllanthus amarus 
Pair 
Paired Differences 
t test df 
P value 
Significant 
(2 tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
2.4252 1.399 0.135 2.1569 2.693 17.922 106 0.000* 
4.3772 2.803 0.315 3.7491 5.005 13.876 78 0.000* 
6.5980 2.970 0.415 5.7625 7.433 15.862 50 0.000* 
8.6087 3.933 0.820 6.9075 10.309 10.495 22 0.000* 
11.550 6.121 3.064 1.8096 21.290 3.774 3 0.033 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.12:  Bilirubin values of the patients after treatment with Livercare 
Churna.  
Sr. no 
of 
patients 
Age  Bilirubin value mg % after different week treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 17 4.1 2.2 1 - - - 
2 47 3.9 2.9 1.8 1 - - 
3 49 5.7 2.1 1.2 - - - 
4 51 6.9 4.6 3.1 2.3 1.7 0.8 
5 31 4.9 2.6 1 - - - 
6 53 8 4.4 2.1 0.9 - - 
7 47 8.9 5.4 3.1 1 - - 
8 40 7.9 6.3 5.3 3.1 2.7 0.9 
9 47 9.7 4.3 3.1 2 1 - 
10 50 6.8 4.2 3.4 2.1 1 - 
11 44 3.2 1.7 0.9 - - - 
12 46 9.9 7.8 5.4 4.3 2.1 0.9 
13 35 5.5 3.3 2 0.9 - - 
14 55 3.7 2.1 0.9 - - - 
15 50 11.5 8.9 6.5 3.1 1 - 
16 60 7.7 4.3 3.2 2.1 1.3 0.9 
17 43 3.9 1.1 - - - - 
18 45 4.5 2.9 0.9 - - - 
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19 40 7.6 6.2 4.9 2.4 1.4 1 
20 29 2.4 1.7 0.9 - - - 
21 44 9.5 6.3 4.3 2.1 1 - 
22 25 4.1 3.2 2.5 1.8 0.9 - 
23 17 6.7 4.3 3.2 1.8 1.1 - 
24 40 2.9 1.2 - - - - 
25 35 8 6.1 4.3 3.1 1 - 
26 25 5.3 5.2 4.6 2.8 1.2 - 
27 21 6.5 4.3 3.2 1.8 1 - 
28 52 4 1.8 1 - - - 
29 45 4.8 3.2 2 1.3 0.9 - 
30 62 30 21.2 12.6 7.3 4.9 1.2 
31 50 2 1.4 1 - - - 
32 45 5.7 4.5 2.2 1 - - 
33 50 7.3 4.3 3.2 1.8 1 - 
34 30 6 4.9 4 2.1 1.1 - 
35 19 6.2 4.8 3.2 2.2 0.9 - 
36 45 4 2.3 1 - - - 
37 25 3.2 1.9 1.4 0.9 - - 
38 25 4 2.4 1.6 1 - - 
39 27 6.6 5.1 3.8 2.1 1.1 - 
40 17 2.4 2 1.5 1 - - 
41 57 5.3 2.9 1.6 1 - - 
42 45 4.7 2.1 1.1 - - - 
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43 60 5.1 2.6 1.2 - - - 
44 49 5.5 2.6 1.1 - - - 
45 36 4.7 1.9 0.9 - - - 
46 49 6.9 6.2 4.4 3.2 2.1 0.9 
47 50 4.3 3.2 2.1 1 - - 
48 40 7.4 5.9 3.6 2.2 1.7 0.9 
49 40 6.7 5.8 3.2 1.8 0.9 - 
50 39 3.9 1.2 - - - - 
51 41 13.2 11.2 8.9 6.4 2.8 1 
52 45 5.6 2.8 0.9 - - - 
53 29 5.3 2.4 1.8 0.9 - - 
54 52 3.5 1.3 0.9 - - - 
55 50 7.8 4.7 3.8 1.1 - - 
56 49 6.8 5.3 4.3 2.1 1 - 
57 39 3.8 1 - - - - 
58 11 7 3.2 1.1 - - - 
59 19 5.5 2.2 1.1 - - - 
60 52 4.5 3.9 2.3 1 - - 
61 21 12.2 8.4 5.9 3.4 1 - 
62 29 10.3 8 4.7 2.1 0.9 - 
63 40 6.9 3.1 1.2 - - - 
64 55 1.9 1.1 - - - - 
65 50 14.9 8.4 5.3 2.9 1.1 - 
66 39 4.3 1.8 0.9 - - - 
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67 38 4 2.1 1 - - - 
68 19 3.2 2.3 1.2 0.9 - - 
69 35 6.2 5.4 3.8 2.4 1.1 - 
70 45 5.5 3.2 1.2 - - - 
71 31 5.6 3.1 2.4 1.1 - - 
72 49 2.6 0.9 - - - - 
73 45 2.4 1 - - - - 
74 53 3.4 1.8 0.9 - - - 
75 48 1.9 0.9 - - - - 
76 20 2.1 1 - - - - 
77 17 3.6 1.9 1 - - - 
78 27 16 10.3 7.6 5 3.1 0.9 
79 31 3.9 1.8 0.9 - - - 
80 50 1.3 1 - - - - 
81 35 12 9.7 6.4 3 1 - 
82 39 3.9 1 - - - - 
83 29 3.4 1 - - - - 
84 41 2.1 1 - - - - 
85 22 2.9 1 - - - - 
86 31 6.7 4.1 2.3 1 - - 
87 47 3.4 1 - - - - 
88 28 5.1 2.3 1 - - - 
89 12 4.4 1 - - - - 
90 41 1.4 1 - - - - 
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91 36 3.2 1 - - - - 
92 44 5.2 3.1 0.9 - - - 
93 39 4.9 2.8 1.1 - - - 
Average  5.8516 3.6483 2.7373 2.1659 1.4516 0.94 
 
Table 5.13.a: P value of bilirubin after Livercare Churna treatment 
Group 
(week)  
   Mean  Standard 
Deviation  
Standard 
Error of Mean  
Median 
Initial 5.851 3.758 0.3614 4.85 
First 3.648 2.996 0.2938 2.9 
Second 2.737 2.105 0.2297 2.0 
Third 2.165 1.347 0.1869 2.05 
Fourth 1..451 0.8450 0.1449 1.075 
Sixth 0.940 0.1020 0.03075 0.9 
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Table 5.13.b: Paired samples test of bilirubin after treatment with 
Livercare Churna 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
Table 5.14:  Bilirubin values of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no of 
patients 
Age Bilirubin value mg % after different week treatment 
Initial(zero 
week) First Second Third Fourth Sixth 
1 32 4.2 2.1 1 - - - 
2 34 6.9 4.2 2.2 1.1 - - 
3 50 13.4 8.9 6.3 4.8 3.1 1 
4 39 6.9 5.4 4.9 4 3.1 1.7 
Pai
r 
Paired Differences 
t test df 
P value 
Significant 
(2 tailed) Mean 
Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
2.1561 1.3007 0.1314 1.8953 2.4169 16.409 97 0.000* 
3.7794 2.1930 0.2483 3.2850 4.2739 15.221 77 0.000* 
5.5416 3.4018 0.4910 4.5538 6.5294 11.286 47 0.000* 
7.6322 4.2186 0.7576 6.0848 9.1796 10.073 30 0.000* 
10.410 7.1326 2.2555 5.3076 15.5123 4.615 9 0.001* 
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5 39 22.1 18.3 12.2 9.4 6.3 2.1 
6 60 14 12.1 8.3 6.9 3.4 1.2 
7 32 7.4 4.3 3.1 2.7 1 - 
8 49 11 8.4 5.9 3.7 1.2 - 
9 55 6.2 3.9 1.3 - - - 
10 60 4.3 2.4 0.9 - - - 
11 35 6.9 3.6 1.7 0.9 - - 
12 36 4.9 2.4 1 - - - 
13 58 13.7 8.9 6.2 3.4 2.1 0.9 
14 40 7.4 3.2 1.2 - - - 
15 50 2.9 1.4 0.9 - - - 
16 29 3.7 2.1 1 - - - 
17 38 4 1.9 1 - - - 
18 42 5.1 2.9 1 - - - 
19 59 3.4 2.1 0.9 - - - 
20 11 4.3 2.1 1 - - - 
21 32 6.4 3.2 2.4 1.3 0.9 - 
22 60 7 4.3 2.1 1.7 0.9 - 
23 35 3.9 1.6 1 - - - 
24 59 7 3.2 2.1 1 - - 
25 49 4.4 2.1 1.7 0.9 - - 
26 21 3.9 2.1 1.4 1 - - 
27 60 2.9 1.4 0.9 - - - 
28 45 6.4 3.9 2.1 1 - - 
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29 50 8.2 6.8 4.6 2.8 1.2 - 
30 55 6.3 4.2 2.4 1.1 - - 
31 51 6.4 4.2 1.9 1 - - 
32 23 4.2 2.2 1.2 1 0.9 - 
33 20 5.7 2.6 1.2 - - - 
34 22 3.2 1.2 - - - - 
35 48 5.3 2.9 1.1 - - - 
36 47 4.3 3.2 2.8 1.9 1 - 
37 41 5.9 4 2.2 1 - - 
38 32 7.4 5.4 3.2 2.8 1.1 - 
39 21 4.4 2.2 0.9 - - - 
40 21 4.3 2.3 1.4 0.9 - - 
41 22 1.3 0.9 - - - - 
42 50 3.3 1.1 - - - - 
43 42 1.4 1 - - - - 
44 30 5.6 3.2 1 - - - 
45 18 10 8.3 5.8 1.2 - - 
46 30 1.3 1 - - - - 
47 40 7.1 4.3 2.3 1 - - 
48 35 2.7 1 - - - - 
49 28 8.3 6.3 3.9 2 1 - 
50 37 12.1 9.1 8.4 6.1 2.3 1 
51 49 3 1.8 0.9 - - - 
52 30 5.9 3 1.2 - - - 
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53 29 3.8 1.4 - - - - 
54 41 6.1 4.8 1.9 1 - - 
55 42 5.9 3.2 1.1 - - - 
56 37 1.6 0.9 - - - - 
57 18 11.2 9.3 6.1 4.1 1.2 - 
58 13 3.2 1.1 - - - - 
59 23 19 12.7 9.5 6.1 3.1 1 
60 28 2.9 1.1 - - - - 
61 45 13.25 10.8 9.7 3.2 1.2 - 
62 15 5.7 5 3.8 1.2  - 
63 50 7.4 6.2 4.1 1.8 0.9 - 
64 32 2.1 1 - - - - 
65 43 8.3 6.8 4.9 3.2 1.8 0.9 
66 36 10.1 8 5.8 3.2 1.1 - 
67 38 1.2 0.9 - - - - 
68 35 3.2 2.2 1.1 - - - 
69 51 3.1 2.1 1.1 - - - 
70 55 6.2 4.8 2.9 1.8 0.9 - 
71 43 3.1 1.4 0.9 - - - 
72 46 4.1 2 1 - - - 
73 59 1.6 1 - - - - 
74 39 7.6 6.4 4.3 2.6 1.1 - 
75 55 6.3 4.2 2.9 1.8 0.9 - 
76 35 3.2 1.8 1 0.9 - - 
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77 51 1.9 1 - - - - 
78 45 4.8 3.2 1.7 0.9 - - 
79 40 4.8 2.1 1  - - 
80 17 16 12.2 9.3 6.2 4.1 1.1 
81 50 4.9 4.1 2.1 0.9 - - 
82 50 3.7 1 - - - - 
83 20 3.1 2.7 1 - - - 
84 51 5.1 2.3 1 - - - 
85 55 4.1 2.7 1 - - - 
86 50 6.6 4 1.9 0.9 - - 
87 39 4 2.1 1 - - - 
88 47 6.9 4 2.7 1.3 0.9 - 
89 37 5.7 2.9 1 - - - 
90 40 3.7 1.9 0.8 - - - 
91 51 6.7 3.2 2 0.9 - - 
92 47 8.4 6.2 5 3.9 2.1 0.9 
93 49 10.7 7.4 4.9 2.1 0.9 - 
94 39 3.2 1.9 1 - - - 
95 35 4.9 2.3 1.7 0.9 - - 
Average  6.0163 3.9042 2.7912 2.4062 1.775 1.18 
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Table 5.15.a: P value of bilirubin after treatment with Hepatogard forte 
Tablet. 
Group 
(week) 
Mean Standard 
Deviation 
Standard 
Error of Mean 
Medi
an 
Initial 6.016 3.702 0.3630 5.1 
First 3.904 3.076 0.3045 2.9 
Second 2.791 2.457 0.2665 1.7 
Third 2.406 1.897 0.2656 1.7 
Fourth 1.775 1.266 0.2351 1.2 
Sixth 1.180 0.3816 0.1150 1.0 
Table 5.15.b: Paired samples test of bilirubin after treatment with 
Hepatogard forte Tablet 
Pai
r 
Paired Differences 
t test  df 
P value 
Significa
nt (2 
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
2.163 1.112 0.107 1.949 2.376 20.111 106 0.000* 
3.896 2.202 0.234 3.429 4.362 16.597 87 0.000* 
5.975 2.554 0.347 5.277 6.672 17.185 53 0.000* 
8.320 3.560 0.639 7.014 9.627 13.011 30 0.000* 
12.55 4.592 1.384 9.469 15.639 9.066 10 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.16:  Comparative average bilirubin values for different week 
treatment using Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet. 
Week 
Phyllanthus 
amarus 
Livercare 
Churna 
Hepatogard forte 
Tablet 
Initial 5.9401 5.8516 6.0163 
First 3.5149 3.6483 3.9042 
Second 2.7202 2.7373 2.7912 
Third 1.8470 2.1659 2.4062 
Fourth 1.2565 1.4516 1.7750 
Sixth 1.0560 0.9400 1.1800 
 
Comparatively values of Billirubin
0
1
2
3
4
5
6
7
INITIAL FIRST SECOND THIRD FOURTH SIX
Week
B
il
li
ru
b
in Phyllanthus Amarus
Liver care
Hepatogard forte
 
Figure 5.3: Bilirubin v/s Week. Column graph showing comparative 
values of bilirubin for different week treatment using Phyllanthus 
amarus, Livercare Churna and Hepatogard forte Tablet as 
hepatoprotective drugs. 
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For Phyllanthus amarus the mean bilirubin value of the group on zero 
day is considered as 100%. In comparison with zero week, bilirubin level are 
recovered on first week 46.18%, on second week 64.92%, on third week 
79.65%, on fourth week 87.63% and sixth weeks 91.13% respectively. The P 
value is < 0.0001.  
For Livercare Churna the mean bilirubin value of the group on zero day 
is considered as 100%. In comparison with zero week, bilirubin level are 
recovered on first week 37.7%, on second week 53.33%, on third week 
63.07%, on fourth week 75.21% and sixth weeks 83.93% respectively. The P 
value is < 0.0001.  
For Hepatogard forte Tablet the mean bilirubin value of the group on 
zero day is considered as 100%. In comparison with zero week, bilirubin level 
are recovered on first week 35.10%, on second week 55.07%, on third week 
60.06%, on fourth week 70.46% and sixth weeks 80.36% respectively. The P 
value is < 0.0001.  
Table 5. 17: Percentage recovery of bilirubin with different formulations 
Treatment %Recovery 
Formulation First week 
Second 
week 
Third week 
Fourth 
week 
Sixth week 
Phyllanthus 
amarus 
46.18 64.92 79.65 87.63 91.13 
Livercare 
Churna 
37.70 53.33 63.07 75.21 83.93 
Hepatogard 
forte Tablet 
35.10 55.07 66.06 70.46 80.36 
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Table 5.18: Haemoglobin values of the patients after treatment with 
Phyllanthus amarus.  
Sr. no 
of 
patients 
Age Hb values after different weeks treatment 
Initial 
(zero 
week) First Second Third Forth Six 
1 28 8.4 9.2 - - - - 
2 51 12.1 12.2 - - - - 
3 20 12.2 12.4 - - - - 
4 16 10.2 10.3 10.4 10.5 10.5 - 
5 42 12.6 12.7 12.7 12.8 12.8 - 
6 17 10.7 10.8 10.9 - - - 
7 65 12.2 12.4 - - - - 
8 65 9.8 9.9 - - - - 
9 36 10.3 10.4 10.4 10.5 - - 
10 42 11.2 11.3 - - - - 
11 35 11.2 11.3 11.4 11.6 - - 
12 21 10.6 10.8 10.9 11.1 - - 
13 32 10.4 10.5 11.1 - - - 
14 32 9.8 10.1 10.2 - - - 
15 28 10.2 10.3 10.4 12.1 12.1  
16 45 10.2 10.5 10.7 - - - 
17 17 11.4 11.8 - - - - 
18 32 10.7 10.9 - - - - 
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19 20 11.3 11.5 12.3 12.5 12.6 - 
20 38 11.3 11.3 11.4 11.6 11.7 11.8 
21 19 11.7 11.9 12.1 12.3 - - 
22 38 10.8 10.9 - - - - 
23 16 9 9.1 9.3 9.6 9.8 10 
24 19 13 13.1 13.4 13.5 - - 
25 22 12 12.1 12.4 12.5 - - 
26 65 12.2 12.4 12.6 12.7 - - 
27 35 11.9 12.1 12.5 - - - 
28 32 10.4 10.6 10.6 - - - 
29 42 13.2 13.3 - - - - 
30 43 12.1 12.2 12.3 12.5 12.7 12.8 
31 28 12.7 12.8 12.8 12.9 12.9 - 
32 50 12.2 12.4 12.7 12.9 13 - 
33 55 9.2 9.3 9.5 9.7 - - 
34 45 10.9 10.9 11 11.1 - - 
35 55 9.1 9.5 9.5 - - - 
36 40 10.2 10.4 10.5 - - - 
37 20 9.1 9.3 9.5 9.6 - - 
38 50 12.2 12.4 12.4 - - - 
39 45 11.4 11.6 11.6 - - - 
40 50 9.5 9.7 9.9 9.9 10.1 - 
41 50 10.2 10.7 10.7 10.9 - - 
42 45 11.4 11.9 11.9 - - - 
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43 32 12.2 12.6 12.6 12.7 12.8 - 
44 55 12.2 12.4 12.6 - - - 
45 21 9.2 9.4 9.7 9.9 10.1 - 
46 50 9.4 9.6 9.9 10 10.3 - 
47 19 11.4 11.5 - - - - 
48 42 11.2 11.4 11.5 11.6 - - 
49 71 11.2 11.4 - - - - 
50 38 10.2 10.4 10.5 10.5 10.5 - 
51 30 9.2 9.4 9.5 9.6 - - 
52 30 10.2 10.4 - - - - 
53 54 9.7 9.9 - - - - 
54 42 10.7 10.9 11 - - - 
55 22 10.1 10.3 10.3 - - - 
56 42 11.1 11.3 11.4 11.4 - - 
57 46 12.1 12.1 12.2 12.4 12.4 - 
58 11 10.6 10.8 - - - - 
59 38 9.4 9.6 9.6 9.6 - - 
60 70 10.4 10.6 - - - - 
61 20 11.9 12 12.1 12.2 - - 
62 23 10.4 10.6 10.7 - - - 
63 35 12.2 12.4 12.5 12.6 - - 
64 36 12.7 12.8 12.9 - - - 
65 24 11.8 12.4 12.5 - - - 
66 40 13.6 13.8 - - - - 
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67 28 12.4 12.5 12.6 12.7 - - 
68 13 11.3 11.5 - - - - 
69 45 12.7 12.9 13 13.1 - - 
70 15 10.4 10.6 - - - - 
71 32 10.3 10.5 10.5 10.6 - - 
72 55 8.3 8.5 8.6 8.7 8.8 - 
73 11 11.3 11.5 11.5 - - - 
74 30 12 12.6 12.6 12.6 - - 
75 12 11.2 12.4 12.5 - - - 
76 13 11.7 11.9 - - - - 
77 65 11.9 12 12.1 12.3 12.5 - 
78 30 12.9 13.2 - - - - 
79 50 13.4 13.6 13.7 - - - 
80 49 11.7 11.9 12 12.1 12.1 - 
81 45 13.2 13.3 13.4 - - - 
82 36 11 11.1 11.2 11.4 11.5 - 
83 40 10.6 10.7 10.7 - - - 
84 11 9.9 10 10.1 10.1 10.2 - 
85 50 8.6 8.8 8.9 - - - 
86 35 8.6 8.8 8.9 - - - 
87 30 9.9 10 10 10.1 - - 
88 25 13.2 13.2 13.2 - - - 
89 65 12.4 12.4 12.5 - - - 
90 30 12.4 12.4 - - - - 
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91 35 10.6 10.7 - - - - 
92 50 11.3 11.4 11.5 11.5 - - 
93 37 8.7 8.8 - - - - 
94 53 7.1 7.2 7.3 7.5 - - 
95 42 8.7 8.8 8.9 9 - - 
96 12 10.1 10.3 10.4 10.4 - - 
97 40 10.9 11 11.1 11.2 11.3 11.4 
98 45 8.4 8.6 - - - - 
99 27 8.7 8.8 8.9 8.9 - - 
100 25 10.1 10.3 - - - - 
101 21 11.4 11.6 11.6 - - - 
102 30 10.2 10.3 10.3 10.4 10.5 - 
103 20 12.6 12.7 12.8 - - - 
104 51 10.6 10.8 - - - - 
105 5 10.2 10.3 10.4 10.5 10.5 - 
106 42 11.6 11.7 - - - - 
107 32 9.1 9.3 9.4 9.5 - - 
Average  10.8962 11.0850 11.1658 11.1352 11.3782 11.5 
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Table 5.19.a: P value of Hb after treatment with Phyllanthus amarus  
Group Mean Standard 
Deviation 
Standard  
Error of Mean 
Median 
Initial 10.896 1.336 0.1286 10.9 
First 11.085 1.332 0.1282 11.043 
Second 11.166 1.358 0.1518 11.133 
Third 11.135 1.374 0.1906 11.168 
Fourth 11.387 1.211 0.2472 11.439 
Sixth 11.5 1.005 0.4494 11.5 
 
Table 5.19.b: Paired samples test of Hb after treatment with Phyllanthus 
amarus 
Pai
r 
Paired Differences 
t test df 
P value 
Significan
t  (2 
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
-.188 .157 .015 -.218 -.158 -12.40 106 0.000* 
-.303 .199 .022 -.348 -.259 -13.56 78 0.000* 
-.429 .278 .038 -.507 -.351 -11.02 50 0.000* 
-.582 .395 .082 -.753 -.411 -7.073 22 0.000* 
-.675 .236 .118 -1.051 -.299 -5.713 3 0.011 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.20: Haemoglobin values of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients 
Hb value after different weeks treatment 
Age 
Initial First Second Third Fourth Sixth 
1 17 11.5 11.6 11.7 - - - 
2 47 10.5 10.6 10.7 10.7 - - 
3 49 11.2 11.4 11.5 - - - 
4 51 9.6 9.8 9.9 10 10 10.1 
5 31 11.6 11.7 11.9 - - - 
6 53 12.1 12.3 12.4 12.5 - - 
7 47 9.1 9.4 9.5 9.5 - - 
8 40 12.2 12.4 12.6 12.7 12.8 12.8 
9 47 8.6 8.7 8.8 8.9 9 - 
10 50 11.4 11.6 11.7 11.8 11.9 - 
11 44 11.4 11.6 11.7 - - - 
12 46 10.7 10.9 11 11 11.5 11.6 
13 35 9.6 9.7 9.8 9.8 - - 
14 55 10.9 11 11.1 - - - 
15 50 12.2 12.4 12.5 12.5 12.5 - 
16 60 10.1 10.4 10.7 10.8 10.8 10.8 
17 43 10.3 10.6 - - - - 
18 45 10.2 10.4 10.5 - - - 
19 40 9.4 9.6 9.7 9.7 9.8 9.9 
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20 29 10.7 10.9 11 - - - 
21 44 8.9 9 9.1 9.3 9.4 - 
22 25 12.1 12.3 12.4 12.4 12.5 - 
23 17 10.3 10.4 10.5 10.6 10.6 - 
24 40 10.2 10.7 - - - - 
25 35 11.2 11.4 11.4 11.5 11.6 - 
26 25 11.2 11.3 11.4 11.6 11.6 - 
27 21 10.1 10.4 10.6 10.7 10.9 - 
28 52 10.1 10.4 10.8 - - - 
29 45 8.7 8.8 8.9 9.1 9.2 - 
30 62 8.2 8.6 9 9.2 9.3 9.5 
31 50 9.2 9.4 9.6 - - - 
32 45 11.2 11.3 11.4 11.5 - - 
33 50 10.7 10.8 10.8 10.9 10.9 - 
34 30 9.3 9.5 9.8 10 10.1 - 
35 19 11.2 11.2 11.3 11.4 11.5 - 
36 45 9.3 9.4 9.6 - - - 
37 25 9.3 9.6 9.8 9.9 - - 
38 25 11.4 11.6 11.7 11.8 - - 
39 27 9.3 9.6 9.8 10 10.1 - 
40 17 11.3 11.6 11.7 11.8 - - 
41 57 13 13.2 13.3 13.4 - - 
42 45 13.2 13.3 13.4 - - - 
43 60 12.6 12.8 12.9 - - - 
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44 49 12.1 12.2 12.4 - - - 
45 36 12.7 12.7 12.8 - - - 
46 49 8.7 8.8 9 9.2 9.3 9.5 
47 50 9.3 9.4 9.6 9.9 - - 
48 40 8.2 8.4 8.6 8.7 8.8. 8.9 
49 40 7.9 8.1 8.2 8.3 8.4 - 
50 39 12.4 12.6 - - - - 
51 41 9.4 9.5 9.7 9.8 9.8 9.9 
52 45 12.1 12.3 12.4 - - - 
53 29 8.5 8.6 8.8 8.9 - - 
54 52 11.7 11.9 12 - - - 
55 50 11.3 11.5 11.5 11.6 - - 
56 49 10.2 10.4 10.5 10.6 10.7 - 
57 39 12.2 12.5 - - - - 
58 11 10.2 10.4 10.6 - - - 
59 19 11.2 11.2 11.3 - - - 
60 52 6 6.4 6.7 7.2 - - 
61 21 12.5 12.6 12.8 12.8 12.9 - 
62 29 9.8 9.9 10 10.1 10.2 - 
63 40 13.7 13.8 13.9 - - - 
64 55 12.6 12.7 - - - - 
65 50 13 13.2 13.3 13.3 13.4 - 
66 39 10.1 10.3 10.4 - - - 
67 38 11.4 11.6 11.7 - - - 
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68 19 9.2 9.4 9.5 9.6 - - 
69 35 8.1 8.4 8.5 8.6 8.8 - 
70 45 8.2 8.8 9 - - - 
71 31 10.7 10.9 11 11.1 - - 
72 49 10.3 10.3 - - - - 
73 45 11.6 11.7 - - - - 
74 53 9.7 9.9 10 - - - 
75 48 10.3 10.5 - - - - 
76 20 10.9 11 - - - - 
77 17 11 11.2 11.4 - - - 
78 27 9.2 9.4 9.5 9.5 9.6 9.6 
79 31 11.2 11.4 11.5 - - - 
80 50 10.9 10.9 - - - - 
81 35 9.4 9.6 9.7 9.8 9.8 - 
82 39 10.7 10.9 - - - - 
83 29 10.4 10.9 - - - - 
84 41 11.1 11.6 - - - - 
85 22 10.1 10.7 - - - - 
86 31 8.9 9.2 9.4 9.5 - - 
87 47 11.4 11.6 - - - - 
88 28 9.6 9.9 10 - - - 
89 12 9.4 9.8 - - - - 
90 41 10.3 10.5 - - - - 
91 36 10.8 11.3 - - - - 
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92 44 10.9 11 11.2 - - - 
93 39 10.3 10.5 10.6 - - - 
Average  10.50645 10.7086 10.73867 10.5 10.63 10.26 
 
Table 5.21. a: P value of Hb after treatment with Livercare Churna 
Group 
(week) 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median 
Initial 10.506 1.395 0.1402 10.4 
First 10.708 1.368 0.1389 10.709 
Second 10.738 1.413 0.1599 10.719 
Third 10.50 1.381 0.1972 10.5 
Fourth 10.63 1.299 0.2296 10.615 
Sixth 10.260 1.107 0.3339 9.9 
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Table 5.21.b: Paired samples test of Hb after treatment with Livercare 
Churna 
Pair  
Paired Differences 
t test df 
P value 
Significant 
(2 tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
.0234 .856 .082 -.140 .18749 .282 106 0.778 
-.076 1.811 .197 -.469 .31701 -.385 83 0.701 
.142 2.195 .304 -.468 .75361 .467 51 0.642 
.025 2.459 .434 -.861 .91178 .057 31 0.955 
-.690 .264 .083 -.879 -.5008 -8.25 9 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
Table 5.22: Haemoglobin values of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no 
of 
patients 
Age 
Hb values after different week treatments 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 12.3 12.4 12.4 - - - 
2 34 13.6 13.7 13.7 13.7 - - 
3 50 11 11.1 11.2 11.2 11.2 11.3 
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4 39 11.2 11.2 11.3 11.4 11.4 11.4 
5 39 10.1 10.1 10.2 10.3 10.3 10.4 
6 60 11.2 11.2 11.3 11.3 11.3 11.4 
7 32 9.3 9.3 9.4 9.4 9.5 - 
8 49 11.8 12 12.1 12.1 12.1 - 
9 55 10.6 10.6 10.7 - - - 
10 60 11.4 11.5 11.5 - - - 
11 35 10.3 10.4 10.4 10.5 - - 
12 36 13.4 13.4 13.5 - - - 
13 58 12.1 12.2 12.2 12.2 12.3 12.3 
14 40 11.2 11.3 11.4 - - - 
15 50 12.1 12.2 12.3 - - - 
16 29 12.7 12.8 12.8 - - - 
17 38 12.7 12.7 12.8 - - - 
18 42 12.8 12.8 12.9 - - - 
19 59 11.9 12 12 - - - 
20 11 12.1 12.2 12.2 - - - 
21 32 10.4 10.5 10.5 10.6 10.6 - 
22 60 11.4 11.5 11.6 11.6 11.6 - 
23 35 12.3 12.4 12.4 - - - 
24 59 9.6 9.7 9.7 9.7 - - 
25 49 11.2 11.3 11.3 11.4 - - 
26 21 11.4 11.4 11.5 11.5 - - 
27 60 9.8 9.9 9.9 - - - 
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28 45 12.9 13 13 13 - - 
29 50 11.4 11.5 11.6 11.6 11.7 - 
30 55 10.2 10.3 10.3 10.4 - - 
31 51 11.2 11.4 11.4 11.5 - - 
32 23 10.2 10.4 10.5 10.5 10.6 - 
33 20 13.7 13.7 13.7 - - - 
34 22 8.1 8.2 - - - - 
35 48 5.4 2.8 1.1 - - - 
36 47 10.1 10.3 10.3 10.4 10.5 - 
37 41 11.7 11.8 11.9 12 - - 
38 32 11.3 11.4 11.5 11.5 11.5 - 
39 21 10.7 10.9 11 - - - 
40 21 14.5 14.5 14.5 14.6 - - 
41 22 9.8 10 - - - - 
42 50 11 11.1 - - - - 
43 42 13.1 13.2 - - - - 
44 30 12.4 12.4 12.4 - - - 
45 18 10.8 10.9 10.9 11 - - 
46 30 13.2 13.3 - - - - 
47 40 12.1 12.2 12.2 12.3 - - 
48 35 11.2 11.3 - - - - 
49 28 11.7 11.7 11.8 11.8 11.9 - 
50 37 12.2 12.2 12.3 12.4 12.4 12.5 
51 49 9.9 10 10.3 - - - 
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52 30 10.8 10.9 11 - - - 
53 29 11.2 11.4 - - - - 
54 41 8.9 9 9.1 9.2 - - 
55 42 8.4 8.7 8.9 - - - 
56 37 12.3 12.4 - - - - 
57 18 10.8 10.9 11 11 11.1 - 
58 13 10.3 10.5 - - - - 
59 23 11.6 11.8 11.9 11.9 12 12.1 
60 28 13.2 13.4 - - - - 
61 45 12 12.2 12.5 12.5 12.6 - 
62 15 11.6 11.8 11.9 12  - 
63 50 9.6 9.8 9.9 10 10.1 - 
64 32 9.3 9.4 - - - - 
65 43 8.3 8.5 8.6 8.7 8.8 8.8 
66 36 9.1 9.2 9.4 9.5 9.6 - 
67 38 10.2 10.3 - - - - 
68 35 10.1 10.2 10.3 - - - 
69 51 6.8 6.9 7 - - - 
70 55 11.1 11.2 11.3 11.3 11.4 - 
71 43 12.3 12.5 12.5 - - - 
72 46 12.1 12.3 12.3 - - - 
73 59 13.2 13.4 - - - - 
74 39 8.3 8.4 8.6 8.7 8.8 - 
75 55 10.9 11 11.1 11.2 11.2 - 
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76 35 8.2 8.4 8.5 8.5 - - 
77 51 12.1 12.2 - - - - 
78 45 12.2 12.3 12.4 12.4 - - 
79 40 8.9 8.9 9  - - 
80 17 7.3 7.5 7.6 7.7 7.8 7.8 
81 50 11.7 11.8 11.9 11.9 - - 
82 50 12.7 12.7 - - - - 
83 20 13.6 13.9 14 - - - 
84 51 11.4 11.6 11.7 - - - 
85 55 12.5 12.6 12.7 - - - 
86 50 10.9 11.1 11.1 11.3 - - 
87 39 13.7 13.9 14 - - - 
88 47 11.4 11.6 11.6 11.7 11.7 - 
89 37 12.4 12.5 12.6 - - - 
90 40 13.7 13.9 14 - - - 
91 51 12.6 12.8 12.8 12.9 - - 
92 47 10.7 10.9 11 11.1 11.1 11.1 
93 49 8 8.3 8.3 8.3 8.4 - 
94 39 9 9.3 9.3 - - - 
95 35 9.2 9.3 9.4 9.4 - - 
Average  11.0873 11.1778 11.1637 11.0645 10.8392 10.91 
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Table 5.23.a: P value of Hb after treatment with Hepatogard forte Tablet 
Group 
(week) 
Mean Standard 
Deviation 
Standard 
Error of Mean 
Median 
Initial 11.087 1.682 0.1699 11.2 
First 11.177 1.774 0.1801 11.4 
Second 11.163 1.900 0.2099 11.4 
Third 11.064 1.394 0.1972 11.3 
Fourth 10.839 1.245 0.2311 11.2 
Sixth 10.910 1.447 0.4362 11.3 
 
Table 5.23.b: Paired samples test of Hb after treatment with Hepatogard 
forte Tablet 
Pair  
Paired Differences 
t test df 
P value 
Significant 
(2 tailed) Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
-.0972 .273 .0264 -.1496 -.0447 -3.676 106 0.000* 
-.1409 .489 .0521 -.2445 -.0372 -2.703 87 0.008 
-.250 .102 .0139 -.2779 -.2220 -17.95 53 0.000* 
-.322 .125 .0225 -.3687 -.2764 -14.28 30 0.000* 
-.354 .129 .0390 -.4414 -.2676 -9.092 10 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.24:  Comparative average haemoglobin values for different week 
treatment using Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet. 
Week 
Phyllanthus 
amarus 
Livercare 
Churna 
Hepatogard forte 
Tablet 
Initial 10.8962 10.5064 11.0873 
First 11.0850 10.7086 11.1778 
Second 11.1658 10.7386 11.1637 
Third 11.1352 10.5000 11.0645 
Fourth 11.3782 10.6300 10.8392 
Sixth 11.5000 10.2600 10.9100 
 
 
 
Figure 5.4: Haemoglobin v/s Week. Column graph showing comparative 
values of haemoglobin for different week treatment using Phyllanthus 
amarus, Livercare Churna and Hepatogard forte Tablet as 
hepatoprotective drugs. 
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For Phyllanthus amarus the mean haemoglobin values of group on 
zero day is consider 100% (10.89). In comparison with zero week, 
haemoglobin level increase on first, second and third week, on fourth and 
sixth week haemoglobin level decreases slightly but in comparison with zero 
week it is increased. The P value is insignificant for haemoglobin. 
For Livercare Churna the mean haemoglobin values of group on zero 
day is 10.50 gm%. In comparison with zero week, haemoglobin level increase 
on first, and second, on third and fourth week haemoglobin level decreases 
slightly but in comparison with zero week it is increased. On sixth week 
haemoglobin level decreased compared to zero week.  The P value is 
insignificant for haemoglobin. 
For Hepatogard forte Tablet the mean haemoglobin values of group on 
zero day is 11.087 gm%. In comparison with zero week, haemoglobin level 
increase on first and second week, on third, fourth and sixth week 
haemoglobin level decreases slightly but in comparison with zero week it is 
decreased. The P value is insignificant for haemoglobin 
Actually there is an increasing heamoglobin values in each patients in 
each group of treatment. However there is decrease in average heamoglobine 
values in third fourth and sixth week of treatment because number of patients 
being treated for longer duration are having severe liver damage and less 
heamoglobin. Number of patients are also less in these long (4 to 6 week) 
treatments, so mean heamoglobin decreases in these later weeks    
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Table 5.25: Blood pressure values of the patients after treatment with 
Phyllanthus amarus.  
Sr. no 
of 
patients 
Age Blood pressure after different weeks treatment 
Initial 
(zero 
week) First Second Third Forth Six 
1 28 80-120 80-120 - - - - 
2 51 80-120 80-120 - - - - 
3 20 80-120 80-120 - - - - 
4 16 80-120 80-120 80-120 80-120 80-120 - 
5 42 90-130 90-130 80-120 80-120 80-120 - 
6 17 80-120 80-120 80-120 - - - 
7 65 80-120 80-120 - - - - 
8 65 80-120 80-120 - - - - 
9 36 80-120 80-120 80-120 80-120 - - 
10 42 80-120 80-120 - - - - 
11 35 80-120 80-120 80-120 80-120 - - 
12 21 80-120 80-120 80-120 80-120 - - 
13 32 80-120 80-120 80-120 - - - 
14 32 80-120 80-120 80-120 - - - 
15 28 80-120 80-120 80-120 80-120 80-120 - 
16 45 90-130 90-130 80-120 - - - 
17 17 80-120 80-120 - - - - 
18 32 80-120 80-120 - - - - 
Chapter 5  RESULT AND DISCUSSION  
171 
 
19 20 80-120 80-120 80-120 80-120 80-120 - 
20 38 80-120 80-120 80-120 80-120 80-120 80-120 
21 19 80-120 80-120 80-120 80-120 - - 
22 38 80-120 80-120 - - - - 
23 16 80-120 80-120 80-120 80-120 80-120 80-120 
24 19 80-120 80-120 80-120 80-120 - - 
25 22 80-120 80-120 80-120 80-120 - - 
26 65 100-140 100-140 90-130 90-130 - - 
27 35 80-120 80-120 80-120 - - - 
28 32 80-120 80-120 80-120 - - - 
29 42 80-120 80-120 - - - - 
30 43 80-120 80-120 80-120 80-120 80-120 80-120 
31 28 80-120 80-120 80-120 80-120 80-120 - 
32 50 80-120 80-120 80-120 80-120 80-120 - 
33 55 100-120 80-120 80-120 80-120 - - 
34 45 80-120 80-120 80-120 80-120 - - 
35 55 80-120 80-120 80-120 - - - 
36 40 80-120 80-120 80-120 - - - 
37 20 80-120 80-120 80-120 80-120 - - 
38 50 80-120 80-120 80-120 - - - 
39 45 80-120 80-120 80-120 - - - 
40 50 100-120 90-130 80-120 80-120 80-120 - 
41 50 80-120 80-120 80-120 80-120 - - 
42 45 80-120 80-120 80-120 - - - 
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43 32 80-120 80-120 80-120 80-120 80-120 - 
44 55 80-120 80-120 80-120 - - - 
45 21 80-120 80-120 80-120 80-120 80-120 - 
46 50 90-130 90-130 90-130 90-13- 90-130 - 
47 19 80-120 80-120 - - - - 
48 42 80-120 80-120 80-120 80-120 - - 
49 71 80-120 80-120 - - - - 
50 38 80-120 80-120 80-120 80-120 80-120 - 
51 30 80-120 80-120 80-120 80-120 - - 
52 30 80-120 80-120 - - - - 
53 54 80-120 80-120 - - - - 
54 42 80-120 80-120 80-120 - - - 
55 22 80-120 80-120 80-120 - - - 
56 42 80-120 80-120 80-120 80-120 - - 
57 46 100-140 90-130 90-130 90-130 90-130 - 
58 11 80-120 80-120 - - - - 
59 38 80-120 80-120 80-120 80-120 - - 
60 70 90-130 80-120 - - - - 
61 20 80-120 80-120 80-120 80-120 - - 
62 23 80-120 80-120 80-120 - - - 
63 35 80-120 80-120 80-120 80-120 - - 
64 36 80-120 80-120 80-120 - - - 
65 24 80-120 80-120 80-120 - - - 
66 40 80-120 80-120 - - - - 
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67 28 80-120 80-120 80-120 80-120 - - 
68 13 80-120 80-120 - - - - 
69 45 80-120 80-120 80-120 80-120 - - 
70 15 80-120 80-120 - - - - 
71 32 80-120 80-120 80-120 80-120 - - 
72 55 100-140 90-130 90-130 90-130 90-130 - 
73 11 80-120 80-120 80-120 - - - 
74 30 80-120 80-120 80-120 80-120 - - 
75 12 80-120 80-120 80-120 - - - 
76 13 80-120 80-120 - - - - 
77 65 90-130 80-120 80-120 80-120 80-120 - 
78 30 80-120 80-120 - - - - 
79 50 100-140 90-120 90-130 - - - 
80 49 80-120 80-120 80-120 80-120 80-120 - 
81 45 100-140 100-140 90-130 - - - 
82 36 80-120 80-120 80-120 80-120 80-120 - 
83 40 90-130 90-130 90-130 - - - 
84 11 80-120 80-120 80-120 80-120 80-120 - 
85 50 90-130 90-130 90-130 - - - 
86 35 80-120 80-120 80-120 - - - 
87 30 80-120 80-120 80-120 80-120 - - 
88 25 80-120 80-120 80-120 - - - 
89 65 90-130 90-130 90-130 - - - 
90 30 80-120 80-120 - - - - 
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91 35 80-120 80-120 - - - - 
92 50 90-130 90-130 90-130 90-130 - - 
93 37 80-120 80-120 - - - - 
94 53 90-130 90-130 90-130 90-130 - - 
95 42 80-120 80-120 80-120 80-120 - - 
96 12 80-120 80-120 80-120 80-120 - - 
97 40 90-130 90-130 90-130 90-130 90-130 90-130 
98 45 80-120 80-120 - - - - 
99 27 80-120 80-120 80-120 80-120 - - 
100 25 80-120 80-120 - - - - 
101 21 80-120 80-120 80-120 - - - 
102 30 80-120 80-120 80-120 80-120 80-120 - 
103 20 80-120 80-120 80-120 - - - 
104 51 80-120 80-120 - - - - 
105 5 80-120 80-120 80-120 80-120 80-120 - 
106 42 80-120 80-120 - - - - 
107 32 80-120 80-120 80-120 80-120 - - 
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Table 5.26: Blood pressure values of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients 
Age 
Blood pressure after different weeks treatment 
Initial 
(zero 
week) 
First Second Third Fourth Sixth 
1 17 80-120 80-120 80-120 - - - 
2 47 90-130 80-120 80-120 80-120 - - 
3 49 100-140 100-140 90-130 - - - 
4 51 80-120 80-120 80-120 80-120 80-120 80-120 
5 31 80-120 80-120 80-120 - - - 
6 53 80-120 80-120 80-120 80-120 - - 
7 47 90-130 90-130 80-120 80-120 - - 
8 40 80-120 80-120 80-120 80-120 80-120 80-120 
9 47 80-120 80-120 80-120 80-120 80-120 - 
10 50 80-120 80-120 80-120 80-120 80-120 - 
11 44 80-120 80-120 80-120 - - - 
12 46 80-120 80-120 80-120 80-120 80-120 80-120 
13 35 80-120 80-120 80-120 80-120 - - 
14 55 90-130 80-120 80-120 - - - 
15 50 100-140 90-130 90-130 90-130 80-120 - 
16 60 80-120 80-120 80-120 80-120 80-120 80-120 
17 43 80-120 80-120 - - - - 
18 45 80-120 80-120 80-120 - - - 
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19 40 80-120 80-120 80-120 80-120 80-120 80-120 
20 29 80-120 80-120 80-120 - - - 
21 44 80-120 80-120 80-120 80-120 80-120 - 
22 25 80-120 80-120 80-120 80-120 80-120 - 
23 17 80-120 80-120 80-120 80-120 80-120 - 
24 40 80-120 80-120 - - - - 
25 35 80-120 80-120 80-120 80-120 80-120 - 
26 25 80-120 80-120 80-120 80-120 80-120 - 
27 21 80-120 80-120 80-120 80-120 80-120 - 
28 52 80-120 80-120 80-120 - - - 
29 45 80-120 80-120 80-120 80-120 80-120 - 
30 62 80-120 80-120 80-120 80-120 80-120 80-120 
31 50 80-120 80-120 80-120 - - - 
32 45 90-130 90-130 80-120 80-120 - - 
33 50 80-120 80-120 80-120 80-120 80-120 - 
34 30 80-120 80-120 80-120 80-120 80-120 - 
35 19 80-120 80-120 80-120 80-120 80-120 - 
36 45 80-120 80-120 80-120 - - - 
37 25 80-120 80-120 80-120 80-120 - - 
38 25 80-120 80-120 80-120 80-120 - - 
39 27 80-120 80-120 80-120 80-120 80-120 - 
40 17 80-120 80-120 80-120 80-120 - - 
41 57 80-120 80-120 80-120 80-120 - - 
42 45 80-120 80-120 80-120 - - - 
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43 60 80-120 80-120 80-120 - - - 
44 49 80-120 80-120 80-120 - - - 
45 36 80-120 80-120 80-120 - - - 
46 49 90-130 90-130 90-130 90-130 90-130 90-130 
47 50 80-120 80-120 80-120 80-120 - - 
48 40 80-120 80-120 80-120 80-120 80-120 80-120 
49 40 90-130 90-130 90-130 90-130 90-130 - 
50 39 80-120 80-120 - - - - 
51 41 80-120 80-120 80-120 80-120 80-120 80-120 
52 45 80-120 80-120 80-120 - - - 
53 29 80-120 80-120 80-120 80-120 - - 
54 52 80-120 80-120 80-120 - - - 
55 50 80-120 80-120 80-120 80-120 - - 
56 49 100-140 80-120 80-120 80-120 80-120 - 
57 39 80-120 80-120 - - - - 
58 11 80-120 80-120 80-120 - - - 
59 19 80-120 80-120 80-120 - - - 
60 52 80-120 80-120 80-120 80-120 - - 
61 21 80-120 80-120 80-120 80-120 80-120 - 
62 29 80-120 80-120 80-120 80-120 80-120 - 
63 40 80-120 80-120 80-120 - - - 
64 55 80-120 80-120 - - - - 
65 50 80-120 80-120 80-120 80-120 80-120 - 
66 39 80-120 80-120 80-120 - - - 
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67 38 80-120 80-120 80-120 - - - 
68 19 80-120 80-120 80-120 80-120 - - 
69 35 80-120 80-120 80-120 80-120 80-120 - 
70 45 80-120 80-120 80-120 - - - 
71 31 80-120 80-120 80-120 80-120 - - 
72 49 80-120 80-120 - - - - 
73 45 80-120 80-120 - - - - 
74 53 90-130 90-130 80-120 - - - 
75 48 80-120 80-120 - - - - 
76 20 80-120 80-120 - - - - 
77 17 80-120 80-120 80-120 - - - 
78 27 80-120 80-120 80-120 80-120 80-120 80-120 
79 31 80-120 80-120 80-120 - - - 
80 50 90-130 80-120 - - - - 
81 35 80-120 80-120 80-120 80-120 80-120 - 
82 39 80-120 80-120 - - - - 
83 29 80-120 80-120 - - - - 
84 41 80-120 80-120 - - - - 
85 22 80-120 80-120 - - - - 
86 31 80-120 80-120 80-120 80-120 - - 
87 47 80-120 80-120 - - - - 
88 28 80-120 80-120 80-120 - - - 
89 12 80-120 80-120 - - - - 
90 41 80-120 80-120 - - - - 
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91 36 80-120 80-120 - - - - 
92 44 80-120 80-120 80-120 - - - 
93 39 80-120 80-120 80-120 - - - 
 
Table 5.27: Blood pressure values of the patients after treatment with 
Hepatogard forte Tablet  
Sr. no 
of the 
patients 
Age Blood pressure after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 80-120 80-120 80-120 - - - 
2 34 80-120 80-120 80-120 80-120 - - 
3 50 100-140 100-140 100-140 90-130 90-130 90-130 
4 39 80-120 80-120 80-120 80-120 80-120 80-120 
5 39 80-120 80-120 80-120 80-120 80-120 80-120 
6 60 80-120 80-120 80-120 80-120 80-120 80-120 
7 32 80-120 80-120 80-120 80-120 80-120 - 
8 49 100-140 100-140 100-140 90-130 90-130 - 
9 55 80-120 80-120 80-120 - - - 
10 60 90-130 90-130 80-120 - - - 
11 35 80-120 80-120 80-120 80-120 - - 
12 36 80-120 80-120 80-120 - - - 
13 58 90-130 90-130 90-130 90-130 90-130 90-130 
14 40 90-130 90-130 80-120 - - - 
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15 50 90-130 90-130 80-120 - - - 
16 29 80-120 80-120 80-120 - - - 
17 38 80-120 80-120 80-120 - - - 
18 42 80-120 80-120 80-120 - - - 
19 59 90-130 90-130 90-130 - - - 
20 11 80-120 80-120 80-120 - - - 
21 32 80-120 80-120 80-120 80-120 80-120 - 
22 60 80-120 80-120 80-120 80-120 80-120 - 
23 35 80-120 80-120 80-120 - - - 
24 59 80-120 80-120 80-120 80-120 - - 
25 49 80-120 80-120 80-120 80-120 - - 
26 21 80-120 80-120 80-120 80-120 - - 
27 60 80-120 80-120 80-120 - - - 
28 45 80-120 80-120 80-120 80-120 - - 
29 50 80-120 80-120 80-120 80-120 80-120 - 
30 55 80-120 80-120 80-120 80-120 - - 
31 51 80-120 80-120 80-120 80-120 - - 
32 23 80-120 80-120 80-120 80-120 80-120 - 
33 20 80-120 80-120 80-120 - - - 
34 22 80-120 80-120 - - - - 
35 48 80-120 80-120 80-120 - - - 
36 47 80-120 80-120 80-120 80-120 80-120 - 
37 41 80-120 80-120 80-120 80-120 - - 
38 32 80-120 80-120 80-120 80-120 80-120 - 
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39 21 80-120 80-120 80-120 - - - 
40 21 80-120 80-120 80-120 80-120 - - 
41 22 80-120 80-120 - - - - 
42 50 80-120 80-120 - - - - 
43 42 80-120 80-120 - - - - 
44 30 80-120 80-120 80-120 - - - 
45 18 80-120 80-120 80-120 80-120 - - 
46 30 80-120 80-120 - - - - 
47 40 80-120 80-120 80-120 80-120 - - 
48 35 80-120 80-120 - - - - 
49 28 80-120 80-120 80-120 80-120 80-120 - 
50 37 80-120 80-120 80-120 80-120 80-120 80-120 
51 49 80-120 80-120 80-120 - - - 
52 30 80-120 80-120 80-120 - - - 
53 29 80-120 80-120 - - - - 
54 41 90-130 90-130 80-120 80-120 - - 
55 42 80-120 80-120 80-120 - - - 
56 37 80-120 80-120 - - - - 
57 18 80-120 80-120 80-120 80-120 80-120 - 
58 13 80-120 80-120 - - - - 
59 23 80-120 80-120 80-120 80-120 80-120 80-120 
60 28 80-120 80-120 - - - - 
61 45 80-120 80-120 80-120 80-120 80-120 - 
62 15 80-120 80-120 80-120 80-120 - - 
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63 50 90-130 90-130 80-120 80-120 80-120 - 
64 32 80-120 80-120 - - - - 
65 43 80-120 80-120 80-120 80-120 80-120 80-120 
66 36 80-120 80-120 80-120 80-120 80-120 - 
67 38 80-120 80-120 - - - - 
68 35 80-120 80-120 80-120 - - - 
69 51 80-120 80-120 80-120 - - - 
70 55 80-120 80-120 80-120 80-120 80-120 - 
71 43 80-120 80-120 80-120 - - - 
72 46 80-120 80-120 80-120 - - - 
73 59 80-120 80-120 - - - - 
74 39 80-120 80-120 80-120 80-120 80-120 - 
75 55 80-120 80-120 80-120 80-120 80-120 - 
76 35 80-120 80-120 80-120 80-120 - - 
77 51 80-120 80-120 - - - - 
78 45 80-120 80-120 80-120 80-120 - - 
79 40 80-120 80-120 80-120 - - - 
80 17 80-120 80-120 80-120 80-120 80-120 80-120 
81 50 100-140 100-140 90-130 90-130 - - 
82 50 100-140 100-140 - - - - 
83 20 80-120 80-120 80-120 - - - 
84 51 80-120 80-120 80-120 - - - 
85 55 100-140 100-140 100-140 - - - 
86 50 80-120 80-120 80-120 80-120 - - 
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87 39 80-120 80-120 80-120 - - - 
88 47 100-120 100-120 90-120 90-130 80-120 - 
89 37 80-120 80-120 80-120 - - - 
90 40 80-120 80-120 80-120 - - - 
91 51 100-140 90-120 90-120 90-130 - - 
92 47 80-120 80-120 80-120 80-120 80-120 80-120 
93 49 80-120 80-120 80-120 80-120 80-120 - 
94 39 80-120 80-120 80-120 - - - 
95 35 80-120 80-120 80-120 80-120 - - 
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Table 5.28: Comparative blood pressure values for different week 
treatment using Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet.  
Sr. 
no 
Drug 
Total 
num of 
patients 
No of 
patients 
having 
BP 
Normalized Reduced 
Remain 
unchanged 
1 Phyllanthus 
amarus 
107 18 6 5 7 
2 Livercare 
Churna 
93 10 8 2 - 
3 Hepatogard 
forte Tablet 
95 14 6 4 4 
 
During clinical study selected 107 patients of Phyllanthus amarus 
group were found infected with jaundice among them 18 patients have 
hypertension. After treatment with Phyllanthus amarus 6 patients were 
normalized, 5 patients slightly reduced hypertension and 7 patients remained 
unchanged. 93 patients of Livercare Churna group were found infected with 
jaundice among them 10 patients have hypertension. After treatment with 
Livercare Churna 8 patients were normalized, 2 patients slightly reduced 
hypertension. 95 patients of Hepatogard forte Tablet were found infected with 
jaundice among them 14 patients have hypertension. After treatment with 
Hepatogard forte Tablet 6 patients were normalized, 4 patients slightly 
reduced hypertension and 4 patients remained unchanged. 
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Table 5.29: Urine sugar values of the patients after treatment with 
Phyllanthus amarus  
Sr. no 
of 
patients 
Age Urine sugar after different weeks treatment 
Initial 
(zero 
week) First Second Third Forth Six 
1 28 Normal Normal - - - - 
2 51 Normal Normal - - - - 
3 20 Normal Normal - - - - 
4 16 Normal Normal Normal Normal Normal - 
5 42 Normal Normal Normal Normal Normal - 
6 17 Normal Normal Normal - - - 
7 65 Normal Normal - - - - 
8 65 Normal Normal - - - - 
9 36 Normal Normal Normal Normal - - 
10 42 Normal Normal - - - - 
11 35 Normal Normal Normal Normal - - 
12 21 Normal Normal Normal Normal - - 
13 32 Normal Normal Normal - - - 
14 32 Normal Normal Normal - - - 
15 28 Normal Normal Normal Normal Normal - 
16 45 XX X Normal - - - 
17 17 Normal Normal - - - - 
18 32 Normal Normal - - - - 
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19 20 Normal Normal Normal Normal Normal - 
20 38 Normal Normal Normal Normal Normal Normal 
21 19 Normal Normal Normal Normal - - 
22 38 Normal Normal - - - - 
23 16 Normal Normal Normal Normal Normal Normal 
24 19 Normal Normal Normal Normal - - 
25 22 Normal Normal Normal Normal - - 
26 65 Normal Normal Normal Normal - - 
27 35 Normal Normal Normal - - - 
28 32 Normal Normal Normal - - - 
29 42 Normal Normal - - - - 
30 43 Normal Normal Normal Normal Normal Normal 
31 28 Normal Normal Normal Normal Normal - 
32 50 X X Normal Normal Normal - 
33 55 XX X X Normal - - 
34 45 Normal Normal Normal Normal - - 
35 55 Normal Normal Normal - - - 
36 40 Normal Normal Normal - - - 
37 20 Normal Normal Normal Normal - - 
38 50 XX X Normal - - - 
39 45 Normal Normal Normal - - - 
40 50 XX XX X Normal Normal - 
41 50 Normal Normal Normal Normal - - 
42 45 Normal Normal Normal - - - 
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43 32 Normal Normal Normal Normal Normal - 
44 55 XX X X - - - 
45 21 Normal Normal Normal Normal Normal - 
46 50 XX X X Normal Normal - 
47 19 Normal Normal - - - - 
48 42 Normal Normal Normal Normal - - 
49 71 Normal Normal - - - - 
50 38 Normal Normal Normal Normal Normal - 
51 30 Normal Normal Normal Normal - - 
52 30 Normal Normal - - - - 
53 54 Normal Normal - - - - 
54 42 Normal Normal Normal - - - 
55 22 Normal Normal Normal - - - 
56 42 Normal Normal Normal Normal - - 
57 46 XX X X X Normal - 
58 11 Normal Normal - - - - 
59 38 Normal Normal Normal Normal - - 
60 70 XX X - - - - 
61 20 Normal Normal Normal Normal - - 
62 23 Normal Normal Normal - - - 
63 35 Normal Normal Normal Normal - - 
64 36 Normal Normal Normal - - - 
65 24 Normal Normal Normal - - - 
66 40 Normal Normal - - - - 
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67 28 Normal Normal Normal Normal - - 
68 13 Normal Normal - - - - 
69 45 Normal Normal Normal Normal - - 
70 15 Normal Normal - - - - 
71 32 Normal Normal Normal Normal - - 
72 55 XX XX X X Normal - 
73 11 Normal Normal Normal - - - 
74 30 Normal Normal Normal Normal - - 
75 12 Normal Normal Normal - - - 
76 13 Normal Normal - - - - 
77 65 XX Normal Normal Normal Normal - 
78 30 Normal Normal - - - - 
79 50 XX X X - - - 
80 49 Normal Normal Normal Normal Normal - 
81 45 X X Normal - - - 
82 36 Normal Normal Normal Normal Normal - 
83 40 X X Normal - - - 
84 11 Normal Normal Normal Normal Normal - 
85 50 XX X Normal - - - 
86 35 Normal Normal Normal - - - 
87 30 Normal Normal Normal Normal - - 
88 25 Normal Normal Normal - - - 
89 65 XX X X - - - 
90 30 Normal Normal - - - - 
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91 35 X X - - - - 
92 50 XX X X X - - 
93 37 Normal Normal - - - - 
94 53 X X Normal Normal - - 
95 42 Normal Normal Normal Normal - - 
96 12 Normal Normal Normal Normal - - 
97 40 X X Normal Normal Normal Normal 
98 45 Normal Normal - - - - 
99 27 Normal Normal Normal Normal - - 
100 25 Normal Normal - - - - 
101 21 Normal Normal Normal - - - 
102 30 Normal Normal Normal Normal Normal - 
103 20 Normal Normal Normal - - - 
104 51 Normal Normal - - - - 
105 5 Normal Normal Normal Normal Normal - 
106 42 X Normal - - - - 
107 32 Normal Normal Normal Normal - - 
 
Chapter 5  RESULT AND DISCUSSION  
190 
 
Table 5.30: Urine Sugar values of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients 
Age Urine sugar after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 17 Normal Normal Normal - - - 
2 47 Normal Normal Normal Normal - - 
3 49 Normal Normal Normal - - - 
4 51 X X X Normal Normal Normal 
5 31 Normal Normal Normal - - - 
6 53 Normal Normal Normal Normal - - 
7 47 Normal Normal Normal Normal - - 
8 40 Normal Normal Normal Normal Normal Normal 
9 47 Normal Normal Normal Normal Normal - 
10 50 X X X Normal Normal - 
11 44 Normal Normal Normal - - - 
12 46 Normal Normal Normal Normal Normal Normal 
13 35 Normal Normal Normal Normal - - 
14 55 X Normal Normal - - - 
15 50 XX XX X X X - 
16 60 Normal Normal Normal Normal Normal Normal 
17 43 Normal Normal - - - - 
18 45 Normal Normal Normal - - - 
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19 40 Normal Normal Normal Normal Normal Normal 
20 29 Normal Normal Normal - - - 
21 44 Normal Normal Normal Normal Normal - 
22 25 Normal Normal Normal Normal Normal - 
23 17 Normal Normal Normal Normal Normal - 
24 40 Normal Normal - - - - 
25 35 Normal Normal Normal Normal Normal - 
26 25 Normal Normal Normal Normal Normal - 
27 21 Normal Normal Normal Normal Normal - 
28 52 X X Normal   - 
29 45 Normal Normal Normal Normal Normal - 
30 62 Normal Normal Normal Normal Normal Normal 
31 50 Normal Normal Normal - - - 
32 45 Normal Normal Normal Normal - - 
33 50 Normal Normal Normal Normal Normal - 
34 30 Normal Normal Normal Normal Normal - 
35 19 Normal Normal Normal Normal Normal - 
36 45 X X Normal - - - 
37 25 Normal Normal Normal Normal - - 
38 25 Normal Normal Normal Normal - - 
39 27 Normal Normal Normal Normal Normal - 
40 17 Normal Normal Normal Normal - - 
41 57 X X Normal Normal - - 
42 45 Normal Normal Normal - - - 
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43 60 Normal Normal Normal - - - 
44 49 X X Normal - - - 
45 36 Normal Normal Normal - - - 
46 49 X X Normal Normal Normal Normal 
47 50 Normal Normal Normal Normal - - 
48 40 Normal Normal Normal Normal Normal Normal 
49 40 X X X Normal Normal - 
50 39 Normal Normal - - - - 
51 41 Normal Normal Normal Normal Normal Normal 
52 45 Normal Normal Normal - - - 
53 29 Normal Normal Normal Normal - - 
54 52 X X Normal - - - 
55 50 Normal Normal Normal Normal - - 
56 49 XX XX X X X - 
57 39 Normal Normal - - - - 
58 11 Normal Normal Normal - - - 
59 19 Normal Normal Normal - - - 
60 52 Normal Normal Normal Normal - - 
61 21 Normal Normal Normal Normal Normal - 
62 29 Normal Normal Normal Normal Normal - 
63 40 Normal Normal Normal - - - 
64 55 Normal Normal - - - - 
65 50 Normal Normal Normal Normal Normal - 
66 39 Normal Normal Normal - - - 
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67 38 Normal Normal Normal - - - 
68 19 Normal Normal Normal Normal - - 
69 35 Normal Normal Normal Normal Normal - 
70 45 Normal Normal Normal - - - 
71 31 Normal Normal Normal Normal - - 
72 49 Normal Normal - - - - 
73 45 Normal Normal - - - - 
74 53 Normal Normal Normal - - - 
75 48 Normal Normal - - - - 
76 20 Normal Normal - - - - 
77 17 Normal Normal Normal - - - 
78 27 Normal Normal Normal Normal Normal Normal 
79 31 Normal Normal Normal - - - 
80 50 Normal Normal - - - - 
81 35 Normal Normal Normal Normal Normal - 
82 39 Normal Normal - - - - 
83 29 Normal Normal - - - - 
84 41 Normal Normal - - - - 
85 22 Normal Normal - - - - 
86 31 Normal Normal Normal Normal - - 
87 47 Normal Normal - - - - 
88 28 Normal Normal Normal - - - 
89 12 Normal Normal - - - - 
90 41 Normal Normal - - - - 
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91 36 Normal Normal - - - - 
92 44 Normal Normal Normal - - - 
93 39 Normal Normal Normal - - - 
 
Table 5.31: Urine Sugar values of the patients after treatment with 
Hepatogard forte Tablet  
Sr. no 
of 
patients 
Age Urine sugar after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 Normal Normal Normal - - - 
2 34 Normal Normal Normal Normal - - 
3 50 X X X X X X 
4 39 Normal Normal Normal Normal Normal Normal 
5 39 Normal Normal Normal Normal Normal Normal 
6 60 Normal Normal Normal Normal Normal Normal 
7 32 Normal Normal Normal Normal Normal - 
8 49 Normal Normal Normal Normal Normal - 
9 55 XX XX XX - - - 
10 60 X X X - - - 
11 35 Normal Normal Normal Normal - - 
12 36 Normal Normal Normal - - - 
13 58 XX XX XX XX X X 
14 40 Normal Normal Normal - - - 
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15 50 Normal Normal Normal - - - 
16 29 Normal Normal Normal - - - 
17 38 Normal Normal Normal - - - 
18 42 Normal Normal Normal - - - 
19 59 XX XX XX - - - 
20 11 Normal Normal Normal - - - 
21 32 Normal Normal Normal Normal Normal - 
22 60 X X X X X - 
23 35 Normal Normal Normal - - - 
24 59 Normal Normal Normal Normal - - 
25 49 Normal Normal Normal Normal - - 
26 21 Normal Normal Normal Normal - - 
27 60 X X X - - - 
28 45 Normal Normal Normal Normal - - 
29 50 Normal Normal Normal Normal Normal - 
30 55 Normal Normal Normal Normal - - 
31 51 X Normal Normal Normal - - 
32 23 Normal Normal Normal Normal Normal - 
33 20 Normal Normal Normal - - - 
34 22 Normal Normal - - - - 
35 48 Normal Normal Normal - - - 
36 47 Normal Normal Normal Normal Normal - 
37 41 Normal Normal Normal Normal - - 
38 32 Normal Normal Normal Normal Normal - 
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39 21 Normal Normal Normal - - - 
40 21 Normal Normal Normal Normal - - 
41 22 Normal Normal - - - - 
42 50 Normal Normal - - - - 
43 42 Normal Normal - - - - 
44 30 Normal Normal Normal - - - 
45 18 Normal Normal Normal Normal - - 
46 30 Normal Normal - - - - 
47 40 Normal Normal Normal Normal - - 
48 35 Normal Normal - - - - 
49 28 Normal Normal Normal Normal Normal  
50 37 Normal Normal Normal Normal Normal Normal 
51 49 Normal Normal Normal - - - 
52 30 Normal Normal Normal - - - 
53 29 Normal Normal - - - - 
54 41 X X X X - - 
55 42 Normal Normal Normal - - - 
56 37 Normal Normal - - - - 
57 18 Normal Normal Normal Normal Normal - 
58 13 Normal Normal - - - - 
59 23 Normal Normal Normal Normal Normal Normal 
60 28 Normal Normal - - - - 
61 45 X X X X X - 
62 15 Normal Normal Normal Normal - - 
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63 50 Xx X X X X - 
64 32 Normal Normal - - - - 
65 43 Normal Normal Normal Normal Normal Normal 
66 36 Normal Normal Normal Normal Normal - 
67 38 Normal Normal - - - - 
68 35 Normal Normal Normal - - - 
69 51 X X Normal - - - 
70 55 Normal Normal Normal Normal Normal - 
71 43 Normal Normal Normal - - - 
72 46 Normal Normal Normal - - - 
73 59 Normal Normal - - - - 
74 39 Normal Normal Normal Normal Normal - 
75 55 X X X X X - 
76 35 Normal Normal Normal Normal - - 
77 51 Normal Normal -  - - 
78 45 Normal Normal Normal Normal - - 
79 40 Normal Normal Normal - - - 
80 17 Normal Normal Normal Normal Normal Normal 
81 50 XX XX XX X - - 
82 50 XX XX - - - - 
83 20 Normal Normal Normal - - - 
84 51 Normal Normal Normal - - - 
85 55 Normal Normal Normal - - - 
86 50 X X X X - - 
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87 39 Normal Normal Normal - - - 
88 47 XX XX XX XX X - 
89 37 Normal Normal Normal - - - 
90 40 Normal Normal Normal - - - 
91 51 XX XX XX XX - - 
92 47 Normal Normal Normal Normal Normal Normal 
93 49 Normal Normal Normal Normal Normal - 
94 39 Normal Normal Normal - - - 
95 35 Normal Normal Normal Normal - - 
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Table 5.32: Comparative urine sugar values of Phyllanthus amarus, 
Livercare Churna and Hepatogard forte Tablet as hepatoprotective drug  
Sr. 
no 
Drug Total 
numbe
r of 
patient 
No of 
patients 
having 
urine 
sugar 
Norma
lized 
Reduce
d 
Remain 
unchang
ed 
1 Phyllanthus 
amarus 
107 21 14 7 - 
2 Livercare 
Churna 
93 12 10 2 - 
3 Hepatogard 
forte Tablet 
95 18 2 4 12 
 
During clinical study selected 107 patients of Phyllanthus amarus 
group were found infected with jaundice among them 21 patients have higher 
urine sugar level. After treatment with Phyllanthus amarus 14 patients was 
normalized, 7 patients reduced the sugar level and no patient remained 
unchanged. 93 patients of Livercare Churna group were found infected with 
jaundice among them 12 patients have higher urine sugar level. After 
treatment with Livercare Churna 10 patients were normalized, 2 patients 
reduced urine sugar and no patients with unchanged urine sugar. 95 patients 
of Hepatogard forte Tablet were found infected with jaundice among them 18 
patients have higher urine sugar level. After treatment with Hepatogard forte 
Tablet 2 patients were normalized, 4 patients reduced the sugar level and 12 
patients remained unchanged. 
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Table 5.33: Urine Creatinine levels of the patients after treatment with 
Phyllanthus amarus.  
Sr. No 
of 
patients 
Age 
Urine Creatinine after different weeks treatment 
Initial 
(zero 
week) 
First Second Third Forth Six 
1 28 Positive Normal - - - - 
2 51 Positive Normal - - - - 
3 20 Positive Normal - - - - 
4 16 Positive Positive Positive Positive Normal - 
5 42 Positive Positive Positive Positive Normal - 
6 17 Positive Positive Normal - - - 
7 65 Normal Normal - - - - 
8 65 Positive Normal - - - - 
9 36 Positive Positive Positive Normal - - 
10 42 Positive Normal - - - - 
11 35 Positive Positive Positive Normal - - 
12 21 Positive Positive Positive Normal - - 
13 32 Positive Positive Normal - - - 
14 32 Positive Positive Normal - - - 
15 28 Positive Positive Normal Positive Normal - 
16 45 Positive Normal Normal - - - 
17 17 Positive Normal - - - - 
18 32 Positive Normal - - - - 
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19 20 Positive Positive Positive Positive Normal - 
20 38 Positive Positive Positive Positive Positive Normal 
21 19 Positive Positive Positive Normal - - 
22 38 Positive Positive - - - - 
23 16 Positive Positive Positive Positive Positive Normal 
24 19 Positive Positive Positive Normal - - 
25 22 Positive Positive Positive Normal - - 
26 65 Positive Positive Positive Normal - - 
27 35 Positive Positive Normal - - - 
28 32 Positive Positive Normal - - - 
29 42 Positive Normal - - - - 
30 43 Positive Positive Positive Positive Positive Normal 
31 28 Positive Positive Positive Positive Normal - 
32 50 Positive Positive Positive Positive Normal - 
33 55 Positive Positive Normal Normal - - 
34 45 Positive Positive Positive Normal - - 
35 55 Positive Positive Normal - - - 
36 40 Positive Positive Normal - - - 
37 20 Positive Positive Positive Normal - - 
38 50 Positive Positive Positive - - - 
39 45 Positive Positive Normal - - - 
40 50 Positive Positive Positive Positive Normal - 
41 50 Positive Positive Positive Normal - - 
42 45 Positive Positive Normal - - - 
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43 32 Positive Positive Positive Positive Normal - 
44 55 Positive Positive Normal - - - 
45 21 Positive Positive Normal Positive Normal - 
46 50 Positive Positive Positive Positive Normal - 
47 19 Positive Normal - - - - 
48 42 Positive Positive Positive Normal - - 
49 71 Positive Normal - - - - 
50 38 Positive Normal Positive Normal Normal - 
51 30 Positive Positive Positive Normal - - 
52 30 Positive Normal - - - - 
53 54 Positive Normal - - - - 
54 42 Positive Positive Normal - - - 
55 22 Positive Positive Normal - - - 
56 42 Positive Positive Positive Normal - - 
57 46 Positive Positive Positive Positive Normal - 
58 11 Positive Positive - - - - 
59 38 Positive Positive Positive Normal - - 
60 70 Positive Normal - - - - 
61 20 Positive Positive Positive Normal - - 
62 23 Positive Positive Normal - - - 
63 35 Positive Positive Positive Normal - - 
64 36 Positive Positive Positive - - - 
65 24 Positive Positive Normal - - - 
66 40 Positive Normal - - - - 
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67 28 Positive Positive Positive Normal - - 
68 13 Positive Normal - - - - 
69 45 Positive Positive Positive Normal - - 
70 15 Positive Normal - - - - 
71 32 Positive Positive Positive Normal - - 
72 55 Positive Positive Positive Positive Normal - 
73 11 Positive Positive Normal - - - 
74 30 Positive Positive Positive Normal - - 
75 12 Positive Positive Normal - - - 
76 13 Positive Normal - - - - 
77 65 Positive Positive Positive Positive Normal - 
78 30 Positive Normal - - - - 
79 50 Positive Positive Normal - - - 
80 49 Positive Positive Positive Positive Normal - 
81 45 Positive Positive Positive - - - 
82 36 Positive Positive Positive Positive Normal - 
83 40 Positive Positive Normal - - - 
84 11 Positive Positive Positive Positive Normal - 
85 50 Positive Positive Normal - - - 
86 35 Positive Positive Normal - - - 
87 30 Positive Positive Positive Positive - - 
88 25 Positive Positive Normal - - - 
89 65 Positive Positive Normal - - - 
90 30 Positive Normal - - - - 
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91 35 Positive Normal - - - - 
92 50 Positive Positive Positive Normal - - 
93 37 Positive Positive - - - - 
94 53 Positive Positive Positive Positive - - 
95 42 Positive Positive Positive Normal - - 
96 12 Positive Positive Positive Normal - - 
97 40 Positive Positive Positive Positive Positive Normal 
98 45 Positive Positive - - - - 
99 27 Positive Positive Positive Positive - - 
100 25 Positive Normal - - - - 
101 21 Positive Positive Normal - - - 
102 30 Positive Positive Positive Positive Normal - 
103 20 Positive Positive Normal - - - 
104 51 Positive Normal - - - - 
105 5 Positive Positive Positive Positive Positive - 
106 42 Positive Normal - - - - 
107 32 Positive Positive Positive Normal - - 
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Table 5.34: Urine Creatinine levels of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients 
Age Urine Creatinine after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 17 Positive Positive Normal - - - 
2 47 Positive Positive Positive Normal - - 
3 49 Positive Positive Normal - - - 
4 51 Positive Positive Positive Positive Positive Normal 
5 31 Positive Positive Normal - - - 
6 53 Positive Positive Positive Normal - - 
7 47 Positive Positive Positive Normal - - 
8 40 Positive Positive Positive Positive Positive Normal 
9 47 Positive Positive Positive Positive Positive - 
10 50 Positive Positive Positive Positive Normal - 
11 44 Positive Positive Positive - - - 
12 46 Positive Positive Positive Positive Positive Normal 
13 35 Positive Positive Positive Normal - - 
14 55 Positive Positive Normal - - - 
15 50 Positive Positive Positive Positive Normal - 
16 60 Positive Positive Positive Positive Positive Normal 
17 43 Positive Normal - - - - 
18 45 Positive Positive Normal - - - 
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19 40 Positive Positive Positive Positive Positive Normal 
20 29 Positive Positive Normal - - - 
21 44 Positive Positive Positive Positive Positive - 
22 25 Positive Positive Positive Positive Normal - 
23 17 Positive Positive Positive Positive Normal - 
24 40 Positive Normal - - - - 
25 35 Positive Positive Positive Positive Normal - 
26 25 Positive Positive Positive Positive Normal - 
27 21 Positive Positive Positive Positive Normal - 
28 52 Positive Positive Normal - - - 
29 45 Positive Positive Positive Positive Normal - 
30 62 Positive Positive Positive Positive Positive Normal 
31 50 Positive Positive Normal - - - 
32 45 Positive Positive Positive Positive - - 
33 50 Positive Positive Positive Positive Normal - 
34 30 Positive Positive Positive Positive Positive - 
35 19 Positive Positive Positive Positive Normal - 
36 45 Positive Positive Positive - - - 
37 25 Positive Positive Positive Normal - - 
38 25 Positive Positive Positive Normal - - 
39 27 Positive Positive Positive Positive Normal - 
40 17 Positive Positive Positive Normal - - 
41 57 Positive Positive Positive Normal - - 
42 45 Positive Positive Normal - - - 
Chapter 5  RESULT AND DISCUSSION  
207 
 
43 60 Positive Positive Normal - - - 
44 49 Positive Positive Normal - - - 
45 36 Positive Positive Normal - - - 
46 49 Positive Positive Positive Positive Positive Normal 
47 50 Positive Positive Positive Normal - - 
48 40 Positive Positive Positive Positive Positive Normal 
49 40 Positive Positive Positive Positive Normal - 
50 39 Positive Normal - - - - 
51 41 Positive Positive Positive Positive Positive Normal 
52 45 Positive Positive Normal - - - 
53 29 Positive Positive Positive Normal - - 
54 52 Positive Positive Normal - - - 
55 50 Positive Positive Positive Normal - - 
56 49 Positive Positive Positive Positive Normal - 
57 39 Positive Normal - - - - 
58 11 Positive Positive Normal - - - 
59 19 Positive Positive Normal - - - 
60 52 Positive Positive Positive Normal - - 
61 21 Positive Positive Positive Positive Normal - 
62 29 Positive Positive Positive Positive Normal - 
63 40 Positive Normal Normal - - - 
64 55 Positive Normal - - - - 
65 50 Positive Positive Positive Positive Normal - 
66 39 Positive Positive Normal - - - 
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67 38 Positive Positive Normal - - - 
68 19 Positive Positive Positive Normal - - 
69 35 Positive Positive Positive Positive Normal - 
70 45 Positive Positive Normal - - - 
71 31 Positive Positive Positive Normal - - 
72 49 Positive Normal - - - - 
73 45 Positive Normal - - - - 
74 53 Positive Positive Normal - - - 
75 48 Positive Normal - - - - 
76 20 Positive Normal - - - - 
77 17 Positive Positive Normal - - - 
78 27 Positive Positive Positive Positive Positive Normal 
79 31 Positive Positive Normal - - - 
80 50 Positive Positive - - - - 
81 35 Positive Positive Positive Positive Normal - 
82 39 Positive Normal - - - - 
83 29 Positive Normal - - - - 
84 41 Positive Normal - - - - 
85 22 Positive Normal - - - - 
86 31 Positive Positive Positive Normal - - 
87 47 Positive Normal - - - - 
88 28 Positive Positive Normal - - - 
89 12 Positive Normal - - - - 
90 41 Positive Normal - - - - 
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91 36 Positive Normal - - - - 
92 44 Positive Positive Normal - - - 
93 39 Positive Positive Normal - - - 
 
Table 5.35: Urine Creatinine levels of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no 
of 
patients 
Age Urine Creatinine after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 Positive Positive Normal - - - 
2 34 Positive Positive Positive Normal - - 
3 50 Positive Positive Positive Positive Positive Normal 
4 39 Positive Positive Positive Positive Positive Positive 
5 39 Positive Positive Positive Positive Positive Positive 
6 60 Positive Positive Positive Positive Positive Normal 
7 32 Positive Positive Positive Positive Normal - 
8 49 Positive Positive Positive Positive Normal - 
9 55 Positive Positive Normal - - - 
10 60 Positive Positive Normal - - - 
11 35 Positive Positive Positive Normal - - 
12 36 Positive Positive Normal - - - 
13 58 Positive Positive Positive Positive Positive Normal 
14 40 Positive Positive Normal - - - 
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15 50 Positive Positive Normal - - - 
16 29 Positive Positive Normal - - - 
17 38 Positive Positive Normal - - - 
18 42 Positive Positive Normal - - - 
19 59 Positive Positive Normal - - - 
20 11 Positive Positive Normal - - - 
21 32 Positive Positive Positive Positive Normal - 
22 60 Positive Positive Positive Positive Normal - 
23 35 Positive Positive Normal - - - 
24 59 Positive Positive Positive Normal - - 
25 49 Positive Positive Positive Normal - - 
26 21 Positive Positive Positive Normal - - 
27 60 Positive Positive Normal - - - 
28 45 Positive Positive Positive Normal - - 
29 50 Positive Positive Positive Positive Normal - 
30 55 Positive Positive Positive Normal - - 
31 51 Positive Positive Positive Normal - - 
32 23 Positive Positive Positive Positive Normal - 
33 20 Positive Positive Normal - - - 
34 22 Positive Normal - - - - 
35 48 Positive Positive Normal - - - 
36 47 Positive Positive Positive Positive Normal - 
37 41 Positive Positive Positive Normal - - 
38 32 Positive Positive Positive Positive Normal - 
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39 21 Positive Positive Normal - - - 
40 21 Positive Positive Positive Normal - - 
41 22 Positive Normal - - - - 
42 50 Positive Normal - - - - 
43 42 Positive Normal - - - - 
44 30 Positive Positive Positive - - - 
45 18 Positive Positive Positive Normal - - 
46 30 Positive Normal - - - - 
47 40 Positive Positive Positive Normal - - 
48 35 Positive Normal - - - - 
49 28 Positive Positive Positive Normal Normal - 
50 37 Positive Positive Positive Positive Positive Normal 
51 49 Positive Positive Normal - - - 
52 30 Positive Positive Normal - - - 
53 29 Positive Normal - - - - 
54 41 Positive Positive Positive Normal - - 
55 42 Positive Positive Normal - - - 
56 37 Positive Normal - - - - 
57 18 Positive Positive Positive Positive Normal - 
58 13 Positive Normal - - - - 
59 23 Positive Positive Positive Positive Positive Normal 
60 28 Positive Normal - - - - 
61 45 Positive Positive Positive Positive Normal - 
62 15 Positive Positive Positive Normal - - 
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63 50 Positive Positive Positive Positive Normal - 
64 32 Positive Normal - - - - 
65 43 Positive Positive Positive Positive Positive Normal 
66 36 Positive Positive Positive Positive Normal - 
67 38 Positive Normal - - - - 
68 35 Positive Positive Normal - - - 
69 51 Positive Positive Normal - - - 
70 55 Positive Positive Positive Positive Normal - 
71 43 Positive Positive Normal - - - 
72 46 Positive Positive Normal - - - 
73 59 Positive Normal - - - - 
74 39 Positive Positive Positive Positive Normal - 
75 55 Positive Positive Positive Positive Normal - 
76 35 Positive Positive Positive Normal - - 
77 51 Positive Normal - - - - 
78 45 Positive Positive Positive Normal - - 
79 40 Positive Positive Normal - - - 
80 17 Positive Positive Positive Positive Positive Normal 
81 50 Positive Positive Positive Normal - - 
82 50 Positive Normal - - - - 
83 20 Positive Positive Normal - - - 
84 51 Positive Positive Normal - - - 
85 55 Positive Positive Normal - - - 
86 50 Positive Positive Positive Normal - - 
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87 39 Positive Positive Normal - - - 
88 47 Positive Positive Positive Positive Normal - 
89 37 Positive Positive Normal - - - 
90 40 Positive Positive Normal - - - 
91 51 Positive Positive Positive Normal - - 
92 47 Positive Positive Positive Positive Positive Normal 
93 49 Positive Positive Positive Positive Normal - 
94 39 Positive Positive Normal - - - 
95 35 Positive Positive Positive Normal - - 
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Table 5.36: Comparative urine Creatinine levels for different week 
treatment with Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet  
Sr. 
no 
Drug Total 
number 
of 
patients 
No of 
patients 
having 
positive 
Creatinine 
Normalized Reduced Remain 
unchanged 
1 Phyllanthus 
amarus 
107 107 107 - - 
2 Livercare 
Churna 
93 93 93 - - 
3 Hepatogard 
forte Tablet 
95 95 93 02 - 
 
During clinical study selected 107 patients of Phyllanthus amarus group were 
found infected with jaundice among them 107 patients were urine Creatinine 
positive. After treatment with Phyllanthus amarus all 107 patients were 
normalized. 93 patients of Livercare Churna group were found infected with 
jaundice among them 93 patients were urine Creatinine positive. After 
treatment with Livercare Churna all 93 patients were normalized. 95 patients 
of Hepatogard forte Tablet group were found infected with jaundice among 
them 95 patients were urine Creatinine positive. After treatment with 
Hepatogard forte Tablet all 93 patients were normalized and 2 patients 
decreases the urine Creatinine level. 
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Table 5.37: HBsAg values of the patients after treatment with 
Phyllanthus amarus  
Sr. no 
of 
patients 
Age HBsAg after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 28 Negative Negative - - - - 
2 51 Negative Negative - - - - 
3 20 Negative Negative - - - - 
4 16 Negative Negative Negative Negative Negative - 
5 42 Negative Negative Negative Negative Negative - 
6 17 Negative Negative Negative - - - 
7 65 Negative Negative - - - - 
8 65 Negative Negative - - - - 
9 36 Negative Negative Negative Negative - - 
10 42 Negative Negative - - - - 
11 35 Negative Negative Negative Negative - - 
12 21 Negative Negative Negative Negative - - 
13 32 Positive Positive Negative - - - 
14 32 Negative Positive Negative - - - 
15 28 Negative Positive Negative Negative Negative - 
16 45 Negative Negative Negative - - - 
17 17 Negative Negative - - - - 
18 32 Negative Negative - - - - 
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19 20 Negative Negative Negative Negative Negative - 
20 38 Positive Negative Negative Negative Negative Negative 
21 19 Negative Negative Negative Negative - - 
22 38 Negative Negative - - - - 
23 16 Positive Negative Negative Negative Negative Negative 
24 19 Negative Negative Negative Negative - - 
25 22 Negative Negative Negative Negative - - 
26 65 Negative Negative Negative Negative - - 
27 35 Negative Negative Negative - - - 
28 32 Negative Negative Negative - - - 
29 42 Negative Negative - - - - 
30 43 Positive Negative Negative Negative Negative Negative 
31 28 Negative Negative Negative Negative Negative - 
32 50 Positive Negative Negative Negative Negative - 
33 55 Negative Negative Negative Negative - - 
34 45 Negative Negative Negative Negative - - 
35 55 Negative Negative Negative - - - 
36 40 Negative Negative Negative - - - 
37 20 Negative Negative Negative Negative - - 
38 50 Negative Negative Negative - - - 
39 45 Negative Negative Negative - - - 
40 50 Negative Negative Negative Negative Negative - 
41 50 Positive Negative Negative Negative - - 
42 45 Negative Negative Negative - - - 
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43 32 Negative Negative Negative Negative Negative - 
44 55 Negative Negative Negative - - - 
45 21 Positive Negative Negative Negative Negative - 
46 50 Positive Negative Negative Negative Negative - 
47 19 Negative Negative - - - - 
48 42 Negative Negative Negative Negative - - 
49 71 Negative Negative - - - - 
50 38 Positive Negative Negative Negative Negative - 
51 30 Negative Negative Negative Negative - - 
52 30 Negative Negative - - - - 
53 54 Negative Negative - - - - 
54 42 Negative Negative Negative - - - 
55 22 Negative Negative Negative - - - 
56 42 Negative Negative Negative Negative - - 
57 46 Negative Negative Negative Negative Negative - 
58 11 Negative Negative - - - - 
59 38 Negative Negative Negative Negative - - 
60 70 Negative Negative - - - - 
61 20 Negative Negative Negative Negative - - 
62 23 Negative Negative Negative - - - 
63 35 Positive Negative Negative Negative - - 
64 36 Positive Negative Negative - - - 
65 24 Negative Negative Negative - - - 
66 40 Negative Negative - - - - 
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67 28 Negative Negative Negative Negative - - 
68 13 Negative Negative - - - - 
69 45 Negative Negative Negative Negative - - 
70 15 Negative Negative - - - - 
71 32 Positive Negative Negative Negative - - 
72 55 Positive Negative Negative Negative Negative - 
73 11 Negative Negative Negative - - - 
74 30 Positive Negative Negative Negative - - 
75 12 Negative Negative Negative - - - 
76 13 Negative Negative - - - - 
77 65 Negative Negative Negative Negative Negative - 
78 30 Negative Negative - - - - 
79 50 Positive Negative Negative - - - 
80 49 Positive Negative Negative Negative Negative - 
81 45 Negative Negative Negative - - - 
82 36 Negative Negative Negative Negative Negative - 
83 40 Positive Negative Negative - - - 
84 11 Negative Negative Negative Negative Negative - 
85 50 Negative Negative Negative - - - 
86 35 Negative Negative Negative - - - 
87 30 Negative Negative Negative Negative - - 
88 25 Negative Negative Negative - - - 
89 65 Negative Negative Negative - - - 
90 30 Negative Negative - - - - 
Chapter 5  RESULT AND DISCUSSION  
219 
 
91 35 Negative Negative - - - - 
92 50 Negative Negative Negative Negative - - 
93 37 Negative Negative - - - - 
94 53 Positive Negative Negative Negative - - 
95 42 Positive Negative Negative Negative - - 
96 12 Negative Negative Negative Negative - - 
97 40 Positive Negative Negative Negative Negative Negative 
98 45 Negative Negative - - - - 
99 27 Positive Negative Negative Negative - - 
100 25 Negative Negative - - - - 
101 21 Negative Negative Negative - - - 
102 30 Positive Negative Negative Negative Negative - 
103 20 Negative Negative Negative - - - 
104 51 Negative Negative - - - - 
105 5 Negative Negative Negative Negative Negative - 
106 42 Negative Negative - - - - 
107 32 Negative Negative Negative Negative - - 
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Table 5.38: HBsAg values of the patients after treatment with Livercare 
Churna  
Sr. no 
of 
patients 
Age 
HBsAg after different weeks  treatment 
Initial 
(zero 
week) 
First Second Third Fourth Sixth 
1 17 Negative Negative - - - - 
2 47 Negative Negative Negative - - - 
3 49 Negative Negative - - - - 
4 51 Positive Negative Negative Negative Negative Negative 
5 31 Negative Negative - - - - 
6 53 Negative Negative Negative - - - 
7 47 Positive Negative Negative - - - 
8 40 Positive Negative Negative Negative Negative Negative 
9 47 Positive Negative Negative Negative - - 
10 50 Negative Negative Negative Negative - - 
11 44 Negative Negative - - - - 
12 46 Positive Negative Negative Negative Negative Negative 
13 35 Negative Negative Negative - - - 
14 55 Positive Negative - - - - 
15 50 Positive Negative Negative Negative - - 
16 60 Positive Negative Negative Negative Negative Negative 
17 43 Negative - - - - - 
18 45 Positive Negative - - - - 
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19 40 Positive Negative Negative Negative Negative Negative 
20 29 Negative Negative - - - - 
21 44 Negative Negative Negative Negative - - 
22 25 Positive Negative Negative Negative - - 
23 17 Negative Negative Negative Negative - - 
24 40 Negative - - - - - 
25 35 Positive Negative Negative Negative - - 
26 25 Positive Negative Negative Negative - - 
27 21 Negative Negative Negative Negative - - 
28 52 Negative Negative - - - - 
29 45 Negative Negative Negative Negative - - 
30 62 Positive Negative Negative Negative Negative Negative 
31 50 Negative Negative - - - - 
32 45 Negative Negative Negative - - - 
33 50 Positive Negative Negative Negative - - 
34 30 Negative Negative Negative Negative - - 
35 19 Positive Negative Negative Negative - - 
36 45 Negative Negative - - - - 
37 25 Negative Negative Negative - - - 
38 25 Positive Negative Negative - - - 
39 27 Negative Negative Negative Negative - - 
40 17 Negative Negative Negative - - - 
41 57 Negative Negative Negative - - - 
42 45 Negative Negative - - - - 
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43 60 Negative Negative - - - - 
44 49 Negative Negative - - - - 
45 36 Negative Negative - - - - 
46 49 Positive Negative Negative Negative Negative Negative 
47 50 Negative Negative Negative - - - 
48 40 Positive Negative Negative Negative Negative Negative 
49 40 Negative Negative Negative Negative - - 
50 39 Negative - - - - - 
51 41 Positive Negative Negative Negative Negative Negative 
52 45 Negative Negative - - - - 
53 29 Negative Negative Negative - - - 
54 52 Negative Negative - - - - 
55 50 Negative Negative Negative - - - 
56 49 Positive Negative Negative Negative - - 
57 39 Negative - - - - - 
58 11 Negative Negative - - - - 
59 19 Negative Negative - - - - 
60 52 Negative Negative Negative - - - 
61 21 Positive Negative Negative Negative - - 
62 29 Negative Negative Negative Negative - - 
63 40 Negative Negative - - - - 
64 55 Negative - - - - - 
65 50 Positive Negative Negative Negative - - 
66 39 Negative Negative - - - - 
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67 38 Negative Negative - - - - 
68 19 Negative Negative Negative - - - 
69 35 Positive Negative Negative Negative - - 
70 45 Negative Negative - - - - 
71 31 Negative Negative Negative - - - 
72 49 Negative - - - - - 
73 45 Negative - - - - - 
74 53 Negative Negative - - - - 
75 48 Negative - - - - - 
76 20 Negative - - - - - 
77 17 Negative Negative - - - - 
78 27 Positive Negative Negative Negative Negative Negative 
79 31 Negative Negative - - - - 
80 50 Positive Negative - - - - 
81 35 Positive Negative Negative Negative - - 
82 39 Negative - - - - - 
83 29 Negative - - - - - 
84 41 Negative - - - - - 
85 22 Positive - - - - - 
86 31 Positive Negative Negative - - - 
87 47 Negative - - - - - 
88 28 Negative Negative - - - - 
89 12 Negative - - - - - 
90 41 Negative - - - - - 
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91 36 Negative - - - - - 
92 44 Negative Negative - - - - 
93 39 Positive Negative - - - - 
 
Table 5.39: HBsAg values of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no 
of 
patients 
Age 
HBsAg after different weeks treatment 
Initial 
(zero 
week) 
First Second Third Fourth Sixth 
1 32 Negative Negative Negative - - - 
2 34 Negative Negative Negative Negative - - 
3 50 Negative Negative Negative Negative Negative Negative 
4 39 Positive Negative Negative Negative Negative Negative 
5 39 Positive Negative Negative Negative Negative Negative 
6 60 Positive Negative Negative Negative Negative Negative 
7 32 Negative Negative Negative Negative Negative - 
8 49 Negative Negative Negative Negative Negative - 
9 55 Negative Negative Negative - - - 
10 60 Negative Negative Negative - - - 
11 35 Negative Negative Negative Negative - - 
12 36 Negative Negative Negative - - - 
13 58 Positive Negative Negative Negative Negative Negative 
14 40 Positive Negative Negative - - - 
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15 50 Negative Negative Negative - - - 
16 29 Negative Negative Negative - - - 
17 38 Negative Negative Negative - - - 
18 42 Positive Negative Negative - - - 
19 59 Negative Negative Negative - - - 
20 11 Negative Negative Negative - - - 
21 32 Negative Negative Negative Negative Negative - 
22 60 Positive Negative Negative Negative Negative - 
23 35 Negative Negative Negative - - - 
24 59 Negative Negative Negative Negative - - 
25 49 Negative Negative Negative Negative - - 
26 21 Positive Negative Negative Negative - - 
27 60 Negative Negative Negative - - - 
28 45 Negative Negative Negative Negative - - 
29 50 Negative Negative Negative Negative Negative - 
30 55 Positive Negative Negative Negative - - 
31 51 Negative Negative Negative Negative - - 
32 23 Negative Negative Negative Negative Negative - 
33 20 Negative Negative Negative - - - 
34 22 Negative Negative - - - - 
35 48 Negative Negative Negative - - - 
36 47 Negative Negative Negative Negative Negative - 
37 41 Negative Negative Negative Negative - - 
38 32 Negative Negative Negative Negative Negative - 
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39 21 Negative Negative Negative - - - 
40 21 Negative Negative Negative Negative - - 
41 22 Negative Negative - - - - 
42 50 Negative Negative - - - - 
43 42 Negative Negative - - - - 
44 30 Negative Negative Negative - - - 
45 18 Positive Negative Negative Negative - - 
46 30 Negative Negative - - - - 
47 40 Negative Negative Negative Negative - - 
48 35 Negative Negative - - - - 
49 28 Positive Negative Negative Negative Negative - 
50 37 Positive Negative Negative Negative Negative Negative 
51 49 Negative Negative Negative - - - 
52 30 Positive Negative Negative - - - 
53 29 Negative Negative - - - - 
54 41 Negative Negative Negative Negative - - 
55 42 Negative Negative Negative - - - 
56 37 Negative Negative - - - - 
57 18 Positive Negative Negative Negative Negative - 
58 13 Negative Negative - - - - 
59 23 Positive Negative Negative Negative Negative Negative 
60 28 Negative Negative - - - - 
61 45 Negative Negative Negative Negative Negative - 
62 15 Negative Negative Negative Negative - - 
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63 50 Positive Negative Negative Negative Negative - 
64 32 Negative Negative - - - - 
65 43 Negative Negative Negative Negative Negative Negative 
66 36 Positive Negative Negative Negative Negative - 
67 38 Negative Negative - - - - 
68 35 Negative Negative Negative - - - 
69 51 Negative Negative Negative - - - 
70 55 Positive Negative Negative Negative Negative - 
71 43 Negative Negative Negative - - - 
72 46 Negative Negative Negative - - - 
73 59 Negative Negative - - - - 
74 39 Negative Negative Negative Negative Negative - 
75 55 Positive Negative Negative Negative Negative - 
76 35 Negative Negative Negative Negative - - 
77 51 Negative Negative - - - - 
78 45 Negative Negative Negative Negative - - 
79 40 Negative Negative Negative - - - 
80 17 Positive Negative Negative Negative Negative Negative 
81 50 Positive Negative Negative Negative - - 
82 50 Negative Negative - - - - 
83 20 Negative Negative Negative - - - 
84 51 Negative Negative Negative - - - 
85 55 Negative Negative Negative - - - 
86 50 Negative Negative Negative Negative - - 
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87 39 Positive Negative Negative - - - 
88 47 Negative Negative Negative Negative Negative - 
89 37 Positive Negative Negative - - - 
90 40 Negative Negative Negative - - - 
91 51 Negative Negative Negative Negative - - 
92 47 Positive Negative Negative Negative Negative Negative 
93 49 Positive Negative Negative Negative Negative - 
94 39 Positive Negative Negative - - - 
95 35 Positive Negative Negative Negative - - 
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Table 5.40: Comparative HBsAg values for different weeks treatment 
with Phyllanthus amarus, Livercare Churna and Hepatogard forte Tablet  
Sr 
no 
Drug Total 
no of 
patient
s 
No of 
patients 
having 
HepatitisB 
Norma
lized 
Reduced Remain 
unchang
ed 
1 Phyllanthus 
amarus 
107 22 22 - - 
2 Livercare 
Churna 
93 30 30 - - 
3 Hepatogard 
forte Tablet 
95 27 27 - - 
 
During clinical study selected 107 patients of Phyllanthus amarus 
group were found infected with jaundice among them 22 patients were 
Hepatitis B positive. After treatment with Phyllanthus amarus all 22 patients 
were normalized. 93 patients of Livercare Churna group were found infected  
with jaundice among them 30 patients were Hepatitis B positive. After 
treatment with Livercare Churna all 30 patients were normalized. 95 patients 
of Hepatogard forte Tablet were found infected with jaundice among them 27 
patients were Hepatitis B positive. After treatment with Hepatogard forte 
Tablet all 27 patients were normalized. 
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Table 5.41: Comparative asthma values for different weeks treatment 
with Phyllanthus amarus, Livercare Churna and Hepatogard forte Tablet.  
Sr. 
no 
Drug Total no. 
of 
patients 
No of 
patients 
having 
Asthma 
No. of 
patients  
Normaliz
ed from 
asthma 
Reduction 
in severity 
of asthma 
No of 
patients 
remain 
unchanged 
1 Phyllanthus 
amarus 
107 4 - 3 1 
2 Livercare 
Churna 
93 2 - 2 - 
3 Hepatogard 
forte Tablet 
95 2 - 1 1 
During clinical study selected 107 patients of Phyllanthus amarus 
group were found to be infected with jaundice among them 4 patients had 
problem of asthma. After treatment with Phyllanthus amarus, there was 
reduction in asthmatic severity in the three patients and there was no 
improvement in one patient in asthma. 93 patients of Livercare Churna group 
were found infected with jaundice among them 2 patients had a problem of 
asthma. After treatment with Livercare Churna, there was reduction in 
asthmatic severity in all the two patients. 95 patients of Hepatogard forte 
Tablet were found infected with jaundice among them 2 patients had a 
problem of asthma. After treatment with Hepatogard forte Tablet there was 
improvement in the condition of asthmatic one patient while there was no 
improvement in another patient in asthma. 
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Table 5.42: Comparative hair growth values for different weeks 
treatment with Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet.  
Sr. no Drug Total no. of 
patients 
Increase in 
hair growth 
in number of 
patients 
Remain 
unchanged 
in number of 
patients 
1 Phyllanthus 
amarus 
107 10 97 
2 Livercare 
Churna 
93 18 75 
3 Hepatogard 
forte Tablet 
95 13 82 
 
During clinical study selected 107 patients of Phyllanthus amarus group were 
found infected with jaundice among them patient’s hair growth was observed. 
After treatment with Phyllanthus amarus 10 patients have shown about 1-1.5 
cm growth of hair. 10 patients remained unchanged. 93 patients of Livercare 
Churna group were found infected with jaundice among them patient’s hair 
growth was observed. After treatment with Livercare Churna 18 patients have 
shown about 1-1.5 cm growth of hair and 75 patients remained unchanged. 
95 patients of Hepatogard forte Tablet were found infected with jaundice 
among them patient’s hair growth was observed. After treatment with 
Hepatogard forte Tablet 13 patients have shown about 1 cm growth of hair 
and 82 patients remained unchanged. 
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Table 5.43: Comparative kidney stone study for different weeks 
treatment with Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet  
Sr 
no 
Drug Total 
no. of 
patients 
No of 
patients 
having 
Kidney 
stone 
Patient 
number/stone size 
/ place 
Stone 
size after 
treatment 
1 Phyllanthus 
amarus 
107 2 39/5mm/right kidney 
27/4mm/left kidney 
4mm 
4mm 
2 Livercare 
Churna 
93 1 66/ 6mm / left 
kidney 
4mm 
3 Hepatogard 
forte Tablet 
95 - - 
 
- 
 
During clinical study selected 107 patients of Phyllanthus amarus group were 
found infected with jaundice among them 2 patients have complain of pain of 
kidney stone. Pain and Sonography report showed presence of stone. After 
the treatment with Phyllanthus amarus there was reduction in the stone size 
from 5mm to 4mm and in one patient there was no change in the stone size. 
93 patients of Livercare Churna group were found infected with jaundice 
among them 1 patient showed presence of kidney stone in Sonography 
report. After the treatment with Livercare Churna the size of stone was 
reduced from 6mm to 4mm.   
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Table 5.44: Comparative pimples values for different weeks treatment 
with Phyllanthus amarus, Livercare Churna and Hepatogard forte Tablet  
Sr. 
no 
Drug Total 
no. of 
patients 
No of 
patients 
having 
Pimples 
Normalized Reduced Remain 
unchanged 
1 Phyllanthus 
amarus 
107 6 - 3 3 
2 Livercare 
Churna 
93 7 - 5 2 
3 Hepatogard 
forte Tablet 
95 4 - 2 2 
 
During clinical study selected 107 patients of Phyllanthus amarus group were 
found infected with jaundice among them 6 patients have pimple. After the 
treatment with Phyllanthus amarus there was reduction in size in 3 patients 
and in 3 patients it remained unchanged. 93 patients of Livercare Churna 
group were found infected with jaundice among them 7 patients have pimples. 
After treatment with Livercare Churna no patients was normalized but there 
was reduction in pimples size in 5 patients and it remained unchanged in 2 
patients. 95 patients of Hepatogard forte Tablet were found infected with 
jaundice among them 4 patients have pimples. After treatment with 
Hepatogard forte Tablet there was reduction pimple size in 2 patients and no 
change in remaining 2 patients. 
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Table 5.45: Comparative cough values for different weeks treatment 
Phyllanthus amarus, Livercare Churna and Hepatogard forte Tablet  
Sr. 
no 
Drug Total 
no of 
patients 
No of 
patients 
having 
Cough 
Normalized Reduced Remain 
unchanged 
1 Phyllanthus 
amarus 
107 4 - 4 - 
2 Livercare 
Churna 
93 2 - 1 1 
3 Hepatogard 
forte Tablet 
95 2 - 1 1 
 
During clinical study selected 107 patients of Phyllanthus amarus group were 
found infected with jaundice among them 4 patients have problem of cough. 
After the treatment with Phyllanthus amarus there was relief in cough in all the 
4 patients and no patient remained unchanged. 93 patients of Livercare 
Churna group were found infected with jaundice among them 2 patients have 
problem of cough. After the treatment with Livercare Churna there was relief 
in cough of one patient and 1 patient remained unchanged. 95 patients of 
Hepatogard forte Tablet were found infected with jaundice among them 2 
patients have problem of cough. After the treatment with Hepatogard forte 
Tablet there was relief in cough of 1 patient and 1 patient remained 
unchanged. 
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Table 5.46: Comparative study of arthritis condition for different weeks 
treatment with Phyllanthus amarus, Livercare Churna and Hepatogard 
forte Tablet  
Sr. 
no 
Drug Total 
no of 
patients 
No of 
patients 
having 
Arthritis 
Normalized Reduced Remain 
unchanged 
1 Phyllanthus 
amarus 
107 2 - 1 1 
2 Livercare 
Churna 
93 2 - 1 1 
3 Hepatogard 
forte Tablet 
95 1 - - 1 
 
During clinical study selected 107 patients of Phyllanthus amarus group were 
found infected with jaundice among them 2 patients have a problem of 
arthritis. After the treatment with Phyllanthus amarus there was relief in pain 
of arthritis in 1 patient and 1 patient remained unchanged. 93 patients of 
Livercare Churna group were found infected with jaundice among them 2 
patients have a problem of arthritis. After the treatment with Livercare Churna 
there was relief in pain of arthritis in 1 patient and 1 patient remained 
unchanged. 95 patients of Hepatogard forte Tablet were found infected with 
jaundice among them 1 patient has a problem of arthritis. After the treatment 
with Hepatogard forte Tablet there was no improvement in the pain of above 
arthritic patient.  
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SUMMARY 
Liver is a versatile organ in the body concerned with regulation 
of internal chemical environment.  Therefore, damage to the liver 
inflicted by hepatotoxic agents is of grave consequence.  There is an 
ever increasing need for an agent which could protect liver damage 
especially of one which facilitates regeneration by the proliferation of 
parenchymal cells after damage and arrests growth of fibrous tissue.  
In the present study of hepatoprotective activity was observed in the 
patients having liver damage. 
 In the present study, fresh herb of Phyllanthus amarus was collected, 
authentified and shade dried.  The dried material was reduced to a 
powder of required particle size. 
 Study of physicochemical parameters of fresh powdered material of 
Phyllanthus amarus was carried out which comply with the parameters 
given in Ayurvedic Pharmacopoeia of India and Indian herbal 
Pharmacopoeia.  
 Marketed hepatoprotective formulations (Hepatogaurd forte Tablet and 
Livercare Churna) were collected from the local market. On TLC study 
the Petrolium ether extract of herb and the market formulations showed 
presence of Phyllanthin and Hypophyllanthin an active constituent of 
Phyllanthus amarus. 
 Evaluation of parameters such as SGPT, Billirubin, Hb, Creatinine, 
HBsAg, urine sugar were carried out in the patients of jaundice after 
forming an Ethical committee and taking the written consent of the 
patients.  
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 Treatment with Phyllanthus amarus powder, Livercare Churna and 
Hepatogard forte Tablets orally for the period of 1 to 3weeks, to 4 and 
6weeks was carried out as per severity of the condition and recovery of 
the patients.  
 Evaluation parameters such as SGPT, Billirubin showed significant P 
value <0.001 treatment with Phyllanthus amarus herb powder, 
Livercare Churna and Hepatogard forte Tablets.  
 Drug Phyllanthus amarus, and marketed formulation Livercare Churna 
showed better hepatoprotective effects than marketed formulation 
Hepatogaurd forte Tablet. 
 There was also improvement in Hb, reduction in blood pressure, urine 
sugar, removal of HBsAg, reduction in kidney stone size, reduction in 
asthmatic discomfort, reduction in pimples. 
 The multiple claims described for a single herb in Ayurveda or 
traditional system of medicines seems to be true. Phyllanthus amarus 
and its formulations have hepatoprotective activity and also tonic 
(increase Hb %), antidiabetis (decreases urine sugar), reduce blood 
pressure, dissolve kidney stone, useful in asthma, cough, etc. 
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Annexure I 
 
Phyllanthus amarus is utilized as Hepatoprotective drug 
 
1) Patients name: 
2) Address: 
 
3) Contact number: 
4) Patients age: 
5) Patients sex: 
6) Patients weight: 
7) Patients diagnosis: Hepatitis A/ Hepatitis B/ Hepatitis C 
 
8) Drug is given: 
(a) Eclipta Prostrata 
(b) Hepatogard forte Tablet 
(c) Livercare Churna 
 
9) Dose of drug: OD/BD/TD 
 
10) Duration of illness:1) One day 2)2-3 days 3)Week 
4) Fort night 5) Month 6) Chronic 
 
11) Patient habituated like: 
 House wife   yes/no 
 Farmer   yes/no 
 Business   yes/no 
 Smoking   yes/no 
 Tobacco consumption yes/no 
 Alcohol consumption yes/no 
 Narcotic consumption yes/no 
 Pregnancy   yes/no 
 Feeding   yes/no 
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12) Laboratory tests 
 
 
 
13) Patient improvement in other disease 
 
 
SR 
no 
SGPT  
Liver 
problem 
HB 
(tonicity) 
Urine 
(Creatinine) 
Billirubin Urine 
Sugar 
(Diabetes) 
HBsAg 
1
st
       
2
nd
       
3
rd
       
4
th
       
6
th
       
SR no Blood 
pressure 
Kidney 
stone 
Hair 
growth/ 
dandruff 
Pimples Arthritis Asthma Cough 
 
1
st
        
2
nd
        
3
rd
        
4
th
        
6
th
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